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ABSTRACT 
ENGINEERING THE NANOPARTICLE SURFACE FOR PROTEIN 
RECOGNITION AND APPLICATIONS 
MAY 2009 
MRINMOY DE, B.Sc., VIDYASAGAR UNIVERSITY, INDIA 
M. Sc., INDIAN INSTITUTE OF TECHNOLOGY, BOMBAY, INDIA 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Prof. Vincent M. Rotello 
Proteins and nanoparticles (NPs) provide a promising platform for 
supramolecular interaction. We are currently exploring both fundamental and applied 
aspects of this interaction. On the fundamental side, we have fabricated a series of 
water-soluble anionic and cationic NPs to interact with cationic and anionic proteins 
respectively. A Varity of studies such as, activity assay, fluorescence titration, 
isothermal titration calorimetry etc. were carried out to quantify the binding properties 
of these functional NPs with those proteins. Those studies reveal the prospect of tuning 
the affinity between the nanoparticles and proteins by the surface modification. On the 
application side, we have used this protein-nanoparticle interaction in protein refolding 
where we successfully refolded the thermally denatured proteins toward its native 
structure. We have also applied this particle-protein recognition to create a 
biocompatible protein sensor using a protein-NP conjugate. Green fluorescent protein 
and a series of cationic NPs were used for a protein sensor for the identification of 
protein analytes through displacement process. We have extended this application even 
in sensing the proteins in human serum. 
  viii
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CHAPTER 1 
 
NANOPARTICLES IN PROTEIN SURFACE RECOGNITION 
1.1 Introduction 
The recognition of proteins surfaces is an important issue in biomaterials,1 
where controlled detection of protein surfaces presents a major challenge for the 
creation of materials for biomedical applications.2, 3 On the other hand, protein-surface 
interactions can provide a model for protein-protein interactions, origin of a number of 
cellular processes, such as cellular signal transduction, DNA transcription, and protein 
antigen/antibody recognition.4, 5 Additionally engineered protein-surface interactions 
are central of diverse bio-applications such as biosensing,6 biocatalysis,7 protein 
purification8 and controlled culturing of cells.9 For example, Herceptin:Her2/neu 
interaction,10 have many therapeutic implications Interruption of this protein-protein 
interactions has been used by Chmielewski11 to inhibit the dimerization and hence 
activity of HIV-1 protease. In other example Fletchera et. al. demonstrated that the Bcl-
2-like proteins bind in small proportion of apoptotic Bax protein molecules with an 
exposed BH3 domain on the mitochondrial membrane, to prevent Bax-imposed cell 
death and hence can control the programmed cell death (apoptosis) process.12 Therefore 
the ability to modify and control the protein interaction by modulating surface 
chemistry provides a means for probing these interactions in a systematic fashion which 
is almost inaccessible using purely protein-based systems.  
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1.2 Protein Surface Recognition using Synthetic Receptors 
Protein surface recognition is an emerging target in chemotherapeutics13 and 
provides a potent tool for the regulation of protein-protein interactions central to a 
number of cellular processes as mentioned above. Clearly, control and recognize the 
protein-protein interactions are a fertile target for the fields of chemical biology and 
pharmaceutical science.  
In general protein-protein interaction involves three kinds of interfaces (Figure 
1.1). The first one is surface-surface interactions,14 which observed in the majority of 
protein-protein interactions. The second is surface-loop binding,15 as it is observed in 
well known p53-MDM2 interaction and the least observed is complementary α-helices 
interaction.16 
 
Figure 1.1. Motifs for protein-protein interactions (reproduced from Alberts et al in 
Molecular Biology of the Cell, 3rd ed. p 217).  
 
Recognition of protein surfaces using synthetic receptors is based on 
noncovalent host-guest interaction as observed in small molecule systems. However the 
regulation of biomolecules remains a far more significant challenge. This challenge is 
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primarily due to two basic requirements for an effective recognition between a 
biomacromolecule and its receptor. First of all, a large biomacromolecule-receptor 
contact area is required. For example, relatively large surface areas are required for 
effective binding of protein surfaces (which are solvent exposed) to successfully inhibit 
the active site. Insight into this requirement comes from examination of protein-protein 
interactions, which reveals that a surface area of more than 6 nm2 per protein are 
typically involved in such interactions.17, 18 
A number of “small molecule” systems19 and macromolecular scaffolds have 
been used to address this challenge for protein surface recognition. Most of the research 
in the creation of receptors targeted to protein surfaces has focused on peptides20 and 
peptidomimetic structures,21 where protein self-assembly assists in the creation of large 
constructs featuring controlled structure. Recent “small molecule” systems include the 
receptors Hamilton has developed on calixarene and porphyrin scaffolds,22, 23 
cyclodextrin dimers synthesized by Breslow,24 and Mallik’s transition metal complexes 
targeted against surface-exposed histidines.25 Another very productive method for the 
creation of protein surface receptors uses macromolecular scaffolding. In this aspect, 
Kiessling has used ring opening metathesis polymerization (ROMP) to create libraries 
of macromolecular receptors possessing partially-constrained backbones.26, 27 Such 
systems demonstrate a certain level of success in modulation of biomolecular function; 
but the question of protein surface recognition still remains indistinct. 
The second challenge for protein surface recognition is the complexity of the 
surfaces involved,28 in terms of their multiple electrostatic,29 hydrophobic30 and 
topological features.31, 32 Direction for the design of receptors can be obtained from 
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examination of protein-protein interactions. From these studies, it is clear that proper 
presentation of surface elements is required for the effective recognition of the “hot 
spot”33 present in protein-protein interfaces. Creation of systems complementary to 
these hotspots, however, is an essentially open question, in particular in the area of 
surface-surface interactions. 
1.3 Nanoparticles as Scaffolds for Recognition 
Nanoparticle based receptors, however, offer a platform for biomolecular 
surface recognition which is unique and distinctive in its own way. In this respect 
nanoparticles are promising materials for the creation of artificial receptor for the 
following reasons. The size of the nanoparticle core can be tuned from 1.5 to more than 
10 nm which can provides a suitable platform for the interaction of nanoparticles with 
proteins and other biomolecules (Figure 1.2).34  
 
Figure 1.2. Schematic representation for relative size of a 2 nm gold nanoparticle with 
11-mercaptoundecanoic acid monolayer and aspirin crystal (small molecule), papain 
(protein), and a 24 mer DNA duplex. 
 
Secondly nanoparticles can be fabricated with a wide range of surface 
functionality thus providing a versatile system for creation of surface-specific receptors. 
The third important feature is the range of metal and semiconductor cores can be 
generated featuring useful properties and application (Table 1.1).35 From table 1.1 
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metallic nanoparticle (i.e. Au, Ag etc.) are become more popular for molecular 
recognition, delivery and sensing where as semiconductor and magnetic nanoparticles 
are drawing the interest as an imaging agent.36 
Table 1.1. Characteristics and corresponding ligand for various metal and 
semiconductor materials as nanometer-sized scaffold (reproduced from reference no. 
36). 
Core material Characteristics  Ligand(s) Applications 
Au Optical absorption, fluorescence and 
fluorescence quenching, stability 
Thiol, disulfide, phosphine, 
amine 
Biomolecular recognition, 
delivery, sensing 
Ag Surface-enhanced fluorescence Thiol Sensing 
Pt Catalytic property Thiol, phosphine, amine, 
isocyanide 
Bio-catalyst, sensing 
CdSe Luminescence, photo-stability Thiol, phosphine, pyridine Imaging, sensing 
Fe2O3 Magnetic property Diol, dopamine derivative, 
amine 
MR imaging and 
biomolecule purification 
SiO2 Biocompatibility Alkoxysilane Biocompatible by surface 
coating  
  
Finally, the self-template nature of this system to guest molecules is allowing an 
increase in the affinity and selectivity upon incubation with the guest molecules. 
Applying these characteristic to the selective recognition of biomacromolecules, 
however, requires suitable surface functionality which can be solved by using reported 
synthetic methods.37 
There are several applications on nanoparticle-biomolecule interactions have 
been reported based on various biological and diagnostic applications.36 Nanoparticles 
can be made-up with a diverse array of metal, alloy, oxide and semiconductor materials, 
using standard reported procedure available in literatures which already mention before 
(Table 1.1). As an example Brust and coworkers have developed a widely used particle 
preparation procedure for metallic nanoparticles by the reduction of metal salt in the 
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presence surfactant and coating ligands (Figure 1.3a)38 Using this method various 
metallic nanoparticles (such as Ag, Pt, Pd, Cu etc.) have been prepared.  In this protocol 
the size of the particle can be controlled by varying the metal-ligand ratio and reaction 
conditions. For efficient biological applications, the most important requirements of the 
nanoparticle are surface functionality and water-solubility. 
To introduce the surface functionality, the most acceptable method is the 
Murray’s place-exchange process (Figure 1.3a),39 where the initial ligands on the 
nanoparticle surface are replaced by external ligands of similar functionality as an 
instance, thiol or disulfide ligands for gold and silver particle. The other well known 
method is direct synthesis of metallic nanoparticles in presence of corresponding ligand 
to generate monolayer-protected clusters (MPCs) and mixed monolayer-protected 
clusters (Nanoparticles). According to the necessity further functionality can be 
introduced through conventional organic protocols.40 Recently, another kind of water-
soluble functionalized nanoparticles were reported by the incorporation of hydrophobic 
nanoparticles into the hydrophobic interiors of surfactant micelles.41, 42 To improve the 
biocompatibility oligo(ethylene glycol) (OEG) and poly(ethylene glycol) (PEG) are 
commonly incorporated into the monolayers.43 The OEG or PEG are hydrophilic in 
nature to improve the water solubility with the added benefit these ligand resist the 
nonspecific interactions with biomolecules. Therefore the slandered nanoparticle for 
controlled biomolecular interactions consists of hydrophobic interior, an OEG or PEG 
layer, and recognition elements on the surface (Figure 1.3b). 
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Figure 1.3. a) Construction of nanoparticles through Brust reduction and subsequent 
modification such as Murray place-exchange reaction (i), (ii) and encapsulation of 
hydrophobic MPCs into surfactant micelles (iii). b) Multifunctional particle monolayers 
featuring a hydrophobic core for stability, OEG or PEG layer for biocompatibility, and 
recognition elements on the surface for interaction with biomolecules. 
1.4 Applications of Nanoparticles in Biology 
Applications of nanometrials in biotechnology merge the interface between 
material science and biology. The development of biocompatible nanometrials for 
enhancing or modifying the bio-properties is the new challenge in the biotechnology 
field. Here I will highlight few recent research activities involving the use and diverse 
applications of nanoparticles in biology. Those applications can be classified in four 
main categories, a) biomolecular interactions, b) application in drug and gene delivery, 
c) biosensing and d) bioimaging. 
1.4.1 Recognition of Biomolecules 
Based on the surface functionality and properties bio-macromolecules can be 
sub-divided into two categories, nucleic acid and proteins. Binding of DNA with 
receptors can be happen in three ways, surface binding, groove binding and 
intercalation.44 A number of small synthetic and natural receptors have been utilized to 
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bind specific DNA sequences,45 and to inhibit46 or activate47 DNA transcription. 
Similar to naturally occurring protein-nucleic acid interactions, nanoparticles with large 
surface area and multivalent recognition unit can serve as an attractive receptor for 
nucleic acids.48 The binding between nanoparticles and DNA can be achieved in three 
ways.  First, nanoparticles can be functionalized with a highly selective complementary 
single strand of DNA, which can display excellent sequence specificity (Figure 1.4a).49 
Secondly, we can use complementary electrostatic interactions to promote high affinity 
of nanoparticle-DNA binding. As the nucleic acids are negatively charged due to its 
phosphate backbone, inserting appropriate cationic ligands onto nanoparticle surface 
can provides effectual receptors for DNA, for example the use of NP1 to recognize a 
37-mer DNA duplex (Figure 1.4b) by our group.50 The binding of the DNA inhibited 
transcription by T7 RNA polymerase, indicating the high affinity of the NP-DNA 
complex, and pointing out a potential use of these systems in gene delivery into cells 
and the protection of DNA from enzymatic cleavage.51 Intercalation provides another 
mechanism for DNA binding, as demonstrated by Murray et al. by useing ethidium 
bromide (Eb) as a means of binding cationic and anionic gold nanoparticles to DNA.52 
 
Figure 1.4. The DNA-nanoparticle interactions. a) Binding of DNA through 
complementary oligonucleotide hybridization. b) Structure of NP1 scaffold and the 
DNA backbone. The interaction is directed by electrostatic interaction.  
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The interaction of protein with nanoparticles is more complex compare to the 
DNA, due to its diverse shape, size and charge on the surface. The complexation 
between protein and nanoparticle can be achieved either by noncovalent interaction 
(e.g. electrostatic, hydrophobic, p-p stacking etc.) or by specific interaction (e.g. 
antigen-antibody interaction, metal complex formation etc.) (Figure 1.5). The 
noncovalent complexation can be achieved by electrostatic interaction by using 
oppositely charged nanoparticle in respect to protein. One system that has been 
explored is the binding of α-chymotrypsin (ChT), utilizing the ring of cationic residues 
around active site of ChT (Figure 1.5a).53 The inhibition of ChT activity was observed 
upon incubation with negatively charged NP 2.54 A two-step binding process with a fast 
reversible association followed by a slower irreversible denaturation was established by 
our group. The above conception of complementary electrostatic interaction was also 
used for positively charged nanoparticles with negatively charged proteins. Positively 
charged nanoparticle bind with negatively charged protein such as β-Galactosidase (β-
Gal), and inhibits its activity which was again reactivated by the addition of glutathione. 
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Figure 1.5. Protein-nanoparticle conjugation. a) Electrostatic targeting of ChT by 
anionic NP 2 b) Structure of NTA-modified magnetic nanoparticles and the NTA-Ni2+ 
functionalized magnetic nanoparticles selectively bind to histidine-tagged proteins. 
 
As nanoparticles can be fabricated with numerous ligands in a small volume, 
they can use as a multivalent receptor to enhance low affinity interactions such as 
carbohydrate-protein interactions.55 As an example, Lin et al. prepared mannose 
functionalized gold nanoparticle56 and it was found that the nanoparticles showed high 
affinity to Con A in compare to single mannose (binding constant: 107 – 108 dm3 mol-1, 
10-100-fold higher affinity than that of monovalent mannose ligands).  
Specific biomacromolecular interactions such as streptavidin/biotin 
complementarity (Ka ~ 1014 M-1) have been used to provide specific protein-NP 
binding.57 Biotin functionalized quantum dots (QDs) were used for specific protein 
binding in time-resolved fluoroimmunoassay.58 Another way to specifically bind 
proteins is through the use of transition metal complexes that can bind with surface-
exposed histidines of proteins. Xu et al. fabricated FePt magnetic nanoparticle NP 3, 
with nickel-terminated nitrilotriacetic acid (NTA).59 These NPs show high affinity and 
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specificity towards histidine-tagged proteins (proteins with six consecutive histidine 
residues) (Figure. 1.5b).  
1.4.2 Application in Targeted Delivery 
For successful delivery, carriers must: 1) form condensed complexes with 
therapeutic molecules, 2) reach the target position, 2) facilitate penetration of the cell 
membrane and (3) unload their payloads inside of cells. In this aspect nanoparticles can 
be used as potential DDSs due to its advantageous characteristics as mentioned 
previously. Nanoparticle based drug delivery can be presented in two categories: 1) 
delivery using surface property or surface bounded drug molecules and 2) nanoparticles 
as a delivery vehicle.  Here three interesting studies are highlighted where nanoparticles 
are used to deliver drug, gene and protein. According to the first category Mixed 
monolayer protected gold clusters were exploited for in vitro delivery of a hydrophobic 
fluorophore (BODIPY); an analog of hydrophobic drugs, and release of the fluorogenic 
ligand in a controlled fashion.60 Cationic nature of the nanoprticles facilitates the 
penetration of cell membrane and the release was triggered by intracellular glutathione 
(GSH) since the concentration of GSH inside the cells is around 1000 fold more than 
extracellular environment. 
RNA technology has appeared in twenty first century as a potential tool for 
curing disease at early stage. Gene can be efficiently silenced by small interfering RNA 
(siRNA), generally consists of 19-21 base pairs. This siRNA has been conjugated by a 
thiol linker with variety of nanoparticles, such as gold,61 quantum dots,62 or iron oxide 
for in vitro delivery.63 Moore et al. designed a superparamagnetic nanoparticle to 
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perform multiple functions such as, carry the siRNA, deliver in a site-specific manner 
and probe the delivery by magnetic resonance imaging as well as optical imaging.63 The 
multifunctional nanoparticle was effective for in vitro and in vivo gene silencing via a 
specific pathway.   
Protein delivery has emerged as a complementary to nucleic acids delivery in 
the field of biomedicine. Nanoparticles can efficiently recognize protein, and hence 
create the opportunity of using them as protein delivery systems. Lin et al have 
fabricated MCM-41 type mesoporous silica nanoparticles (MSN) as protein carriers 
(Figure 1.6).64 These MSN can incorporate cytochrome c, a membrane-impermeable 
protein, into their large pores (diameter = 5.4 nm), and slowly release the proteins in 
active form under physiological conditions. The particles were also effective in delivery 
of cytochrome c human cervical cancer cells (HeLa). 
 
Figure 1.6. Schematic illustration of cellular delivery of cytochrome c using 
mesoporous silica nanoparticles. 
1.4.3 Nanoparticles in Bio-Sensing 
A sensor generally consists of two components: 1) recognition element for target 
binding and 2) transduction element for signaling the binding event. The large surface-
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to-volume ratio with the electronic and optical properties makes the nanoparticles as a 
potential system in sensor application. Nanoparticles are applied in the detection of 
various biomolecules such as, oligonucleotides, proteins, and microorganisms. Based on 
the regulating properties such as absorbance, quenching, conductivity etc. the 
nanoparticle based biological sensing can be sub-categorized in several group, such as, 
1) colorimetric Sensing, 2) fluorescence Sensing 3) electrochemical Sensing etc. Some 
of the very interesting studies of each kind have been highlighted here. In first kind of 
sensing is the controlled assembly of nanomaterials alters the interparticle surface 
plasmon coupling, resulting in a visual color change. Using this control aggregation of 
the particles, a range of biomolecules from polynucleotides to proteins are detected.65  
DNA functionalized nanoparticles have been assembled or aggregates with 
complementary DNA strand through Watson-Crick base pairing which is first described 
by Mirkin et al. in 1996.49 After that, the oligonucleotide mediated nanoparticle 
aggregation process was extensively used for the development of simple and highly 
sensitive colorimetric biosensors for oligonucleotides.66, 67 The general procedure for 
the detection of the oligonucleotides was done by the fabrication of the nanoparticles 
with two complementary single strands DNA of the both ends of targeted 
oligonucleotides. According to the Figure 1.7, the particles are aggregated and changed 
the color of the solution. Using this method oligonuceotides are detected at 
subpicomolar level without the assistance of polymerase chain reaction (PCR).68  
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Figure 1.7. Schematic illustration of a) DNA-induced nanoparticle aggregation and b) 
sensing of DNA triplex binder using DNA-directed AuNP assembly. 
 
The high quenching ability of gold nanoparticles was used for molecular 
beacons construction for sensing the DNA strands using the intensity of fluorescence 
responses.69 According to the reported design, initially the dye molecule remains close 
to the nanoparticle surface due to hairpin structure of the attached DNA, resulting in an 
effective fluorescence quenching through FRET. As shown in the hybridization of 
target DNA opens up the hairpin structure and increase the distance between 
nanoparticle and dye, results in a significant increase in fluorescence. As the fluorescent 
intensity was only depends on the concentration of the target DNA, this system was 
used for DNA sensing.  A range of ssDNA and DNA cleavages ware detected using this 
molecular beacon approach.70 
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1.4.4 Nanoparticles in Bio-Imaging 
Based on the imaging techniques there are two different types of nanoparticles 
are well known, one is luminescent nanoprobes for OI and the other one is magnetic 
nanoparticles for MRI. There are also hybrid nanoparticles are reported which can 
concurrently detected both by OI and MRI.71 These nanoparticles are composed of 
luminescent agent and paramagnetic materials. 
The nanoparticle based optical imaging agent can be subdivided into two 
categories, the most popular one is quantum dots (QDs) and the other one is dye doped 
nanoparticles. The use of QDs for cell imaging was first reported by Nie72 and 
Alivisatos groups in 1998.73 An attractive example of self-illuminating QD conjugate 
was reported by So et al. for in vivo imaging.74 The requirement of external excitation 
for QDs sometimes limits their in vivo application due to opacity. They overcome this 
problem by designing this self-illuminating QD which can luminesce without the need 
for external excitation. They prepared this QD conjugets by coupling with carboxylate 
modified QDs to a mutant of the bioluminescent protein Renilla luciferase. The energy 
released by luciferase-catalyzed substrate catabolism was transferred to QDs via 
resonance energy transfer; end up with the emission from QD (Figure 1.8).  
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Figure 1.8. Conjugation of QDs with luciferase proteins. The luminescence released 
from QD during the luciferase catalyzed oxidation of coelenterazine is tranfered to the 
QD.  Bioluminescence and fluorescence imaging of QD and luciferase protein injected 
at indicated sites (I and III QD, II and IV luciferase protein). (a) Without filters. (b) 
With 575- to 650-nm filter. (c) Fluorescence imaging with filter, 503–555 nm. Adapted 
from reference no. 74. 
 
On the other hand the dye doped silica nanoparticle solves the problem of rapid photo-
bleaching of organic dyes. This dye doped silica particles are biocompatible and non-
toxic.75 
Another important non-invasive imaging technique is MRI. This is a very 
potential method to image in cellular and subcellular level. The MRI technique is based 
on the nuclear magnetic resonance of the interacting protons with each other and with 
the surrounding molecules. With recent development of molecular MRI the magnetic 
particles are used not only as a targeted imaging agent but also can image local enzyme 
activity and develop the multispectral MRI techniques.76 At present monodisperse, 
cross-linked iron oxide (CLIO) nanoparticles reported by R. Weissleder group are 
popular for the MRI.77 The CLIO nanoparticles are highly stable and a large variety of 
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ligands can be conjugated on the surface. This monodisperse, surface modified iron 
oxide nanoparticle CLIO-Cy5.5 and convenient ‘clickable’ nanoparticles ware used for 
targeted imaging with high cellular uptake.78 
Taking the advantage of both OI and MRI, multimodal imaging agents such as 
magnetofluroscent nanoparticles is now gaining the more popularity.79, 80 A realistic 
procedure for development of targeted magnetofluorescent nanoparticles is well 
described in a recent report by R. Weissleder’s group. According to that protocol first 
need to discover or choose the targeting ligands using high-throughput screening 
techniques. Then functionalization of the targeting ligands on the surface of the 
magnetofluorescent nanoparticles needs to do to enhance the target specificity. 
Overall nanoparticles present a prospective platform for the diverse biological 
applications. The surface and core properties of these systems can be engineered for 
multipurpose applications. Other than biomolecular recognition, therapeutic delivery, 
biosensing and bioimaging based applications; various well known applications are also 
reported. As an example, Scrimin’s group reported a peptide functionalized 
nanoparticles which show enzyme-like structure and properties. Those particles not 
only have a good esterolytic catalytic activity but also you can regulate its activity like 
natural enzymes.81 
1.5 Perspective of Fundamental Studies of Protein-Surface Interactions 
Fundamental studies on protein nanoparticle interaction are always an attractive 
point of interest, because it can explore the nature of the interaction which can be used 
for control recognition. Study of protein-surface interactions on planar surfaces, 
  18
however, is complicated by the inherent limitations in characterizing surface-bound 
proteins. While adsorption kinetics can be readily quantified using Quartz Crystal 
Microbalance (QCM)82 and Surface Plasmon Resonance (SPR) methods,83 the limited 
quantity of material contained in a monolayer can make assessing the activity of 
enzymes difficult. Spectroscopic characterization of adsorbed proteins is likewise 
difficult, with available methods generally limited to IR84 and fluorescence 
spectroscopy,85 and techniques such as CD and NMR difficult or impossible to apply. 
Of equal importance is the inherent difficulty of applying powerful thermochemical 
techniques as Isothermal Titration Calorimetry (ITC) to surface recognition processes.  
Nanoparticles provide a highly useful tool for studying protein-surface 
interactions. The high surface area and optical properties of these systems allow ready 
application of CD and fluorescence methods.86 Recent studies have also used 
unfunctionalized silica particles for Differential Scanning Calorimetry (DSC),87 though 
interestingly ITC has not been applied to these systems. Clearly, integration of these 
spectroscopic and calorimetric techniques with the structural diversity that can be 
generated using nanoparticles (vide infra) can provide a powerful tool for understanding 
and protein-surface interactions. Moreover, these interactions can be harnessed in a 
controlled fashion for a wide variety of applications such as protein refolding and 
sensing. 
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CHAPTER 2 
 
TUNABLE INHIBITION AND DENATURATION OF α-CHYMOTRYPSIN 
WITH AMINO ACID-FUNCTIONALIZED GOLD NANOPARTICLES 
2.1 Introduction 
2.1.1 Importance of Protein Surface Binding 
Protein surface binding and recognition by synthetic receptors is an emerging 
field in drug discovery and in medicinal chemistry. Surface recognition by artificial 
receptor is an alternative method to control the activation or inhibition of enzymatic 
process which greatly extends the number of protein targets for therapeutic 
development.1 
Biomolecular interactions are controller of a number of biological activities such 
as, cell enzyme activity,2 surface recognization,3 protein-protein interactions and 
protein- nucleic acid interactions.4 In recent examples, a direct physical interaction 
between the G protein-coupled A(2A) receptor (A(2A)R) and the receptor tyrosine 
kinase fibroblast growth factor receptor (FGFR) was observed where concomitantly 
activate these two classes of receptors, but not individual activation of either one alone. 
caused a robust activation of the MAPK/ERK pathway, which activate the signal 
transduction pathway that couples intracellular responses to the binding of growth 
factors to cell surface receptors. Hence by control on this interaction can open new 
avenues for therapeutic.5 Clearly, the control the protein- protein interactions by protein 
surface recognition represents an important target for chemical biology and 
pharmaceutical science. For the efficient binding by surface recognition we need to 
  26
consider some obstacles during designing synthetic receptors. The difficulty can be 
summarized by two basic requirements for an effective protein surface recognition. The 
first difficulty is high surface area of receptor-target interface. Insight into the 
requirements for receptor-protein contact area comes from examination of protein-
protein interactions,6 where a recent survey by Jones and Thornton7 of non-homologous 
protein dimers found that > 6 nm2 of surface area per protein is typically buried. The 
second difficulty is proper presentation of multivalent recognition elements including 
topological, hydrophobic, electrostatic and polar features.8  
2.1.2 Nanoparticle as an Artificial Receptor 
Nanoparticle based receptors, however, offer a potential platform for 
biomacromolecular surface recognition which is unique and distinctive in its own way.9 
The use of core-shell nanoparticle systems, such as monolayer protected clusters 
(MPCs) and mixed monolayer protected clusters (MMPCs) possess some distinctive 
and significant features that make them promising scaffolds for creation of receptors 
targeted to biomacromolecular surfaces. The first important feature is the size of the 
nanoparticle core can be tuned from 1.5 to 8 nm with overall diameters of 2.5-11 nm.10 
This variability of core sizes provides a suitable platform for the interaction of 
nanoparticles with biomacromolecules on comparable size scales (Chapter 1, Figure 
1.1). The second useful property of nanoparticles is that they can be fabricated with a 
wide range of surface functionality thus providing a versatile route to creation of 
surface-specific receptors. MPCs are easily synthesized in one step via the Brust-
Schiffrin11 reduction forming monolayer protected clusters (MPCs). The selection of 
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thiols used during synthesis controls the functionality of the monolayer surface, while 
the stoichiometry controls the particle size.12 Mixed monolayer protected clusters 
(MMPCs) are easily fabricated using the Murray place displacement reaction4 via 
incubation of functional thiols and MPCs (Chapter 1, Figure 1.2).  This provides a 
unique tool for achieving efficient and specific recognition of protein surface via 
complementary surface interaction. The third important feature of MMPCs is that a 
range of metal and semiconductor cores can be generated featuring useful electronic, 
fluorescence, and magnetic properties which allow for use as probes and/or diagnostic 
agents. Finally, these systems have been shown to self-template to guest molecules 
allowing an increase in the affinity and selectivity upon incubation with the guest 
molecules (Figure 2.1).13, 14 MPCs and MMPCs provide a definite advantage over the 
conventionally used synthetic receptors, which are limited in their ability to mimic 
biological interactions due to their inherent rigidity. 
 
Figure 2.1. Schematic representation of ligand mobility on nanoparticle surface. 
2.1.3 α-Chymotrypsin - A Model Protein 
We decided α-chymotrypsin (ChT) as a model protein for our protein surface 
recognition by using nanoparticles as a receptor. ChT, a serine protease of molecular 
weight 25kDa,15 was used for protein surface recognition for several reasons.16 First 
ChT is well characterized photolytic enzyme with well established activity assessment. 
A series of substrates are already developed to monitor the enzymatic activity by using 
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either absorbance or fluorescence measurement.15 Second the structure of the protein is 
well explored. According to the structural analysis a ring of cationic residue is present 
surrounding the active site (“hot spot”) of the enzyme (Figure 2.2).17 The center of the 
ring, active site of ChT has an abundance of hydrophobic and aromatic residues. Hence 
this “hot spot” is an ideal target for the nanoparticles surface with anionic and 
hydrophobic residues for fundamental studies on surface binding based on 
complementary electrostatic and hydrophobic interactions. Third the change of 
secondary structure can be easily monitored by comparing with well established circular 
dichroism (CD)18 and tryptophan fluorescence response.19 Furthermore the size of this 
enzyme (~ 5 nm diameter) is well appropriate with the range of nanoparticles which can 
be easily synthesized and fabricated.  
 
Figure 2.2. Surface residues on ChT. The ring of cationic residues situated around the 
active site. 
2.1.4 Inhibition of α-Chymotrypsin using Anionic Nanoparticles 
Anionically functionalized nanoparticle (NP 1) was fabricated to target the 
positive circle surrounding the active site channel of ChT.20 Time-dependent inhibition 
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of ChT was observed with anionic particles; however cationic control particles (NP 2) 
had no effect. From initial rate studies (Figure 2.3b), it was determined that between 
four to five ChTs were inhibited per nanoparticle (Binding ratio of nanoparticle:ChT  is 
1:4 to 5). The electrostatic nature of the interactions was supported by the fact of little 
or no interaction was observed with cationic proteins such as elastase or β-
galactosidase. Moreover, dynamic light scattering (DLS) studies confirm that inhibition 
proceeds with only protein nanoparticle interaction without any extended aggregation. 
 
Figure 2.3. a) Anionic and cationic nanoparticle NP 1 and NP 2, respectively. b) Initial 
velocities for ChT hydrolysis of benzoyl tyrosine p-nitroanilide (BTNA).  
 
After that circular dichroism (CD) analysis was used to follow structural 
changes occurring upon protein-nanoparticle binding (Figure 2.4a). From these studies, 
it is clear that the secondary structure of chymotrypsin is dramatically changed with 
time after incubation with NP 1. The conformation of chymotrypsin (3.2 μM) was 
measured after initial mixing with NP 1 and at various time intervals at room 
temperature. Addition of either 0.8 or 2.1 μM nanoparticle affected a substantial 
increase in the intensity of the minimum at 202 nm. But in all cases the characteristic 
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minimum at 230 nm for native ChT was not observed.  Upon further incubation, this 
minimum was shifted to lower wavelengths, indicating a conformational shift toward 
random coil. 
To determine the binding and denaturation rate the inhibition kinetics of the 
nanoparticle were determined. The kinetic study indicated an initial inhibition followed 
by a second phase of time-dependent inhibition. Progress curves were studied at 
different concentrations of nanoparticle, providing the pseudo first-order rate constant 
(kobs) for each concentration of nanoparticle while keeping chymotrypsin and substrate 
concentrations fixed at 10 nM and 150 mM, respectively. Fitting these data provided a 
Ki(app) of the nanoparticle of 10.4±1.3 nM. The zero intercept of this fitted curve 
indicates, as expected, that the inhibition is irreversible. A double reciprocal plot of 
these data results in a non-zero intercept, confirming the two-step mechanism of 
inactivation (Figure 2.4b).21 
 
 
Figure 2.4. a) Circular dichroism of chymotrypsin ([ChT]=3.2 μM) after 24 h 
incubation with NP 1 and after thermal denaturation b) Schematic representation of 
two-step inactivation and denaturation mechanism. 
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2.1.5 Stabilization of Protein Structure by Tailored Nanoparticles 
The above nanoparticle protein interaction results in protein denaturation. In 
practical many applications need to retain the native enzyme structure upon binding. 
According to the proposed hypothesis, the first reversible binding event is electrostatic 
in nature, while the denaturation process results from nonspecific interaction of internal 
hydrophobic residues of protein with the nanoparticle monolayer.  
One way to inhibit the denaturation process during protein-nanoparticle binding 
would be to create a “barrier” between the hydrophobic nanoparticle interior and the 
exterior electrostatic recognition elements. This barrier would have the added benefit of 
enhancing the specificity of the receptor by reducing non-specific hydrophobic 
interactions between the nanoparticle and other proteins. Ethylene glycol oligomers 
provide a likely candidate to serve as a barrier. PEG-based functionality has been 
widely used to impart biocompatibility and antifouling properties on planar substrates22 
and nanoparticles.23 Previous studies have shown that the use of a sandwich structure in 
which a PEG chain is appended to an alkanethiol provides robust particles.24 
To established this hypothesis, 3 nm core CdSe nanoparticles featuring 
composite alkanethiol-tetra(ethylene glycol) (TEG) monolayers were prepared.25 For 
comparison, CdSe nanoparticles are similar to their Au counterparts, with somewhat 
less well-packed monolayers. Also the similar behavior CdSe nanoparticles extend the 
applicability of this system in different core materials with other potential properties. In 
the studies, three different sidechains: hydroxyTEG (NP 3), carboxyTEG, (NP 4), and 
mercaptoundecanoic acid (NP 5) (Figure 2.5) were used to probe the effect of TEG 
spacer.  The interaction between NP 3-NP 5 and ChT was explored via kinetic assay, 
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fluorescence assay, and CD. As expected, NP 3 did not interact with ChT, as evidenced 
by the lack of inhibition, and the absence of change in the tryptophan fluorescence and 
CD signatures of ChT. NP 4 behaved in similar fashion to its counterpart NP 1, with 
rapid inhibition observed. This inhibition was accompanied by a 20 nm red shift in the 
tryptophan fluorescence over a five-hour time span, indicative of dramatic 
reorganization of protein secondary structure. Most eloquently, this reorganization is 
mirrored in the shift in the CD, including the loss of the diagnostic minimum at 230 nm, 
and shift of the minimum from 207 nm to 199 nm, indicative of essentially complete 
denaturation.  
 
Figure 2.5. a) Behavior of nanoparticle NP 3-NP 5 with chymotrypsin. b) CD spectra 
of ChT-nanoparticle mixtures. 
 
Of particular interest is NP 4, which appends a terminal recognition element to 
the TEG protective layer. As with NP 5, NP 4 demonstrates a time-dependent 
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inhibition, although over a much longer period. Structural studies, however, indicate 
little change in protein conformation upon binding. A relatively modest red shift is 
observed in the tryptophan fluoresence, with a shift of only 6 nm observed when 
maximal inhibition is achieved. The retention of native conformation was confirmed by 
CD, where essentially no change in either maxima observed over the 24 hr study. Taken 
together, the results observed with NP 4 indicate that inhibition can be decoupled from 
denaturation.  
Now, from this above study the complexation between nanoparticle and protein 
is only govern by electrostatic interaction, but if we consider the natural protein-protein 
interaction, that is involved along with electrostatic interaction other noncovalent 
interaction such as hydrophobic interaction, π-π stacking and hydrogen bonding. One of 
the goals of creating nanoparticle based artificial receptor is the possible 
multifunctionality on the surface.   Hence the following analysis26, 27 was carried out to 
answer the following two important questions: 1) what level of specificity can we 
obtain through choice of surface functionality and 2) what factors contribute to 
stabilization/denaturation of nanoparticle-bound proteins? 
2.2 Amino Acids Fabricated Nanoparticle as a Recognition Scaffold 
Amino acids provide an attractive means for generating structural diversity.28  In 
the current study, we have fabricated a series of L-amino acids functionalized gold 
nanoparticles and examined their interaction with ChT (Figure 2.6).  The amino acid-
decorated surfaces represent the simplest mimics of protein surfaces.  Their interaction 
with proteins thus exhibits much more resemblance with the naturally occurring 
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protein-protein systems.  In this study, we have found that the interactions between ChT 
and these nanoparticles depend on the surface composition of nanoparticles.  
Significantly, the binding affinity as well as the stability of the protein is regulated by 
the charge and the hydrophobicity of amino acid side chains in the nanoparticles.  
Therefore, it is possible to control the association/dissociation and 
stabilization/denaturation of the protein at the nanoparticle interfaces through variation 
of the extra functionality in the vicinity of carboxylic acid recognition elements. 
 
Figure 2.6. a) Amino acid-decorated nanoparticle surface that consist of carboxylic acid 
recognition elements as well as extra functions for perturbation. b) The relative sizes of 
amino acid-functionalized gold nanoparticles and ChT.  The surface of ChT is patterned 
with the electrostatic surface potential, showing basic and acidic domains on protein 
surface. 
2.2.1 Result and Discussion 
2.2.1.1 Fabrication of Amino Acid-Functionalized Gold Nanoparticles 
ω-functionalized n-alkanethiols have been widely used as building blocks in 
self-assembled monolayers on gold for various applications for several years.29  While a 
number of oligopeptide functionalized thioligands have been  designed and 
synthesized,30, 31 amino acid terminated thioligands have hardly been reported so far.32 
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Eventually, the latter can provide more fundamental information on the monolayer 
construction as well as the corresponding application in either material or biological 
technology.  For example, variation in amino acid side chain structure will allow us to 
probe the effect of hydrophobic groups (e.g. Leu, Val), additional anionic functionality 
(e.g. Asp, Glu), cationic groups (e.g. Arg), and hydrogen bonding functionality (e.g. 
Asn, Gln). 
Carboxylic acid terminated nanoparticle clusters have proven to be able to bind 
ChT and inhibit its activity through complementary electrostatic interaction.20  The 
additional tetra(ethylene glycol) tethers in the nanoparticles, however, minimizes the 
nonspecific protein adsorption and preserve the secondary structure of proteins as 
well.25 In this context, trityl protected 26-mercapto-3,6,9,12,15-pentaoxahexacosan-1-
oic acid 1 was prepared according to Houseman and Mrksich’s protocol33 and used as 
the starting compound for the preparation of amino acid functionalized thioligands.  As 
shown in Scheme 2.1, two methods were used to synthesize aminoacid terminated thiol 
ligands.  In first method, target thioligands 4 were synthesized by the reaction of 1 with 
L-amino acid tert-butyl esters in dry dichloromethane through the activation of 
carboxylic acid function by dicyclohexylcarbodiimide (DCC), followed by removal of 
trityl and tert-butyl groups in trifluoroacetic acid (TFA) with triisopropylsilane as a 
hydride donor.34  Alternatively, the coupling reaction of 1 with N-hydroxysuccinimide 
afforded corresponding active ester, which was further reacted with free L-amino acids 
in a mixed solvent of THF and H2O and treated with TFA to give the amino acid 
ligands 4.  Detailed synthetic procedures are described in experimental section. 
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Scheme 2.1. Synthesis of L-amino acid-terminated thioligands 
 
Once the amino acid functionalized alkanethiols were obtained, they were 
subject to the well-established ligand exchange reaction10 with 1-pentanethiol coated 
gold nanoparticle (C5-NP, d ~ 2.0 nm).11 While C5-NP is highly soluble in 
dichloromethane, the ligand exchanged nanoparticles were fully precipitated from the 
solution.  Thus, the nanoparticles were conveniently collected by centrifugation.  All of 
the resultant nanoparticles show good solubility in water.  Scheme 2.2 illustrates the 
fabrication of amino acid decorated gold nanoparticles and their structures and 
corresponding IDs. As Murray and coworkers’ research has demonstrated that place 
exchange proceeds in a 1:1 stoichiometry,35 ~100 amino acid ligands are estimated to 
be present on our 2 nm core particles.  
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Scheme 2.2. Fabrication of L-amino acid decorated gold nanoparticles through place-
exchange reaction. 
2.2.1.2 ChT Activity Assays and Binding Affinity 
It was previously established that negatively charged nanoparticles can block the 
active site and subsequently diminish the accessibility of negatively charged substrates 
to the catalytic center as the ChT active site is surrounded by cationicresidues, resulting 
in the inhibition of ChT activity.20,25  In order to probe the effect of various amino acid 
residues on nanoparticle, the ChT-catalyzed hydrolysis of SPNA were firstly examined 
in the presence of various concentrations of nanoparticles.  The activities of ChT in the 
presence of nanoparticles were normalized to that of free ChT. 
    The results show that the nanoparticles exhibit quite different degree of 
inhibition on the activity of ChT.  For most amino acid decorated gold nanoparticles, 
the rate of ChT-catalyzed hydrolysis of SPNA decreased upon the increase of 
nanoparticle concentration. This phenomenon clearly suggested the activity inhibition 
through complex formation.  The residual activity reached saturation at higher NP/ChT 
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ratio.  The only exception is Arg terminated gold nanoparticle, which has no inhibition 
on the activity of ChT, indicating that no significant interaction exists between ChT and 
NP_Arg.  By contrast, slight superactivity of ChT was observed in the presence of 
NP_Arg. Apparently, the guanidine side chain of L-arginine might generate a positively 
charged shell at the surface of the nanoparticle, so that the electrostatic interaction 
between ChT and NP_Arg is unfavorable.  All the other hydrophobic, neutral polar or 
negatively charged amino acids decorated gold nanoparticles show considerable 
inhibition of ChT activity, substantially suggesting that the complementary electrostatic 
interaction dominates the formation of ChT-NP complexes.  The normalized activity of 
ChT (3.2 μM) in the presence of NPs (0.8 μM) with variable side chains is represented 
in Figure 2.7a 
 
Figure 2.7. Normalized activity of ChT (3.2 μM) with nanoparticles (0.8 μM) bearing 
various amino acid side chains. b) Nonlinear least-squares curve-fitting analysis of the 
activity assay data ([ChT] = 3.2 μM). 
 
From Figure 2.7a, we also noticed that the inhibition of ChT activity depends 
critically on the side chain properties of nanoparticles.  While no inhibition effect was 
observed for NP_Arg, the nanoparticles with polar side chains, e.g. NP_Asp, NP_Asn 
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and NP_Glu, showed the strongest inhibition of around 80%.  Whereas, the 
nanoparticles with hydrophobic side chains exhibited less pronounced inhibition, e.g. 
NP_Met and NP_Ala showed only 60% inhibition.  This observation is presumably 
attributed to the hydrophobicity difference of ChT active site in the presence of 
different nanoparticles.  Upon interaction with nanoparticles bearing hydrophobic side 
chains, the hydrophobic pockets of ChT active sites were also extended to a certain 
extent in addition to the disadvantageous block of them.  Such hydrophobic active sites 
are considered to be more accessible by SPNA in comparison with that surrounded by 
nanoparticles bearing polar side chains, since the phenylalanine residue in the substrate 
need first to be bound into the active site during the enzyme-promoted cleavage of 
peptide bonds.  As a result, more residual activity of ChT was detected even in the 
presence of higher concentration nanoparticles. 
   The activity assay results were further analyzed by curve fitting analysis to 
assess the association strength between ChT and nanoparticles.  For that we assumed 
that nanoparticles have a number of identical and independent binding sites. The 
microscopic binding constants (KS) and binding ratios (n) can be simultaneously 
estimated by using nonlinear least-squares curve-fitting analysis on the data of activity 
assays (details in experimental section).  Representative fitting curves are shown in 
Figure 2.7b, in which no serious deviations are observed and the excellent curve fits 
indicate the reliability of the binding model.  The binding constants and binding ratios 
are summarized in Table 2.1. 
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Table 2.1. Microscopic binding constant (KS), Gibbs free energy Change (−ΔG), and 
binding ratio (n) for the complexation of ChT with nanoparticles in phosphate buffer (5 
mM, pH 7.4) at 30 °C.  The error of binding constants was usually less than 20%. 
 
Nanoparticle KS / 106 M-1 −ΔG / kJ mol-1 n 
NP_Gly 2.9 37.5 7.3 ±1.5 
NP_Ala 7.8 40.0 6.2 ±0.2 
NP_Asn 2.7 37.3 6.7 ±0.9 
NP_Asp 2.2 36.8 13.1 ±0.3 
NP_Gln 3.0 37.6 6.8 ±0.5 
NP_Glu 2.4 37.0 9.1 ±0.7 
NP_Leu 5.9 39.3 6.4 ±0.4 
NP_Met 13.1 41.3 6.4 ±0.2 
NP_Phe 7.1 39.8 6.8 ±0.7 
NP_Val 8.1 40.1 7.6 ±0.2 
 
Like activity inhibition, the binding constants are also dependent on the nature of 
the side chains of the nanoparticles.  For nanoparticles with hydrophilic amino acid side 
chains the binding constants are around 3×106 M-1, comparable to that of NP_Gly.  
Whereas for nanoparticles with hydrophobic amino acid side chains, considerably 
enhanced binding affinity is observed.  For NP_Met, the highest binding constant of 
1.3×107 M-1 was obtained, which is four times of that for reference nanoparticle 
NP_Gly. This result also indicates that the hydrophobic side chain might aid the 
interaction between nanoparticles and ChT.  To correlate the hydrophobicity effect the 
Gibbs free energy changes for the complexation of ChT with various nanoparticles were 
tentatively plotted against the hydrophobicity index36 of amino acid side chains. The 
correlation suggest that the binding affinity of nanoparticles increases according to the 
hydrophobicity increase of amino acid side chains (Figure 2.8).  
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Figure 2.8. Correlation between Gibbs free energy changes and hydrophobicity index 
of amino acid side chains.  Trend line represents the linear fit of the correlation data. 
 
As is well known, the surface of ChT consists of both cationic and hydrophobic 
patches.37  Therefore, in addition to the well-characterized electrostaltic interactions, 
the hydrophobic amino acid side chains are proposed to be able to selectively interact 
with the hydrophobic patches on the ChT surface when the nanoparticles approach to 
the surface of ChT.  Such supplementary hydrophobic interaction enhances the stability 
of ChT-NP complexes.  However, electrostatic interaction is still the major driving 
force.  For NP_Met, for instance, only 10% of the Gibbs free energy change originates 
from the hydrophobic interaction. At this point it is noteworthy that these binding 
affinities lie still at the lower limit for many enzyme-inhibitor complexes (e.g. 107 to 
1013 M-1),38 probably due to the fact that the geometric compensation between the 
current artificial receptors and the protein is not as good as that in the natural systems.   
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2.2.1.3 Gel Electrophoresis and Binding Ratio 
 From the curve fitting analysis it should be noted that most nanoparticles have 
binding stoichiometries of around 7, except for NP_Asp and NP_Glu that have 
considerably higher values (13 and 9, respectively). This curve fitting analysis 
unambiguously was supported by the gel electrophoresis results of the ChT-NP 
complexation.  Also the narrow bands observed for the ChT-NP complex suggest the 
formation of discrete complexes rather than extended ChT-NP aggregates.  
Additionally, the gel electrophoresis experiments clearly show that the binding 
stoichiometry of monobasic amino acid functionalized nanoparticle (NP_Asn) and ChT 
is 1:7, while the value for NP_Asp and ChT is 1:12 (Figure 2.9). The gel 
electrophoresis studies on the other nanoparticle/ChT systems gave concurrent results 
with activity assays. 
 
Figure 2.9. Gel electrophoresis of ChT and NP_Asn (a) and NP_Asp (b). Nanoparticle 
concentrations were varied at a constant ChT concentration (50 μM). 
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Our previous study revealed that the binding ratio NP 1:ChT is 1:4 to get the 
complete inhibition of ChT  (NP 1 - 11-mercaptoundencanoic acid capped gold 
nanoparticle, d = 5.5 nm).  The diameters of current nanoparticles are significantly 
larger than NP 1 by 4.5 nm (2 nm Au core + ~8 nm for the ligand chain), along with an 
increase in surface area of more than 3-folds.   
As the binding stoichiometry is critically dependent on the area of nanoparticle 
surface, then all the nanoparticles should have a binding ratio of 1:>12.  But this 
binding ratio is not fitted with all nanoparticles. From the structural point of view, the 
number of carboxylates in NP_Asp and NP_Glu are twice than the other nanoparticles.  
Then, it seems that the surface charge density also affect the binding ratio.  X-Ray 
single crystal analysis revealed that 12 positively charged residues (L-Lys and L-Arg) 
are located on the same side of ChT surface (Figure 2.1),17, 37 which are considered to 
take part in the electrostatic interaction with nanoparticles.  On the other hand, it has 
been demonstrated that roughly 100 ligands surround the Au core in 2 nm gold 
nanoparticles.35  Therefore, if the electrostatic interaction takes place in a 1:1 
negative/positive charge ratio, NP_Asn and other monocarboxylic amino acid 
functionalized nanoparticles can bind 8 ChT molecules, while NP_Asp and NP_Glu 
have the capacity of associating 16 ChT molecules.  These values are quite closed to the 
observed binding stoichiometry. 
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Figure 2.10. Schematic representation for the binding modes of ChT with NP_Asn (a) 
and NP_Asp (b).  In the former case, the surface carboxylate functions are proposed to 
reorganize to maximize the electrostatic interactions. 
 
To get direct evidence on the surface charge disparity of these two 
nanoparticles, ζ potentials were measured in 100 mM sodium phosphate buffer solution 
(pH 7.4) at 25.0 °C.  The ζ potentials of NP_Asn and NP_Asp are −26.2 mV and −32.5 
mV, respectively, explicitly showing that the latter possesses a more negatively charged 
surface.  In this situation, one rational explanation for the variant binding ratio is that 
the flexible nanoparticle surfaces would adopt allosteric conformations to achieve the 
maximal amount of electrostatic interactions during the complexation process (Figure 
1.10).  The surface of NP_Asn is less saturated than that of NP_Asp by the protein, 
since the former has fewer recognition elements (i.e. carboxylates) on the surface.  The 
charge complementary interaction between ChT and NP is therefore not only dependent 
on the relative surface areas, but also the number of recognition units.   
2.2.1.4 Circular Dichroism Study 
Circular dichroism (CD) spectra have been extensively used to explore the 
absolute conformation of biological macromolecules.  This powerful tool enables us to 
get much primary information about the effect of nanoparticle association on the 
secondary structure of ChT.  Figure 1.11 illustrates the CD spectra of ChT and ChT 
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with different nanoparticles after 24 h incubation.  It is interesting that the CD spectra of 
ChT are significantly regarded to the amino acid side chains of nanoparticles.  While 
almost no change in the CD spectrum of ChT was observed with NP_Leu, 
nanoparticles with Asn and Asp side chains induced different levels of CD spectral 
changes of ChT, i. e. the impairment of the characteristic minimum at 232 nm and the 
hypochromic shift of the minimum at 204 nm.  The analysis explored that ChT are little 
influenced by the presence of nanoparticles bearing hydrophobic amino acid side chains 
such as NP_Phe or NP_Leu, while ChT experiences considerable CD spectral changes 
in the presence of nanoparticles bearing polar amino acid side chains, e. g. NP_Gln, 
NP_Asp etc. NP_Arg does not perturb the CD spectrum of ChT.  This phenomenon is 
reasonable since no complexation exists between these two species as demonstrated by 
activity assay. The spectral changes are found time-dependent, suggesting that the polar 
amino acid side chains induced the conformational changes of ChT, whereas the 
hydrophobic amino acid side chains promote the retention of ChT structure. 
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Figure 2.11. Circular dichroism spectra of ChT (3.2 μM) and ChT with nanoparticles 
(0.8 μM) after 24 h incubation. 
 
The amounts of secondary structure in proteins, including α-helices, β-sheets, β-
turns and random coils, could be evaluated from the far-UV CD spectra via a number of 
well-established algorithms.39  The current far-UV CD spectra were subject to analyze 
by using CDSSTR method in the CDPro package.  Spectral deconvolution of native 
ChT spectrum in buffer solution showed 6.5% of α-helices, 32.5% of β-sheets, 26% of 
β-turns and 33.8% of random coils, very similar to previously reported values obtained 
through X-ray crystal methods.40  Because no significant CD spectral changes have 
been observed for the interaction between ChT and nanoparticles with hydrophobic 
amino acid side chains and NP_Arg, the calculated compositions of the secondary 
structure were also essentially the same as that of native ChT.  Nevertheless, the 
interaction with nanoparticles bearing hydrophilic amino acid side chains led to evident 
changes in the secondary structure of ChT.  Representatively, the spectral 
deconvolution results for ChT in the presence of NP_Asp showed decreases of α-
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helices and β-turns to 4.2% and 23.7%, respectively, and increases of both β-sheets and 
random coils to 35.3% (For the secondary structure compositions of ChT in the 
presence of other nanoparticles, see Supporting Information).  As is well known that the 
hydrophobic interaction between amino acid side groups in the protein’s interior 
supports the formation of α-helices, the decrease in the α-helix content indicates the 
destabilization of such interaction.  Besides the surface electrostatic interaction with 
ChT, the hydrophilic amino acid side chains are feasible to competitively form 
hydrogen-bonds with the amino acid residues in α-helices, resulting in the 
destabilization of α-helices and the increase of β-sheets and random coils.  By contrast, 
the hydrophobic amino acid side chains might interact with the hydrophobic patches of 
ChT and stabilize the protein’s globular geometry through favorable hydrophobic 
interaction. 
2.2.1.5 Fluorescence and Denaturation Kinetics 
To obtain insight into the denaturation process of ChT in the presence of 
nanoparticles, the characteristic fluorescence of tryptophan residues in ChT was further 
investigated using steady-state fluorescence spectrometry.  As shown in Figure 1.12, the 
intrinsic emission of ChT shows a maximum at 331 nm in buffer solution.  However, 
significant bathochromic shifts and peak broadening were observed after incubation 
with nanoparticles for 24 h.  The maximal fluorescence shift of 23 nm was observed for 
the ChT incubated with NP_Asp, with concomitant broadening of half-maximal 
amplitude from 52 nm to 68 nm.  These phenomena indicate that the initially buried 
tryptophan residues were rather exposed to more polar environment due to the 
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destructure of the protein.41 The denaturation extent of ChT is reflected by the different 
values of fluorescence shift, which is again regard to the properties of amino acid side 
chains in nanoparticles. 
 
Figure 2.12. Fluorescence spectra of ChT (3.2 μM) and ChT with nanoparticles (0.8 
μM) after 24 h incubation. 
 
The denaturation of ChT should occur in a two-state process as described in 
equation (1):   
DN k −⎯→⎯− ChTChT                 (1) 
where ChT-N is the native form and ChT-D the denatured form, k denotes the rate 
constant.  In principle, the denaturation should follow a first-order reaction profile. 
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Figure 2.13. a) Linear plots for the first-order chymotrypsin denaturation in the 
presence of different nanoparticles in 5 mM sodium phosphate buffer (pH 7.4). b) 
Correlation between the denaturation rate constants (k) of ChT and the hydrophobicity 
index of amino acid side chains in nanoparticles. 
  
In Figure 2.13a, the logarithm of native ChT concentration was plotted against time.  
Good linear regressions were found for all systems, unambiguously confirming the first-
order denaturation profiles.  Interestingly, the rate of denaturation decreases 
significantly with the increase of the hydrophobicity of amino acid side chains.  The 
rate constants obtained by the linear regression are listed in Table 2.2 
Table 2.2. Rate constants of the denaturation of ChT in the presence of different 
nanoparticles. 
 
Nanoparticles k / 10-6 M-1 s-1 
NP_Gly 5.79 
NP_Ala 3.73 
NP_Asn 5.33 
NP_Asp 18.92 
NP_Gln 4.08 
NP_Glu 10.18 
NP_Leu 3.31 
NP_Met 0.61 
NP_Phe 0.41 
NP_Val 3.27 
 
From Table 2.2, it can be seen that the denaturation rates are in accordance with the 
extent of final fluorescence shifts after 24 h incubation.  NP_Asp induces the fast 
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denaturation of ChT with a rate constant of 1.89×10-5 M-1 s-1.  For NP_Asn, the rate 
constant drops by two thirds to 5.33×10-6 M-1 s-1.  Similarly, for the L-Glu/L-Gln 
counterparts, the rate constants decrease from 1.02×10-5 M-1 s-1 to 4.08×10-6 M-1 s-1.  
Glycine decorated nanoparticle shows an intermediate denaturation rate constant, 
although it has the highest hydrophobicity among the five amino acids.  The observation 
strongly suggests that the carboxylate functions tend to facilitate the denaturation.  As 
pointed out previously, the competitive hydrogen-bonding formation may destabilize 
the α-helices in ChT and spoil its initial secondary structure.  Furthermore, these 
phenomena are most probably attributed to the fact that the salt bridge (i.e. between the 
N-terminus of Ile16 and the Asp194 side chain) in the protein is more easily broken by 
the charged side chains.  Indeed, the observed denaturation rates for NP_Asp and 
NP_Glu are comparable to the denaturation rate of ChT at pH 11.0 (i.e. k = 1.43×10-5 
M-1 s-1),42 where hydroxide ions are believed involving in the breakage of salt 
bridges.43 
In accordance with the previous observations, the hydrophobic amino acid side 
chains are able to aid in the retention of ChT secondary structure.  NP_Phe, the 
nanoparticle bearing the most hydrophobic side chain, gives a denaturation rate constant 
of only 4.1×10-7 M-1 s-1, decreasing by 50 times in comparison with NP_Asp.  Both CD 
and fluorescence studies revealed that the hydrophobicity of amino acid side chains 
affect the denaturation of ChT.  Therefore, the denaturation rate constants of ChT in 
diverse nanoparticles were again plotted against the hydrophobicity index of amino acid 
side chains in Figure 2.13b.  This correlation strongly suggests that the hydrophobicity 
of amino acid side chains in nanoparticles plays a vital role in preserving ChT structure. 
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Our previous study has shown that the alkyl interior in NP 1 induces the drastic 
denaturation of ChT, whereas the current hydrophobic amino acid side chains might 
stabilize the bound ChT.  One plausible interpretation for these phenomena is that in the 
former case the alkyl chain nonspecifically interacts with the whole surface of ChT and 
therefore destabilizes the protein.  In the latter, however, the hydrophobic amino acid 
side chains specifically interact with the hydrophobic patches in ChT and preserve the 
protein structure much as in the natural protein-protein interaction.  Indeed, selective 
introduction of hydrophobic groups near the hydrophobic region on protein surface has 
proven to be one method of choice for improving protein stabilization. 
2.2.2 Conclusion 
   In summary, we have demonstrated that the functionality of monolayer protected gold 
nanoparticles could be readily tailored by introducing diverse terminal functions.  By 
incorporating simple L-amino acids, nanoparticles exhibit distinctly different inhibition 
ability on ChT activity.  Complementary electrostatic interaction between nanoparticles 
and ChT has proven to be the predominant driving force contributing to the complex 
formation, but the hydrophobic interaction between the hydrophobic patches of 
receptors and proteins might enhance the complex stability to certain extents.  The 
binding ratio lies not only on the surface areas of nanoparticle receptors, but also on 
their surface charge density.  The surface recognition elements are proposed to 
reorganize to achieve the maximal electrostatic interaction upon complexation with 
ChT.  Most importantly, the hydrophobicity of amino acid side chains shows great 
influence on the secondary structure of ChT.  The hydrophobic side chains might 
stabilize the ChT structure, while the hydrophilic side chains display serious negative 
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effects.  Taken together, the control over association/dissociation as well as 
stabilization/denaturation of ChT at the nanoparticle interfaces has been conveniently 
accomplished by introducing additional functions in the vicinity of carboxylic acid 
functions.  These fundamental insight into the interaction between proteins and artificial 
receptors with nanoparticle scaffolds offer opportunities for developing novel core/shell 
receptors with highly specific protein-surface recognition ability, which would possess 
promising applications in protein stabilization, alteration, and delivery. 
2.3 Antipodal Effect of Exterior and Interior Hydrophobic Moieties 
Previously we have reported that carboxylate-terminated gold nanoparticles are 
able to target α-chymotrypsin (ChT).  Significantly, we found that nanoparticle (NP 1) 
featuring simple alkyl carboxylate ligands rapidly denatured the bound ChT molecules, 
while the incorporation of tetra(ethylene glycol) (TEG) spacers onto nanoparticle 
monolayer (NP 5) reduced considerably the extent of denaturation.The denaturation of 
ChT at the interface was presumably ascribed to the nonspecific hydrophobic 
interactions of the protein with the alkyl interior of the monolayer. From the above 
study we also observed that the amino acid-decorated surfaces results both electrostatic 
and hydrophobic interactions between the hydrophobic patches of receptors and the 
protein contribute to the complex stability. The microscopic binding constants for these 
receptor-protein complexes are 106 ~ 107 dm3 mol-1, which roughly increase with the 
hydrophobicity index of amino acid side chains (Figure 12b).  This binding affinity of 
amino acid-functionalized Nanoparticles toward ChT is comparable to the naturally 
occurring protein-inhibitor interaction.44 But more interestingly, the hydrophobic amino 
acids have little effect on the native structure of the bound ChT, while hydrophilic 
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(especially dianionic) amino acids destabilize the protein. Hence the effects of exterior 
and interior hydrophobicity are opposite in nature. To explore this antipodal effect, we 
build a family of 30 L-amino acid-functionalized nanoparticles (Figure 2.14) with 
variant length of oligo(ethylene glycol) (OEG) tethers and explore their interaction with 
ChT. OEG units are well-known to resist nonspecific interaction with biomolecules and 
have extensitively been deposited onto various substrates to afford biocompatible 
monolayers. Hence the varible amino acids at the periphery of nanoparticles allow us to 
detect the side chain effect upon interaction with ChT where the OEG with variable 
chain length can control the nonspecific interaction from hydrophobic monolayer. More 
attractively, we can predict that the effect of various amino acid properties and diverse 
OEG tethers in nanoparticles through organic chemistry offers us a new opportunity to 
gain control over the structure of bound proteins at interface. 
 
Figure 2.14. Chemical structure of amino acid-functionalized nanoparticles with 
variable OEG spacer. 
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2.3.1 Result and Discussion 
2.3.1.1 Activity Assay 
Inhibitory potencies of these nanoparticles were first conducted to evaluate the 
inhibitory potencies by activity assay. With N-succinyl-L-phenylalanine p-nitroanilide 
(SPNA) as substrate, the acitivity of ChT was drastically depressed upon addition of 
most nanoparticless (Figure 1.15). As expected only Arg functionalized nanoparticles 
exhibited no inhibition due to their positively charged side chains. Consequently, the 
complementary electrostatic interaction between ChT and nanoparticles plays the vital 
role in the complex formation.  The enzymatic activity of ChT typically decreased ca. 
60% to 85% upon incubation with excess nanoparticles.  
The binding strength between ChT and Nanoparticles was quantified by 
analyzing the activity assay data through nonlinear least-squares curve-fitting using an 
equal K model where the Nanoparticles were assumed to possess n identical and 
independent binding sites. The results show that microscopic binding constants for 
complexations between ChT and Nanoparticles are between 106 to 107 M-1 (Table 
2.4).45 
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Table 2.3. The binding constants (KS) and binding ratios (n) estimated from activity 
assays for the complexation of ChT with nanoparticles in phosphate buffer (5 mM, pH 
7.4) at 30 °C. 
 
Nanoparticle KS / M-1 n Residual activity at 4:1 (ChT to NP) ratio 
NP_1EG_Gly 1.3×107 7.8±1.2 0.29 
NP_2EG_Gly 1.1×107 7.4±0.8 0.28 
NP_3EG_Gly 8.9×106 6.2±0.3 0.21 
NP_4EG_Gly 2.9×106 7.3±1.5 0.43 
NP_1EG_Asn 6.9×106 8.3±0.6 0.27 
NP_2EG-Asn 3.6×106 7.8±1.0 0.37 
NP_3EG-Asn 2.5×106 6.0±0.5 0.29 
NP_4EG-Asn 2.7×106 6.7±0.9 0.17 
NP_1EG-Asp 7.9×106 13.2±0.9 0.21 
NP_2EG-Asp 1.6×107 11.0±0.4 0.16 
NP_3EG-Asp 9.5×106 11.3±0.5 0.22 
NP_4EG-Asp 2.2×106 13.1±0.3 0.22 
NP_1EG-Glu 6.9×106 11.9±1.4 0.22 
NP_2EG-Glu 6.0×106 12.8±1.1 0.24 
NP_3EG-Glu 4.9×106 9.0±0.5 0.26 
NP_4EG-Glu 2.4×106 9.1±0.7 0.20 
NP_1EG-Leu 5.9×106 7.3±0.4 0.26 
NP_2EG-Leu 4.2×106 7.7±0.8 0.25 
NP_3EG-Leu 9.9×106 6.2±0.1 0.20 
NP_4EG-Leu 5.9×106 6.4±0.4 0.27 
NP_1EG-Phe 8.5×107 8.4±0.6 0.38 
NP_2EG-Phe 2.7×107 8.0±0.3 0.34 
NP_3EG-Phe 1.9×107 6.2±0.2 0.19 
NP_4EG-Phe 7.1×106 6.8±0.8 0.32 
NP_1EG-Val 5.2×106 7.5±0.8 0.25 
NP_2EG_Val 4.7×106 7.8±0.5 0.21 
NP_3EG_Val 9.5×106 8.1±0.3 0.24 
NP_4EG_Val 8.1×106 7.6±0.2 0.23 
 
Interestingly, the length of OEG tethers shows considerable influence on the 
complex stability of ChT and nanoparticles. For most nanoparticles the affinity 
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increases with decreasing length of OEG tether. One plausible interpretation for this 
phenomenon is that the shorter linkers are more pre-organized, decreasing the entropic 
cost of binding. 
 
Figure 2.15. a) Progress curves for the hydrolysis of SPNA in the presence of ChT and 
various concentrations of NP_3EG_Val. [ChT] = 3.2 μM and SPNA [2 mM].46 (Inset) 
Normalized activity of ChT in the presence of varying concentrations of NP_3EG_Val. 
b) Binding constants (logKS) between ChT and Nanoparticles bearing various amino 
acid side chains and OEG tethers, estimated from activity assays. 
 
Both activity assays and gel electrophoresis studies showed that the binding 
capacity of ditopic amino acid terminated Nanoparticles is higher than that of 
monotopic amino acid-functionalized Nanoparticles, in accordance with our previous 
studies.26 For example, the binding stoichiometries of all four L-Asp functionalized 
Nanoparticles are ~11-13, while the binding stoichiometries of monotopic amino acid 
(e.g. L-Leu) functionalized Nanoparticles are ~6-8. Surprisingly, the binding capacity is 
essentially irrespective of the length of OEG tethers for the tested nanoparticles.  These 
reults suggest that the binding ratios are dependent on the surface ‘hot spots’ (i.e. 
carboxylates) rather than proportional to the surface area, which is expected to decrease 
from 300 to 180 nm2 going from the 4EG to the 1EG spacer. In this context, the 
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association between ChT and these Nanoparticles is proposed to operate through 
intermolecular ion pairs and the highly mobile carboxylates on the MMPC periphery 
tend to cluster together to realize the maximal electrostatic interaction with ChT through 
cooperative interactions. 
2.3.1.2 Circular Dichroism Study 
Circular dichroism (CD) spectra of ChT with various nanoparticles were 
subsequently recorded to determine the impact of amino acid side chains as well as the 
OEG tethers on the protein structure.  Figure 2.16 shows the CD spectra of ChT upon 
incubation with a series of L-Leu terminated nanoparticles for 24 h.  While ChT that 
was incubated with NP_4EG_Leu showed negligible CD spectral changes, the protein 
displayed different levels of CD spectral changes upon incubation with L-Leu 
nanoparticles that bear shorter OEG tethers.  Among the four nanoparticles, 
NP_1EG_Leu that possesses the shortest OEG tether induced the most significant 
spectral changes, i.e.  the decrease of the characteristic minimum at 230 nm and the 
blue-shift of the minimum at 204 nm.  The spectral changes were found time-dependent 
This phenomenon clearly shows that the initial structure of ChT is strongly modified by 
nanoparticles.  Deconvolution of the circular dichroism spectra revealed that the 
contents of α-helices drastically decreased along with the augmentation of β-sheets. The 
deconvolution using CONTINLL protocol showed that the α-helices in ChT decreased 
from 16.8% to 6.9%, whereas β-sheets enriched from 30.2% to 36.7% upon incubation 
with NP_1EG_Leu.47  The OEG length-related denaturation indicates that OEG tethers 
can aid in the retention of ChT secondary structure.  The amino acid side chains also 
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displayed different levels of influence on the protein structure.  Compared with 
hydrophobic amino acids like L-Phe, L-Leu and L-Val, hydrophilic amino acids such as 
L-Asp, L-Glu, L-Asn, L-Gln and Gly with the same tethers always induced more 
significant CD spectral changes.  In other words, the hydrophilic residues facilitate the 
denaturation of the proteins. 
 
Figure 2.16. CD spectra of ChT (3.2 μM) in the absence and presence of l-Leu 
functionalized MMPCs (0.8 μM) with different OEG tethers in 5 mM sodium phosphate 
buffer (pH 7.4) after 24 h incubation.  
2.3.1.3 Fluorescence spectrometry 
Fluorescence spectrometry was used to provide kinetic information on the 
conformational changes of ChT in the presence of nanoparticles. As shown in Figure 
2.17a, the steady-state fluorescence spectrum of ChT exhibits a maximum at 331 nm 
with a half-maximal amplitude of 54 nm.  Upon incubation with nanoparticles for 24 h, 
significant bathochromic shifts of fluorescence maxima as well as peak broadenings 
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were observed.  For NP_1EG_Val, the fluorescence maximum was red-shifted to 352 
nm (Δλ = 21 nm) with concomitant broadening of half-maximal amplitude to 68 nm.  
These phenomena indicate that the initially buried tryptophan residues were exposed to 
more polar environment (i.e. water) due to the unfolding of the protein.41 The 
denaturation extent of ChT was found to be governed by both the properties of amino 
acid side chains and the length of OEG tethers in nanoparticles. 
The denaturation of ChT follows a first-order reaction profile.  In Figure 2.17b, 
the logarithm of native ChT concentration is plotted against the incubation period with 
L-Leu functionalized nanoparticles.  Good linear regressions are obtained, confirming 
the first-order reaction.  It can be seen from Figure 2.17b that the denaturation rates 
decrease with the length increase of OEG linkage, i.e. 1EG > 2EG > 3EG > 4EG, which 
is in accordance with the CD study. 
 
Figure 2.17. a) Fluorescence spectra of ChT (3.2 μM) in the absence and presence of L-
Val decorated nanoparticles with different OEG tethers after 24 h incubation. b) Linear 
plots for the first-order ChT denaturation in the presence of L-Leu terminated 
nanoparticles with different OEG tethers. The experiment was run in 5 mM sodium 
phosphate buffer (pH 7.4). 
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The denaturation rate constants of ChT in the presence of various nanoparticles 
were calculated from their kinetic curves and compiled in Figure 2.18. The denaturation 
rate constants vary within a broad range, e.g. from 4.1×10-7 M-1 s-1 for NP_4EG_Phe to 
3.1×10-5 M-1 s-1 for NP_1EG_Asp. The difference in denaturation rates of 3EG and 
4EG particles with ChT decreases with increasing hydrophobicity of the amino acid 
termini.  This trend suggests that the hydrophobic side chains of amino acids only 
marginally affect the structure of the bound protein, while the hydrophilic (especially 
the anionic) side chains promote denaturation.  For the series of 1EG and 2EG, 
however, drastic denaturation of ChT was observed for all amino acids.  Such results 
are presumably attributed to the exposing of the interior alkyl chains to the protein 
surface, which accelerates the conformational mutation of the protein through 
nonspecific hydrophobic interaction.48  The denaturation rates of nanoparticles that bear 
the same amino acid function but different OEG length constantly increase in the order: 
4EG < 3EG < 2EG < 1EG.  The spacers of three or more EG units significantly reduce 
the nonspecific interaction of proteins with interior hydrophobic shell and preserve the 
native structure of proteins. 
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Figure 2.18. Histograms of first-order denaturation rate constants of ChT upon 
incubation with nanoparticles bearing various amino acid side chains and OEG tethers 
in 5 mM sodium phosphate buffer (pH 7.4). 
2.3.2 Conclusion 
In summary, we have demonstrated that in the amino acid-functionalized 
nanoparticles the hydrophobic amino acid side chains favor the retention of the protein 
structure.  The interior alkyl chains, however, spoil the protein secondary structure due 
to nonspecific hydrophobic interactions, which can be significantly impaired by 
introducing tethers with three or more EG units.  Therefore, the tunable denaturation of 
protein is achievable by adjusting either the recognition elements (amino acids) or the 
linkers. 
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2.4 Experimental Section 
2.4.1 General 
α-Chymotrypsin (type II from bovine pancreas, ChT), N-succinyl-L-
phenylalanine p-nitroanilide (SPNA), and tert-butyl esters of amino acids (Gly, L-Phe, 
L-Ala, L-Val, L-Leu, L-Met, and L-Glu) were purchased from Sigma and used as 
received.  All the other chemicals were obtained from Aldrich unless otherwise stated.  
Trityl protected acid 1 was prepared according to the procedure described by Houseman 
and Mrksich.33 The purification of all intermediates and ligands was performed on flash 
chromatography (SiO2, particle size 0.032 - 063 mm).  Pentanethiol capped gold 
nanoparticle (d ~ 2 nm) was prepared according to the reported method.11  
2.4.2 Synthesis of Ligands and Nanoparticles 
General procedure for the preparation of 2_Amino acid.  Trityl protected 
thioacid 1 (680 mg, 1.0 mmol) was dissolved in dry dichloromethane (20 mL) that was 
placed in an ice-bath.  When the temperature reached about 0 °C, corresponding amino 
acid tert-butyl ester hydrochloride (1.0 mmol), DCC (1.5 mmol) and sodium 
bicarbonate (1.0 mmol) were added successively.  The mixture was stirred at room 
temperature for 36 h.  The insoluble stuff was removed by suction filtration.  The 
filtrate was concentrated and charged on SiO2 column for purification.  The yields were 
around 70%. 
General procedure for the preparation of 3_Amino acid. Trityl protected thioacid 
1 (2.7 g, 4.0 mmol) was dissolved in dry dichloromethane (50 mL) placed in an ice-
bath, followed by the addition of N-hydroxysuccinimide (690 mg, 6.0 mmol) and DCC 
  63
(1.25 g, 6.0 mmol).  The reaction was allowed to rise automatically to room temperature 
and stirred for 36 h.  The insoluble stuff was removed by filtration.  The filtrate was 
concentrated and the crude ester was dissolved in THF (30 mL).  Sodium bicarbonate 
(420 mg, 5.0 mmol) was then dissolved in water (30 mL) in another round-bottom flask, 
followed by the addition of the corresponding amino acid (5.0 mmol).  Subsequently, 
the above prepared N-hydroxysuccinimide ester solution in THF was added dropwise to 
the reaction flask.  The reaction proceeded at room temperature for another 36 h.  The 
insoluble materials were removed by suction filtration.  Most THF in the filtrate was 
evaporated under a reduced pressure.  Subsequently, the residue was chilled with ice-
bath and the pH value was adjusted to ca. 2 with 1 M HCl.  The resultant emulsion was 
extracted with ethyl acetate for 4 times.  The organic layers were combined and washed 
thoroughly with brine and dried over anhydrous sodium sulfate.  After filtration, the 
solvent was evaporated and the residue was charged on SiO2 column for purification.  
The overall yields were typically around 30%. 
General procedure for the preparation of 4_Amino acid.  Trityl protected 
thioligands 2 or 3 were dissolved in dry dichloromethane and stoichiometric 
trifluoroacetic acid was added under stirring.  The color of the solution was immediately 
turned to yellow.  Subsequently, triisopropylsilane was added.  The color of the solution 
recovered slowly to colorless.  The reaction was allowed to proceed at room 
temperature for 12 h.  The solvent and excess trifluoroacetic acid and triisopropylsilane 
were removed under reduced pressure.  The residue was charged on SiO2 column for 
purification.  The yields were from 30% to 75%. 
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General procedure for ligand exchange. 1-Pentanethiol coated gold 
nanoparticles (d = 2 nm) were prepared according to the previously reported protocol.  
Place-exchange reactions were conducted to replace the 1-pentanethiol ligand on the 
nanoparticle surface with amino acid functionalized ligands 4.  Typically, 20 mg of 1-
pentanethiol coated gold nanoparticles were added to a solution of 50 mg ligand 4 in 
dichloromethane.  The mixture were stirred at room temperature for 2~3 days.  The 
ligand-exchanged nanoparticles precipitated from the solution automatically and were 
collected by centrifugation.  The nanoparticles were washed thoroughly with 
dichloromethane and dried under high vacuum.  The amino acid decorated gold 
nanoparticles are highly soluble in methanol and water, but insoluble in less polar 
solvents like chloroform and toluene (which are good solvents for the precursor C5-NP).  
As compared with the ligand precursor, the 1H NMR signals of nanoparticles are 
significantly broadening.  No signals of free ligands are observed in all 1H NMR 
spectra. 
2.4.3 Activity Assays 
All of the experiments were performed in sodium phosphate buffer (5 mM, pH 
7.4) with [ChT] = 3.2 μM and variant NP concentrations.  The enzymatic hydrolysis 
reaction was initiated by adding a SPNA stock solution (16 μL) in ethanol to a 
preincubated ChT-NP solution (184 μL) to reach a final SPNA concentration of 2 mM.  
Enzyme activity was followed by monitoring product formation every 15 s for 15 min at 
405 nm with a microplate reader (EL808IU, Bio-Tek Instruments, Winooski, VT).  
Control experiment showed that the autohydrolysis of SPNA was negligible during the 
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time course of activity assay.  The assays were performed in duplicates or triplicates, 
and the averages are reported.  The standard deviation was usually less than 10%. 
Estimation of the Binding Constants from Activity Assay. Assuming that one 
nanoparticle has n identical and independent binding sites that are able to bind one ChT 
molecule each, the complexation of ChT with nanoparticles could be expressed by 
equation S1. 
Site + ChT                           Site  ChT
KS
           (S1) 
where KS denotes the microscopic binding constant.  Because the activity 
decrease of ChT is attributed to the complexation with nanoparticles, the activity 
difference (ΔZ) is assumed to be proportional to the concentration of complexed ChT, 
i.e. ΔZ=α⋅[Site⋅ChT].  The proportionality coefficient α reflects the activity difference 
of unit ChT before and after complexation.  Then KS could be defined as: 
[ ]
[ ][ ] [ ] [ ] )/ChT)(/Site(
/
ChTSite
ChTSite
00
S αα
α
ZZ
ZK Δ−Δ−
Δ=⋅=          (S2) 
Where [Site]0 and [ChT]0 denote the initial concentrations of binding sites and 
ChT, repectively.  The relationship between the concentrations of binding sites and 
nanoparticles is describable by [Site]0=n[NP]0.  After a few manipulation, equation S2 
is solved for ΔZ to give equation S3: 
[ ] [ ] [ ] [ ] [ ] [ ] }NPChT4)/1NPChT()/1NPChT{(
2 00
2
S00S00 nKnKnZ −++−++⋅=Δ α  (S3) 
On the base of Equation S3, microscopic binding constants (KS) and binding 
ratios (i.e. the number of nanoparticles’ binding sites) could be readily determined by 
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using the nonlinear least-squares curve-fitting analysis.  The curve-fitting analysis was 
done on PC using Origin 7.0 program (OriginLab Co., Northampton, USA). 
2.4.4 Gel Electrophoresis 
Agarose gels were prepared in 5 mM sodium phosphate buffer at 1% final 
agarose concentration.  Appropriately sized wells (40 μL) were generated by placing a 
comb in the center of the gel.  A ChT stock solution of 100 μM in 5 mM sodium 
phosphate buffer (pH 7.4) was used to prepare 30 μL samples at the appropriate 
ChT/NP ratios ([ChT] = 50 mM).  After a 30 min incubation period at room 
temperature, 3 μL of 80% glycerol was added to ensure proper well loading (30 μL) and 
a constant voltage (100 V) was applied for 30 min for sufficient separation.  Gels were 
placed in staining solution (0.5% Coomassie blue, 40% methanol, 10% acetic acid 
aqueous solution) for 1 h, followed by extensive destaining (40% methanol, 10% acetic 
acid aqueous solution) until protein bands were clear.  Gels were scanned on a flatbed 
scanner both prior to and after staining to separately visualize particle and ChT bands. 
2.4.5 Zeta Potential 
Amino acid-functionalized gold nanoparticles were dissolved in PBS buffer 
(20mM potassium phosphate and 100mM sodium chloride, pH 7.8) to make a 1 μM 
solution and their zeta potentials were measured on a MALVERN Zetasizer Nano ZS 
instrument.  Three rounds of assays have been performed and the average values were 
reported. 
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Table 2.4. Zeta-potentials for various amino acid-functionalized gold nanoparticles in 
PBS buffer (20 mM potassium phosphate and 100 mM sodium chloride, pH 7.8) at 25.0 
°C 
 
Nanoparticle zeta-potential / mV nanoparticle zeta-potential / mV 
NP_Gly −25.8±1.5 NP_Glu −32.2±0.7 
NP_Ala −24.7±2.1 NP_Leu −25.6±1.5 
NP_Asn −26.2±0.5 NP_Met −25.4±2.0 
NP_Asp −32.5±0.4 NP_Phe −25.7±1.8 
NP_Gln −23.5±1.2 
 
NP_Val −26.4±1.6 
2.4.6 Circular Dichroism 
Far-UV circular dichroism (CD) spectra of ChT (3.2 μM) were measured on a 
JASCO J-720 spectropolarimeter with quartz cuvettes of 1 mm path length at 20 °C.  
The spectra were recorded from 190 to 250 nm as an average of 3 scans at a rate of 20 
nm/min.  The concentration of NP is 0.8 μM and their CD spectra were subtracted to 
eliminate background effects.  Quantitative analyses of the secondary structure content 
were done by deconvolution of the far-UV CD spectra using the CDSSTR method in 
the CDPro program package. 
2.4.7 Fluorescence  
Fluorescence spectra were measured in a conventional quartz cuvette (10 × 10 × 
40 mm) on a Shimadzu RF-5301 PC spectrofluorophotometer at room temperature (ca. 
20 °C).  The samples were excitated at 295 nm, and the emission spectra were recorded 
from 300 to 450 nm.  For the denaturation study, the sample concentrations are the 
same as that in CD study. 
Complexation Study by Using Fluorescence Titration. To corroborate the 
observed binding strength, the complexation of ChT with NP_l-Leu was further 
investigated by fluorescence titration experiment.  As shown in Figure 2.19, the 
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addition of NP_l-Leu drastically quenched the intrinsic fluorescence of ChT.  Because 
the gold nanoparticles are intense absorbers at the excitation and the emission 
wavelengths (i.e. 295 and 330 nm, respectively), this fluorescence quenching is at least 
partially due to their absorption.  In this context, the quenching of ChT by tetra(ethylene 
glycol) terminated gold nanoparticle, which has been proven to not complex with ChT, 
was measured to dispel the effect of nanoparticles’ absorption.  From the quenching 
process of tetra(ethylene glycol) terminated gold nanoparticle, absorbance correction 
factors (θ) that reflect the emission quenching due to nanoparticle absorbance at the 
exciting and emission wavelengths could be determined. The raw and the corrected 
fluorescence intensities of ChT at 330 nm in the presence of NP_Leu are depicted in the 
inset of Figure 4.  The corrected fluorescence changes are unambiguously attributed to 
the production of ChT-NP complex, where an energy-transfer from the tryptophan 
residues in ChT to the gold core is responsible for the fluorescence quenching.  The 
binding constant could be roughly estimated by the analysis of the fluorescence titration 
data.  For the system of ChT and NP_Leu, a binding constant of 5.3×106 M-1 was 
obtained, which is in accordance with the value estimated from the activity assay.   
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Figure 2.19. Fluorescence quenching of ChT (1 μM) in the presence of NP_L-Leu (0 ~ 
0.8 μM). (Inset) The fluorescence intensities monitored at 330 nm (■) and the corrected 
intensities (▲). 
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CHAPTER 3 
 
BIOMIMETIC INTERACTIONS OF PROTEINS WITH  
FUNCTIONALIZED NANOPARTICLES: A THERMODYNAMIC STUDY 
3.1 Introduction 
3.1.1 Biomimetic Systems 
Inspired by biological systems, there are numerous chemical systems were 
developed.1 These systems are studied by controlling chemical process in a well-
defined nanoscale environment, but they have the potential to extend into advanced 
devices for nanofluidics2 and nanochemistry applications.3 Biomimetic system also 
provides a valuable tool for the understanding of biological processes as well as tool for 
the creation of advanced functional synthetic systems.  On the other hand proteins 
provide an important target for the creation of biomimetic systems. Considering this 
target a vast array of protein and metallprotein active site model systems have been 
developed.4, 5 As example, Cyclodextrin derivatives containing trifluoromethyl groups 
at C6 of the A and D rings were synthesized by Bjerre et. al. for the purpose of creating 
artificial enzymes.6  
 In contrast to active site models, there have been far fewer efforts to model the 
surface of proteins, in particular their interactions with other biomacromolecules. 
Effective mimicking of protein surfaces would provide fundamental insight into issues 
such as protein-protein and protein-nucleic acid interactions.  Additionally, replication 
of protein surface behavior provides access to useful catalysts,7 sensors,8 and 
therapeutics.9, 10    
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3.1.2 Nanoparticle as a Biomimetic scaffold  
Nanoparticles provide excellent systems for modeling protein surfaces. In 
particular, they can be readily fabricated with dimensions comparable to biological 
macromolecules.11 Moreover, the synthetic control we can exert on the ligands can be 
used to tune the structure and dynamics of the monolayer surface. For example, peptide-
functionalized NPs have been constructed to function as artificial proteins and 
enzymes,12 glyconanoparticles have been used as useful models of cell adhesion,13, 14  
and a variety of functionalized particles have been used for recognition in aqueous 
media.15, 16 Likewise, nanoparticle-protein interactions have found promising 
applications in modulation of enzymatic activity,17 biosensing,18 separation,19 and 
production of hybrid materials.20 
Two distinct approaches have been used to engineer the protein-nanoparticle 
interface. The first strategy uses the direct introduction of highly specific binding 
moieties onto the particle surface.  For example, biotin-tagged NPs exhibit high affinity 
interactions with proteins of avidin family.21 An alternative approach is to utilize the 
nanoparticle as a multivalent scaffold for the presentation of simple ligands.  With this 
approach the structural attributes of the nanoparticle are brought to bear, including the 
ability to generate the multiple electrostatic, hydrophobic and hydrogen-bonding 
interactions that are found in typical protein-protein interactions.22  
Amino acids present a readily accessed source of the electrostatic, hydrogen 
bonding and hydrophobic elements found in proteins. Our previous investigations have 
demonstrated that amino acid-terminated gold NPs can effectively interact with 
positively charged proteins, showing tunable inhibition of the enzymatic activity.23 
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From binding assays, we observed that complementary electrostatic interactions and 
hydrophobic interactions between nanoparticles and proteins govern complex 
formation.  
3.1.3 Thermodynamic analysis of protein interactions 
In biological system proteins are interacting with DNA,24 protein, peptide,25 
small molecules26 and metal ion27 for numerous cellular processes. Proper 
understanding of the development of these interactions can lead us to multiple 
biological applications.28 To monitor the interaction of proteins with other 
biomolecules, the conventional methods are mostly based on imaging,29 optical analysis 
(eg. Förster Resonance Energy Transfer (FRET))30 and X-ray crystal structure 
analysis.31 In this regard determination of the thermodynamic parameters can explore 
the mechanism in protein-bimolecular complexation which can be used for control the 
interaction.32  For example, the thermodynamic parameters obtained from inhibitors, 
that target the SH2 domain-binding site, show dramatic enthalpy/entropy compensation. 
These data suggest that the v-Src SH2 domain does not have a highly specific 
secondary-binding site, which presents a major difficulty as well as the direction to 
design selective inhibitors.33 As mentioned before, compare to other artificial receptor 
nanomaterials can provide a highly useful tool for studying protein-surface interactions. 
Fundamental studies on protein-nanoparticle interaction are always an attractive point 
of interest, because it can explore the nature of the interaction which can be used for 
control recognition. Incidentally, understanding of thermodynamics behind these 
interactions can help to design proper receptor. Recent studies have used 
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unfunctionalized silica particle-protein interaction for Differential Scanning 
Calorimetry (DSC),34 though interestingly ITC has not been well studied. Clearly, the 
application calorimetric techniques in protein-nanoparticle system can provide a 
powerful tool for understanding the protein-surface interactions. 
3.2 Protein-Nanoparticle Complexation: A Thermodynamic Study 
In this chapter, we investigate the thermodynamics of nanoparticle-protein 
interactions using isothermal titration calorimetry (ITC).  As shown in Figure 3.1, we 
choose structurally diverse anionic amino acid-functionalized gold particles as the 
protein receptors, and explored their interactions with three positively charged proteins: 
α-chymotrypsin (ChT),35 histone,36 and cytochrome c (CytC).37 We choose these three 
model proteins to estimate the effect of both size and charge of the protein molecules. If 
we consider the molecular weight (MW) and overall charge (pI) of these three proteins, 
they are varied with charge and size (Figure 3.1). If we compare between ChT and 
histone, the size is similar but histone is more positively charged. So the 
thermodynamic analysis can explore the effect of charge on the protein. On the other 
hand comparison between Histone and CytC can see the sights of size effect when the 
overall charges are comparable. 
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Figure 3.1. Structural features and relative sizes of amino acid-functionalized gold 
nanoparticles and proteins.  The blue overlapping spheres in the proteins represent the 
positively charged residues on their surface. 
3.2.1 Results and Discussion 
3.2.1.1 Isothermal Titration Calorimetry 
Thermodynamic parameters of particle protein interaction are highly effective 
for determining the nature of interactions.  In this respect ITC can provide useful 
thermodynamic parameters of particle-protein interactions, which a highly effective for 
determining the origin and pattern of interactions. Using ITC the equilibrium constants 
(KS), the molar entropy changes (ΔS) and the molar enthalpy changes (ΔH) can be 
determined simultaneously from a single titration curve. While differential scanning 
calorimetry (DSC) has been used to characterize NP-protein systems, this technique 
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provides only partial information on binding thermodynamics.38  ITC has been 
extensively used to investigate biomacromolecular interactions, directly providing the 
free energy and enthalpy of association, and the entropy from the former two values.39 
We have demonstrated that ChT associates with anionic NPs through 
complementary surface charge interaction. We fabricated several anionic gold NPs 
bearing various L-amino acid functionalities to examine their interactions with ChT, 
histone, and CytC. These proteins have an overall positive charge, albeit with different 
surface characteristics (ref. Figure 3.1).  ITC experiments were carried out at 30 oC by 
titrating protein solutions into the sample cell containing nanoparticles.  As can be seen 
from the titration curves (Figure 3.2), the three NP-protein systems exhibit distinctly 
different heat change profiles.  The complexation of ChT with NP_Phe is exothermic, 
while the complexation of histone with NP_Ala or CytC with NP_Glu involves 
endothermic processes.  The heat changes can be fitted into isothermal functions to 
quantify the corresponding thermodynamic parameters of NP-protein interactions.  
Interestingly, the complexation of NPs with both ChT and histone can be fitted using 
the mode of single set of identical binding sites.  By contrast, the complexation of NPs 
with CytC can only been assessed using a binding mode of two sets of binding sites. 
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Figure 3.2. ITC analyses for the complexation of (a) ChT with NP_Phe, (b) histone 
with NP_Ala, and (c) CytC with NP_Glu in 5 mM sodium phosphate buffer (pH = 7.4).  
The squares represent the integrated heat changes during complex formation and the red 
solid lines the curve fit to the binding isothermal functions. 
 
After the perfect fitting of the curve with the corresponding model (single set or 
double set of identical binding sites), the binding constants (K), enthalpy changes (ΔH) 
and binding ratios are determined from curve fitting analysis. By using the standard 
thermodynamic equations ΔG = -RTlnK and ΔG = ΔH – TΔS (assuming the parameters 
are independent on temperature), the Gibbs free energy changes (ΔG) and entropy 
Changes (ΔS) were calculated. The thermodynamic parameters for the complexation 
protein-nanoparticles are summarized in table 3.1. 
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Table 3.1. Complex stability constants (KS), Gibbs free energy changes (ΔG), enthalpy 
changes (ΔH), entropy changes (TΔS), and binding stoichiometries (n) for the 
complexation of ChT, histone, and CytC with various amino acid-functionalized gold 
NPs (5 mM sodium phosphate, pH 7.4) at 30 °C. 
 
First binding event Second binding event 
Protein NPs KS1 / 
M-1 
-ΔG / 
kJ mol-1
ΔH / 
kJ mol-1
TΔS /
kJ 
mol-1
n KS2 / 
M-1 
-ΔG / 
kJ mol-1 
ΔH / 
kJ mol-1 
TΔS /
kJ 
mol-1
n 
NP_Glu 5.2×105 33.2 -52.1 -18.9 23.6 − − − − − 
NP_Gly 3.6×105 32.2 -38.7 -6.4 7.3 − − − − − 
NP_Leu 7.8×105 34.2 -48.1 -13.9 9.7 − − − − − ChT
 
NP_ Phe 8.6×105 34.4 -56.2 -21.7 10.2 − − − − − 
NP_Ala 6.8×107 45.6 90.1 135.7 3.5 − − − − − 
NP_Gly 6.2×107 45.1 100.7 145.8 4.0 − − − − − Histone 
NP_Met 1.2×108 46.9 92.6 139.5 3.5 − − − − − 
NP_Ala 1.0×107 40.7 51.6 92.3 1.8 4.5×105 32.8 15.7 48.6 5.5
NP_Glu 1.1×107 41.0 56.5 97.5 2.0 3.1×106 37.6 12.5 50.1 11.1
NP_Gly 1.0×107 40.7 107.7 148.3 2.2 2.0×105 30.6 88.7 119.3 4.2
NP_Met 1.0×107 40.7 24.2 64.9 1.9 2.9×105 31.7 24.5 56.2 5.9
CytC 
 
NP_Phe 1.8×107 42.1 29.0 71.1 1.9 6.2×105 33.6 23.2 56.8 9.6
 
3.2.1.2 Protein Dependent Binding Ratio 
According to table 3.1 nanoparticles afford drastically different binding 
stoichiometries with the proteins that depend on both the functionality of NPs and the 
protein type. For example, ChT and histone possess similar molecular sizes, but the 
latter exhibits significantly lower binding ratios to the NPs.  On the other hand, the 
binding capacity of NP_Glu with ChT is almost twice that of other NPs, although they 
have comparable surface area.  Structurally, histone has more positively charged 
residues in comparison with ChT (62 versus 17),35, 36 while NP_Glu possesses double 
anionic carboxylate functionalities.  Taking this information into account, it is 
reasonable to conclude that the complexation stoichiometries are determined by the ion 
pairs involved in electrostatic interactions.  In other words, if the particle has more 
electrostatic recognition elements (i.e. carboxylates) it can bind more proteins; likewise 
if the protein has more cationic residues on surface it requires more NP partners to form 
  81
supramolecular complexes. In contrary, the complexation of NPs with CytC features 
two distinct binding processes, with markedly differing affinities. For nanoparticle-
CytC complexation, the first interaction involves a ~2:1 binding ratio of CytC to NP 
with binding constants ~ 107 M-1, with the subsequent binding much weaker with 
binding stoichiometries from 4 to 11.  By considering the isotropic surfaces of NPs 
against ChT and histone, it seems that the observed phenomena arise from the unique 
structural features of CytC.  It has been demonstrated that with an increase in protein 
concentration CytC molecules undergo reorientation on the surface of citrate-coated 
silver NPs to facilitate interprotein interactions.40  In this context, the orientation change 
and interprotein attraction/repulsion may account for the binding modes of CytC to 
NPs. The two CytC molecules initially bound may orient themselves opposite from 
each other to afford the highest binding affinity. Further bound CytC would generate 
unfavorable interprotein interactions due to electrostatic repulsion (Figure 3.3).  A 
second explanation can be provided by the monolayer model recently proposed by 
Stellacci et al. In this model, the ligands on two hemispheres of the particle feature 
opposing tilt angles, resulting in the appearance of two poles with distinct ligand 
arrangement.41  Thus, an alternative explanation for the binding stoichiometries of NP 
to CytC could be that the first two CytC molecules bind to the NP in the two 
topologically distinct ‘polar’ regions. It is noteworthy that the nanoparticle-protein 
ratios all are in feasible range.  Based on a model of smaller spheres packing on the 
surface of a larger sphere, the maximum binding stoichiometries of the nanoparticles (r 
~ 5 nm) with α-chymotrypsin (r ~ 2.5 nm), cytochrome c (r ~ 1.8 nm), and histone (r ~ 
2.1 nm) are evaluated as 28, 48, and 37, respectively.42 
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Figure 3.3. Schematic illustration for the binding modes of CytC with amino acid-
functionalized NPs in comparison with that of ChT and histone. 
3.2.1.3 Binding Thermodynamics of NP-Protein Interactions 
The thermodynamic data, i.e. change of enthalpy and entropy (ΔH and ΔS) 
obtained from all protein nanoparticle interaction can be used for detection the nature of 
the interaction. We also observed from Table 3.1 that those data not only differ from 
protein to protein but also vary with nanoparticle functionality. For the complexation of 
ChT with all particles features a favorable enthalpy change (ΔH < 0), which is offset 
partially by unfavorable entropy loss (ΔS < 0), affording overall free energy changes 
(ΔG) ranging from -32.2 to -34.4 kJ mol-1.  By contrast, the complexation of NPs with 
histone and CytC is endothermic, providing an unfavorable enthalpic contribution (ΔH 
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> 0) to the free energy of association.  The binding of histone and CytC is as a result 
dominated by a large favorable entropy change (ΔS > 0). The complexation behavior of 
proteins is a complex process that involves not only the synergetic work of noncovalent 
forces including electrostatic, hydrophobic, hydrogen bonding and π-π stacking, but 
also features the desolvation of both NPs and proteins and solvation of newly formed 
complexes. The complexation process may be described in a simplified fashion using 
Equation 3.1. 
[ ] OHOHNPProteinOHNPOHProtein 2222 xxpmpm +−+⋅⋅⇔⋅+⋅ )(                  (3.1) 
According to Equation 3.1, the thermodynamics of complexation depend on two 
simultaneous processes featuring noncovalent bond formation and solvent 
reorganization.  From an enthalpic viewpoint, the formation of noncovalent bonds is 
exothermic (ΔHintrinsic < 0) while the disruption of structurally well-defined solvent 
shells is endothermic (ΔHdesolv > 0).  In this context, the intrinsic bond formation (or 
namely protein-particle interaction) plays a predominant role in the complex formation 
of ChT with NPs according to the observed negative enthalpy changes.  It has been 
proposed that during protein-ligand interactions solvent reorganization accounts for 
great contributions to enthalpy changes.43  Nevertheless, the complex formation 
generally reduces the solvent accessible surface area, resulting in the release of highly 
ordered solvent molecules into bulk solution.  Consequently, the observed enthalpy 
changes are the compensatory outcomes of unfavorable desovlation enthalpy and 
favorable intrinsic enthalpy.44 
Water molecules at interfaces can sometimes enhance the complementarity of 
the interacting surfaces,45, 46 however the negative entropy changes do not necessarily 
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indicate that the hydration of the complex interface remains unchanged or increases in 
comparison with that of the free proteins or protens and particles.  Another important 
unfavorable contribution to the entropy change may arise from the conformational 
restriction of the flexible amino acid residues in both partners upon complexation. 
When the entropy increase due to desolvation is not large enough to remedy the entropy 
loss due to solute freedom reduction, overall unfavorable entropy changes are observed 
for the complexation of NPs with ChT. 
In the complexation of NPs with histone and CytC, the large positive entropy 
change unambiguously indicates the disordering of molecules upon complex formation, 
presumably arising from the release of a large amount of the water of hydration from 
the binding interface.  In comparison with ChT, histone and CytC possess more charged 
residues.  Consequently, the corresponding interaction interfaces involve significantly 
more polar surface.  The large entropic increase for the NP-histone and NP-CytC 
interactions may arise from either the release of more water of hydration or the 
dissociation of water molecules from a more ordered initial state.47  Meanwhile, the 
breakage of well-defined solvent-protein and/or solvent-NP bonds leads to the 
unfavorable enthalpy changes, which counteract a portion of entropy contribution to the 
complex stability. It is also necessary to mention that the binding constants for NP-ChT 
interactions are around ~10-fold lower than those obtained from enzyme activity 
assays,23 presumably due to the fact that in the latter case (i) the final solution contained 
8% (v/v) of ethanol-DMSO (90:10) in the 5 mM phosphate buffer, (ii) 2 mM of N-
succinyl-L-phenylalanine p-nitroanilide (SPNA) was presented as an enzyme substrate 
would be expected to interfere in the protein-NP interactions, (iii) the protein 
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concentrations for the ITC are higher than those used in the activity assay, which would 
be expected to raise the ionic strength of the solution due to the polyelectrolyte nature 
of the protein and finally (iv) the nanoparticle concentrations were calculated on the 
basis of their average molecular weights as described in experimental section. Thus, 
also the binding stoichiometrics between NPs and ChT differ slightly from the 
previously reported ones,23 where the NP concentrations were calibrated according to 
the UV absorbance of the gold core.48 
3.2.1.4 Effect of Hydrophobic in NP-Protein Complexation 
As we observe from the above study that different NPs interact with same 
protein with different extent according to thermodynamic parameters, which lead us to 
the investigation for the effect of head group. Complex stability between particles and 
ChT increases in the order of NP_Glu < NP_Leu < NP_Phe i.e the complex stability 
increases with increasing hydrophobicity.49 These trends track well with the 
hydrophobicity of the particle surfaces. As we know that ChT has hydrophobic patches 
on the protein surface, these observations indicate the role of hydrophobic interactions 
along with electrostatic interactions in complex formation. However this correlation is 
not observed in case of other two proteins, i.e. Cyt c and histone. This can be 
explainable if we consider the nature of surface of the later proteins in compare to ChT 
(Figure 3.1). For the Cyt c, it has 21 positively charged residues (19 Lys and 2 Arg)37 
with minor hydrophobic patches on the surface. Also for the histone protein, it has 62 
positively charged residues (56 Lys and 6 Arg).36 On the other hand for the ChT has lot 
of hydrophobic patches along with positively charged residue (14 Lys and 3 Arg).35 
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Thus the complexation of Cyt c and histone protein with NPs is dominated by 
complementary electrostatic interaction. But for the ChT although electrostatic 
interaction plays the mail role in stable complex formation the hydrophobic interaction 
also act as an accessory binding force. 
To probe the hydrophobic effect, we investigated particle-ChT interactions at 
varying ionic strengths, since the electrostatic forces should be attenuated by the 
presence of competitive ions.50 ITC experiments at various salt concentrations were 
carried out to quantify the corresponding thermodynamic parameters. The 
thermodynamic quantities for the complexation of ChT with three amino acid-
functionalized NPs at various salt concentrations are summarized in Table 3.2. 
 
Table 3.2. Thermodynamic parameters for the complexation of ChT with different 
amino acid-functionalized nanoparticles in various phosphate buffered NaCl solutions 
(5 mM sodium phosphate, pH 7.4) at 30 °C. 
 
NP Salt 
conc. 
KS / 105 
M-1 
ΔG / kJ mol-1 ΔH / kJ mol-1 ΔS / J mol-1 K-1 n 
0 8.6 -34.4 -56.2 -71.5 10.2 
25 6.3 -33.7 -35.2 -5.7 9.5 
35 4.2 -32.7 -22.8 32.4 9.5 
NP_Phe 
50 2.0 -30.8 -17.8 43.1 8.2 
0 7.8 -34.2 -48.1 -46.0 9.7 
25 4.8 -32.9 -28.2 15.6 9.0 
35 1.9 -30.7 -17.7 43.1 6.9 
NP_Leu 
50 NDa 
0 5.2 -33.2 -52.1 -62.3 23.6 
25 2.8 -31.6 -21.7 32.8 22.4 
NP_Glu 
35 NDa 
NP_Gly 0 3.6 -32.2 -38.7 -21.2 7.3 
a Not detectable 
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We can see from Table 3.2 that the thermodynamic quantities depend critically 
on the monolayer components of NPs as well as the salt concentrations. For the 
demonstration for the correlation of thermodynamic parameters (ΔG, ΔH and ΔS) with 
salt concentration we plotted those data in Figure 3.4a. 
As expected, the Gibbs free energy changes (−ΔG) decrease with increasing salt 
concentration for all three NPs owing to the attenuation of electrostatic interactions.  No 
binding was detectable for ChT-NP_Glu in 35 mM and ChT-NP_ Leu in 50 mM or 
higher concentrations of NaCl solution, respectively. For NP_Phe, however, 
considerable complex stability is still preserved at 50 mM NaCl.  In all cases, the 
binding constants increase in the order: NP_Glu < NP_Leu < NP_Phe.  NP_Phe 
always affords higher binding affinity to ChT than NP_Leu does, although they have 
similar hydrophobicity indices. One plausible explanation is that the surface area of L-
Phe is larger than that of L-Leu and can thus provide more efficient hydrophobic 
interactions with the protein. Additionally, there exist the possibility of CH-π 
interaction and π-π stacking of L-Phe with residues in ChT active pocket.51 
The similar observation also obtained from activity assay study. The inhibition 
of ChT activity toward SPNA by three NPs at increasing ionic strengths show different 
trend according to surface functionality on nanoparticle surface. As shown in Figure 
3.4b, three ChT-NP complexes exhibit different profiles of activity restoration upon 
addition of salt, resulting in the activity recovery in the order NP_Glu > NP_Leu > 
NP_Phe.  This supports that amino acid side chains play an important role in the 
binding process.  Taking the structure into account, the observation is similar to ITC 
analysis and that again attributed to the presence of hydrophobic interaction between the 
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protein and L-Leu and L-Phe residues whose effect is amplified along with the 
attenuation of electrostatic forces. 
 
Figure 3.4. a) Thermodynamic parameters for the complexation of ChT with amino acid-
functionalized NPs at various salt concentrations. b) Activity of ChT plotted as a function of 
salt concentration in the presence of anionic amino acid-functionalized NPs.  The 
activity is normalized to that of ChT at respective salt concentrations. 
 
  At low salt concentrations, ChT-NP complexation is driven by enthalpy. With 
increasing salt concentration, the favorable enthalpic components decrease, whereas 
entropy changes become more favorable.  In 50 mM of NaCl solution, the enthalpic and 
entropic contributions to the formation of ChT-NP_Phe complex are comparable. As 
hydrophobic interactions at room temperature are generally dominated by entropic 
effects,52 the more positive entropic changes at higher salt concentrations presumably 
originate from hydrophobic interactions. Hydrophobic interactions, however, are not 
strong enough to maintain the complexes at higher ionic strength where electrostatic 
interaction is fully diminished. 
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3.2.1.5 Enthalpy-Entropy Compensation 
The opposing trends of enthalpy and entropy change with increasing ionic 
strength for NP-ChT interaction as well as comparable DG values for protein-NP 
complexation (For ChT-NP complex 30 to 34 kJ mol-1, for Histone-NP complex 45 to 
46 kJ mol-1 and for Cyt c-NP complex, first binding 40 to 42 kJ mol-1, second binding 
31 to 37 kJ mol-1) indicate enthalpy-entropy compensation. Although no explicit 
relationship between the enthalpic and the entropic terms can be deduced from 
fundamental thermodynamics, the compensation effect has been observed universally in 
host-guest complexation.53, 54  However, the origin of this extrathermodynamic 
relationship is still under controversy, complicated in part by experimental concerns 
regarding the quality of the data.53, 55, 56 In the current study, it should be noted that the 
use of ITC eliminates issues associated with van‘t Hoff approximations. Additionally, 
the wide spread of free energy values provides an excellent benchmark for assessing 
compensation.53 
The physical significance of enthalpy-entropy compensation has been discussed 
in terms of cooperative interaction57 and thermodynamic functions.58 Inoue et al. have 
carried out quantitative correlation analyses of compensatory enthalpy-entropy 
relationships using a wide variety of molecular recognition systems.59 In these analyses, 
the TΔS value was linearly correlated with the ΔH value to give equation 3.2.  When 
equation 2 is introduced to Gibbs-Helmholtz equation followed by differential, equation 
3.3 is obtained. 
TΔS = αΔH + TΔS0                                       (3.2) 
δΔG = (1−α)δΔH                                          (3.3) 
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According to equation 3.3, the slope (α) of ΔH-TΔS plots reflects the 
contribution of enthalpic gains (δΔH) induced by alterations in host, guest, and/or 
solvent to the free energy change (δΔG), as some enthalpy has been canceled by the 
accompanying entropic loss (δΔS).59 The intercept (TΔS0) represents the inherent 
complex stability (ΔG) obtained at ΔH = 0, which means that the complex is stabilized 
even in the absence of enthalpic stabilization in case of positive TΔS0 terms.  By 
employing this correlation approach, the entropy changes (ΤΔS) listed in Table 1 and 
Figure 4 are plotted against corresponding enthalpy changes (ΔH) for the particle-
protein systems studied.  As shown in Figure 3.5a, an excellent linear relationship is 
obtained for these thermodynamic quantities with a correlation coefficient of 0.998.  
The compensation plot for protein-protein and protein nanoparticle interactions is also 
represented in Figure 3.5b for comparison.  
Figure 3.5. Plots of entropy (TΔS) versus enthalpy (ΔH) for (a) NP-protein (number of 
data set n = 23) and (b) the overlap of compensation plots for protein-protein (number 
of data set n = 70) and NP-protein interactions. 
 
Using correlation analyses, it has been suggested that the slope (α) and the 
intercept (TΔS0) can be empirically used as a quantitative measure of the conformational 
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change and the desolvation upon complex formation, respectively.59 In Table 3.3, the 
slope and intercept values of ΔH-TΔS plots for various host-guest complexation, 
protein-nonpeptide ligand, protein-peptide and protein-protein interactions are 
compared with that of NP-protein interaction. The ΔH-TΔS plots for protein-protein, 
protein-nonpeptide molecule and protein peptide interactions are presended in 
Appendix 2 with all thermodynamic values.  As expected, rigid hosts such as cryptands 
and metal porphyrins give smallest slope values, whereas flexible hosts such as glymes 
and lariat crown ethers shows largest slope values.  The α value of particle-protein 
interaction is comparable to that of glyme-cation and substituted cyclodextrin-organic 
molecule interactions, and somewhat larger than that of protein-protein interaction 
(Figure 3.6).  For the four systems involving protein partners, the α values increase in 
the order of nonpeptide ligand < protein < peptide < nanoparticle.  This result indicates 
that the NP-protein couple undergoes large conformational changes during the 
complexation process.  Such conclusion is in good accordance with the structural 
features of monolayer-protected NPs as the flexible ligands are expected to reorganize 
on the NP surface to attain a maximum complex stability.60 
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Table 3.3. Slope (α) and Intercept (TΔS0) of Enthalpy-Entropy Compensation Plots for 
Various Host-Guest Systems.   
 
Host Guest α TΔS0 / kJ mol-
1 
Data set (n) r 
Glyme/podanda Metal ion 1.02 15.9 150 0.98 
Lariat crown ethera Metal ion 0.98 18.6 132 0.96 
Crown ethera Metal ion 0.83 14.2 744 0.92 
Cryptanda Metal ion 0.44 13.6 160 0.65 
Metal porphyrina Pyridine/imidole 0.63 8.4 49 0.94 
Cyclophane/calixarenea Small organic molecule 0.84 15.6 77 0.92 
Native cyclodextrina Small organic molecule 0.82 10.2 1091 0.90 
Substituted cyclodextrina Small organic molecule 1.02 16.7 182 0.97 
Cyclodextrinb Small organic molecule 1.06 14.6 − − 
Organic hostb Small organic molecule in 
water 
0.96 13.2 − − 
Organic hostb Small organic molecule in 
organic solvent 
1.30 17.4 − − 
Protein Nonpeptide ligand 0.89 26.1 277 0.97 
Protein Peptide 0.96 32.7 252 0.98 
Protein Protein 0.92 44.1 70 0.99 
Nanoparticle Protein 1.07 35.2 23 0.99 
a see reference 61. b Recalculated from reference 53 by assuming a temperature of 298.15 K, which 
presumably causes the deviation from the values obtained from reference 61. 
 
 
Figure 3.6. Slope (α) and intercept (TΔS0) values for various host-guest systems. 
Protein-ligand interactions have been divided into protein-peptide and protein-other 
(protein-ligand) interactions.  
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While a number of host-guest systems feature slopes similar to protein-protein 
interactions, dramatic differences are observed in the intercept values (TΔS0) of protein-
partner interactions and other host-guest systems. For the protein-partner interactions, 
the intercept values (TΔS0) increase in the order of nonpeptide ligand < peptide < 
nanoparticle < protein.  The intercept for the particle-protein interactions is substantially 
more positive than that of the other ‘small molecule’ interactions and is comparable to 
protein-protein/peptide interactions.   Protein surface recognition involves large surface 
contact area and the rearrangement of water of hydration around the binding interface.  
Therefore, the large intercepts explicitly indicate that the complexation of proteins with 
both native partners (i.e. proteins) and artificial receptors (i.e. NPs) experiences 
significant desolvation.  As a consequence, the complex formation can be readily driven 
by the positive entropy changes due to the desolvation effect even in the absence of an 
enthalpic gain (i.e. ΔH = 0).  Obviously, for the protein-small ligand interactions, such 
desolvation effect is not as significant as that of protein-protein and protein-particle 
interactions, as there is less desolvation process in this system although proteins serve 
also as a complexation partner. 
Collectively, the enthalpy-entropy compensation analysis reveals the large 
conformational changes and extensive desolvation during the formation of NP-protein 
complexes, consistent with the prototypical protein-protein interactions.  Nanoparticles 
thus provide an excellent biomimetic system that affords both large surface area and 
multivalent binding features.    
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3.2.3 Conclusion 
In summary, we have demonstrated that electrostatic and hydrophobic 
interactions cooperatively control the complexation of amino acid-functionalized NPs 
with proteins, which depends on the surface distributions of charged and hydrophobic 
residues in the protein. The thermodynamic parameters obtained from ITC studies 
revealed dramatic differences in the mode of interaction, with the complexation of NPs 
with ChT enthalpy-driven while the complexation with histone and CytC is entropy-
driven. With ChT as a model protein, it is demonstrated that the electrostatic and 
hydrophobic contributions to the complex stability can be tuned by varying system ionic 
strengths.  The validity of enthalpy-entropy compensation has been examined for the 
NP-protein system.  An excellent linear relationship is obtained for the ΔH-TΔS plot 
with a near unit slope and a large intercept.  These quantitative measurements indicate 
the significant conformational changes and substantial dehydration of the partners. 
These studies also point to strategies that can be used to further optimize synthetic 
receptors for proteins, namely the reduction of the slope (α) value while maintaining or 
enhancing the intercept (TΔS0) value. But significantly, the compensation coefficients of 
nanoparticle-protein binding closely resemble that of natural protein-protein 
interactions, demonstrating the biomimetic nature of these systems. 
3.3 Size Dependent Protein-Nanoparticle Self-Assembly 
Protein-nanoparticle conjugates have numerous applications in biology and 
material science. Along with numerous biological applications,62, 3 assemblies of 
proteins with nanoparticles also provide building blocks for the creation of hybrid 
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bionanomaterials.63, 64 The wide range of sizes and charges of protein molecules 
provide access to a broad range of biomaterials with controlled interparticle spacing,65 
magnetic properties66 and overall structure of the nanocomposites. Each of these 
applications rely extensively on the fundamental aspects of protein-nanoparticle 
interactions. Monolayer-functionalized nanoparticles provide a tunable surface for 
binding with target molecules, enabling controlled nanoparticle-protein interactions. A 
fundamnetal understanding of the thermodynamic parameters of these protein-
nanoparticle interactions provides an important foundation for the application of these 
systems in biological and material applications. 
As we can see from the above experiments, ITC provides a powerful tool for 
investigating the thermodynamics and stoichiometry of supramolecular processes.67 
ITC analysis can be used in nanoparticle-protein assemblies to determine: i) binding 
stoichiometry, ii) stability of the conjugates, and iii) solublility or aggregation of the 
conjugates etc. Likewise, ITC analysis of protein nanoparticle complexation can 
determine the nature of binding (entropic vs. enthalpic), and the effect of surface 
functionality and envioronmental conditions on binding ratios and affinities.68, 69  
Here we want to develop the thermodynamic characterization on the interaction 
of proteins of three different sizes with nanoparticles using ITC to probe the effect of 
relative particle-protein size in complexation (Figure 3.7b). For our studies we used 2 
nm core gold  nanoparticles (~8 nm overall diameter) with variable cationic 
functionality (hydrophobic, hydrophilic and aromatic, Figure 3.7a). The selected 
proteins are anionic in nature to allow sufficient electrostatic interaction. For the 
protein, we choose three anionic proteins of distinctly different size (Fig. 3.7b). Green 
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fluorescence protein (GFP) is the smallest beta barrel shaped protein among these: 3.0 
nm x 4.0 nm (MW = 27 kDa, pI = 5.92).70 Bovine serum albumin (BSA) is the 
triangular prismatic protein with comparable size to the nanoparticle: 8.4 nm x 8.4 nm x 
8.4 nm x 3.1 nm (MW = 66.3 kDa, pI = 4.8).71 The third protein is acid phosphatase 
(PhosA), which is orthorhombic shaped and larger than the receptors: 12.6 nm x 20.7 
nm x 7.3 nm (MW = 110 kDa, pI = 5.2).72 
 
Figure 3.7. a) Chemical structure of the cationic gold nanoparticles (NP1-NP5). b) 
Surface structural features and relative size of three negatively charged proteins used in 
the ITC study. Colour scheme for the proteins: basic residues (blue), acidic residues 
(red), polar residues (green) and nonpolar residues (grey). 
3.3.1 Result and Discussion 
3.3.1.1 Isothermal titration Calorimetry 
The ITC experiments were carried out at 30 oC by titrating protein solutions into 
the nanoparticle solution in the isothermal cell. For our experimental purpose we first 
standardize the relative concentration of nanoparticle and protein to get the suitable heat 
change response. Depending on the protein structure we observed three different types 
of heat change profile from the titration curves (Figure 3.8). 
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Figure 3.8. ITC analysis for the complexation of (a) GFP with NP1, (b) BSA with NP3, 
and (c) PhosA with NP2 in 5 mM sodium phosphate buffer (pH = 7.4).  The squares 
represent the integrated heat changes during complex formation and the lines the curve 
fit to the binding isothermal functions. 
 
The complexation of GFP and BSA with all nanoparticles is endothermic in nature, 
while the complexation of PhosA with nanoparticles exhibits exothermic processes. We 
tried to fit this heat change into various isothermal functions to determine the various 
binding parameter corresponding to NP-protein interactions.  Interestingly, the 
complexation of NPs with both GFP and PhosA can be fitted using the mode of single 
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set of identical binding sites which are either smaller or larger than the size of the 
nanoparticles.  In contrast, the BSA with comparable size to nanoparticles, can only be 
assessed using a binding mode of two sets of binding sites. We also observed the 
precipitation at the end of titration in disparity with other two proteins. Using the 
isothermal curve fitting analysis various thermodynamic parameters such as, binding 
constants (KS), enthalpy changes (ΔH) and binding stoichiometries (n) were determined. 
The Gibbs free energy changes (ΔG) and entropy changes (ΔS) were calculated by using 
the standard thermodynamic equations : ΔG = -RTlnKS and ΔG = ΔH – TΔS.  These 
quantities for the corresponding nanoparticle-protein interactions are summarized in 
Table 3.4.  
Table 3.4. Complex stability constants (KS), Gibbs free energy changes (ΔG), enthalpy 
changes (ΔH), entropy changes (TΔS), and binding stoichiometries (n) for the 
complexation of GFP, BSA and PhosA with various gold NPs (5 mM sodium 
phosphate, pH 7.4) at 30 °C. 
 
First binding event Second binding event 
Protei
n NPs 
KS1 / 
M-1 
-ΔG / 
kJ 
mol-1 
ΔH / 
kJ mol-
1 
TΔS / 
kJ mol-
1 
n KS2 / 
M-1 
-ΔG / 
kJ mol-
1 
ΔH / 
kJ mol-1 
TΔS / 
kJ mol-1
n 
GFP NP1 1.74×106 36.22 42.26 78.48 4.39 − − − − − 
NP1 3.66×107 43.89 18.70 62.59 1.71 1.21×108 46.91 1133.86 1180.77 0.36
NP2 9.63×107 46.33 223.43 269.76 1.89 10.4×108 52.33 615.05 667.38 0.39
NP3 10.7×107 46.60 187.02 233.62 2.11 3.13×108 49.30 1087.84 1137.14 0.34
NP4 26.5×107 48.88 247.27 296.15 2.27 1.04×108 52.33 732.20 775.53 0.39
BSA 
NP5 5.86×107 45.08 164.43 209.51 1.97 8.46×108 51.81 623.42 675.23 0.32
NP1 2.03×105 30.80 -11171 -11140 0.43 − − − − − 
NP2 1.47×105 29.99 -31380 -31350 0.45 − − − − − 
NP3 1.89×105 30.62 -29664 -29633 0.43 − − − − − 
NP4 1.69×105 30.34 -35103 -35073 0.39 − − − − − 
PhosA 
 
NP5 3.16×105 31.92 -21171 -21139 0.44 − − − − − 
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3.3.1.2. Exothermic vs. Endothermic Process 
The thermodynamic quantities listed in Table 3.4 reveals that the complexation 
of proteins involves not only the electrostatic interaction but also the other noncovalent 
forces including hydrophobic, hydrogen bonding and π-π stacking interaction as 
obtained from surface functionality of the nanoparticles. This result suggests that the 
nanoparticle-protein interaction can be controlled by surface modification of artificial 
receptors. Further examination on the change of enthalpy and entropy values explore 
that the complexation of GFP and BSA involves unfavorable enthalpy change (ΔH > 0) 
which is compensated by favorable entropy gain (ΔS > 0), resulting in overall negative 
free energy changes (ΔG). On the other hand, the interaction with the larger protein is 
exothermic process with highly negative change in enthalpy (ΔH < 0), although this 
favorable gain partially offset by unfavorable entropy loss (ΔS < 0). This enthalpy or 
entropy controlled process can be easily explained if we consider the overall 
complexation process as described in Equation 3.6, which is the combination of two 
simultaneous processes (Equations 3.4 and 3.5). 
Protein + NP ⇔  [Protein.NP]           (3.4) 
xH2Op + yH2On ⇔  (x+y-z) H2Op.n + zH2O          (3.5) 
Protein.xH2Op + NP.yH2On ⇔  [Protein.NP](x+y-z)H2Op.n + zH2O (3.6)  
Where, H2Op, H2On, H2Op.n – water molecule associated with protein, 
nanoparticle and protein-nanoparticle complex respectively. 
 
The first process is noncovalant complex formation, where ΔH and ΔS both are 
negative i.e. exothermic process. In contrast, the solvent reorganization process involves 
the disruption of the well defined solvent shells to end up with endothermic process (ΔH 
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> 0 and ΔS > 0). Depending on the contribution of these two processes, the final 
complexation (Equation 3) will be either exothermic (1st process predominant) or 
endothermic (2nd process predominant). In complexation of smaller proteins, GFP and 
BSA, higher degree of surface interaction is occurring which results from the release of 
a large amount of the water of hydration from the binding interface. This process is 
evident from the large positive entropy changes. On the other hand, protein-nanoparticle 
interaction plays the main role for the PhosA indicated by the observed negative 
enthalpy changes. 
3.3.1.3 Diverse Binding Ratio 
Another important observation from the Table 3.4 is the binding ratios and 
binding mode between protein and nanoparticles which are drastically different 
depending on protein size. In case of smaller protein the nanoparticle:GFP binding ratio 
is ~1:4 indicating the nanoparticle is surrounded by proteins.   In contrast for the bigger 
protein, the nanoparticles surround the protein molecule. The similar size protein has 
different binding mode than other two proteins. In case of first binding mode, the 
binding is similar to GFP where each nanoparticle is surrounded by two BSA. The 
following binding involves nanoparticle-protein aggregation and precipitation with 
nanoparticle:BSA binding ratio 1:3. This extended aggregation and precipitation is 
supported by the large positive entropy change (TΔS = 667 – 1180 kJ mol-1) due to the 
release of large amount of bound water molecules (Figure 3.9). This aggregation was 
further established by dynamic light scattering (DLS) study (Figure3.13 in experimental 
section), where aggregates of ~150 nm were formed initially between NP1 and BSA, 
with larger aggregates and concomitant precipitation observed over time. Hence, by 
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controlling the relative protein-nanoparticle concentration we can control the pattern of 
protein-nanoparticle aggregation. 
 
Figure 3.9. a) Schematic depiction of particle-protein assemblies observed in this study. 
b) ITC analysis of BSA-nanoparticle complexation and concentration dependant 
different protein-nanoparticle conjugation. 
3.3.1.4 Consistent Enthalpy-Entropy Compensation 
We also observed from table 1 that enthalpy and entropy changes are always 
balanced to get the favorable free energy changes (ΔG < 0). This indicates enthalpy-
entropy compensation, which is commonly observed for many host-guest complexes.53 
The physical significance of enthalpy-entropy compensation is determined from the 
linear correlation using the relation TΔS = αΔH + TΔS0, where α is the slop and TΔS0 is 
the intercept. The slope and intercept of compensation plots have been related to the 
conformational change and desolvation during complexation, respectively.59 As shown 
in Figure 3.10, an excellent linear relationship is obtained for these thermodynamic 
quantities with a correlation coefficient of 0.999. Herein, near-unit slopes (α = 1.00 for 
protein-NP and 0.94 for protein-protein) suggest that significant conformational 
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changes occur at the interaction interface, which is unambiguously true for similar kind 
of flexible systems.  For the nanoparticle systems, the reorganization of flexible surface 
ligands provides a target-responsive system to afford optimal binding affinity.60  Large 
positive intercept values (TΔS0 = 46.2 kJ mol-1 for protein-NP and 41.5 kJ mol-1 for 
protein-protein) are also obtained for these interactions, reflecting the extensive 
desolvation during complexation.  This means that the complex formation can take 
place even in the absence of an enthalpic gain (i.e. ΔH = 0 kJ mol-1).  Such situation 
may arise when the entropic contribution from the desolvation process becomes major 
factor for the protein-nanoparticle complexation.  
 
Figure 3.10. Plot of entropy (TΔS) versus enthalpy (ΔH) for protein-nanoparticle 
interaction. Inset shows magnification of the correlation data for the BSA and GFP. 
3.3.2 Conclusion  
In summary, we have demonstrated that the thermodynamic properties for 
complexation between protein and nanoparticles depends on the relative size of 
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proteins. In case of smaller and larger proteins the binding mode is similar but the 
arrangements of protein and nanoparticle are in contrary. The most interesting 
phenomenon is observed for protein with comparable size to nanoparticle where the 
binding mode is different than others. We also observed that the complexation 
exclusively depends on the relative concentration of proteins in solutions. In addition, 
we established the potentiality of the ITC study as a powerful tool to resolve the nature 
of supramolecular interaction by determining the thermodynamic parameters which is 
very crucial for further applications. 
3.4 Experimental Section 
3.4.1 Materials 
All the reagents, α-Chymotrypsin (Type II from bovine pancreas, ChT), 
cytochrome c (from equine heart), histone (Type III-S from calf thymus, an isolated 
lysine rich fraction)bovine serum albumin (BSA) and acid phosphatase (PhosA, from 
potato) were purchased from Sigma and used as received. Green fluorescence protein 
(GFP) was expressed according to the known procedure from the Starter cultures from a 
glycerol stock of GFP (Enhanced GFP (eGFP) was cloned into the pET21d vector 
(Novagen) where Hisx6 tag was located at N-terminus) in BL21 (DE3).73 Amino acid-
functionalized gold nanoparticles (NPs) were prepared by place-exchange of 
corresponding thiol ligands with 1-pentanethiol capped gold NPs (diameter ~ 2 nm) 
according to the published procedure.23 The cationic nanoparticles are prepared 
according to our published procedure.18 Disodium hydrogen and sodium dihydrogen 
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phosphate were dissolved in 18 MΩ water to make a 5 mM phosphate buffer solution of 
pH 7.4, which was used as solvent in isothermal titration calorimetries. 
3.4.2 Determination of Molecular weight of Nanoparticles 
TEM measurements on NP_Ala revealed an average particle size of 2.1±0.4 nm 
(Figure 3.11a).  TGA revealed that the weight percentage of organic ligands in the NPs 
is 36% (Figure 3.11b). Based on that, the average molecular weight of the NP is 
estimated as 100 kDa, which was used for the preparation of NP solutions. The detail 
procedure for TEM and TGA are as follows: 
Transmission Electron Microscopy (TEM). The nanoparticle film was drop-cast 
by putting a drop of aqueous nanoparticles on a 300 mesh carbon-coated copper grid. 
The solvent was evaporated at room temperature (ca. 20 °C).  The TEM images were 
taken on a JEOL 200 instrument operated at 200 keV (Figure 3.11a). 
Thermogravimetric analysis (TGA). TGA was performed using a TGA 2950 
high-resolution thermo-gravimetric analyzer (TA Instruments, Inc., New Castle, DE), 
which was equipped with an open platinum pan and an automatically programmed 
temperature controller. The TGA curves were recorded as follows: about 3.5 mg of 
nanoparticles was placed in the TGA pan and heated in a nitrogen atmosphere at a rate 
of 10 °C / min up to 600 °C. 
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Figure 3.11. a) Histogram of size distribution of NP_Ala (333 counts) from TEM 
image.  The average diameter is 2.1±0.4 nm. b)Thermal gravimetric analysis (TGA) 
curve of NP_Ala. 
3.4.3 Isothermal Titration Calorimetry 
An isothermal calorimeter (ITC), purchased from Microcal Inc. (Northampton, 
MA), was used in all microcalorimetric experiments operated at 30 °C.  Each 
microcalorimetric titration experiment consisted of 30-45 successive injections of a 
constant volume (6 μL/injection) of ChT, Cyt-c, Histone, GFP, BSA or PhosA solution 
(100 μM to 400 μM according to binding ratio) into the reaction cell (1.4 mL) charged 
with a NP solution (1.0 to 2.5 μM) in the same buffer.  The heat of dilution of the 
protein solutions when added to the buffer solution in the absence of NPs was 
determined in each run, using the same number of injections and concentration of 
proteins as in the titration experiments.  The dilution enthalpies determined in these 
control experiments were subtracted from the enthalpies measured in the titration 
experiments. The Origin program supplied by Microcal Inc. was used to calculate the 
binding constant (KS) and molar enthalpy change (ΔH) of reaction from the titration 
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curve.  The molar Gibbs free energy changes (ΔG) and entropies (ΔS) of reaction were 
calculated from the experimentally determined KS and ΔH values. 
 
Figure 3.12. ITC analysis of the interaction of ChT with phenylalanine-functionalized 
nanoparticles (a) leucine-functionalized nanoparticles (b) and glutamic acid-
functionalized nanoparticles (c) in 5 mM sodium phosphate buffer (pH = 7.4) at various 
NaCl concentrations 
3.4.4 Activity Assays 
α-Chymotrypsin (3.48 μM) was incubated with amino acid-functionalized 
nanoparticles (1.74 μM) in 5 mM sodium phosphate buffer (pH 7.4) at varying NaCl 
concentrations (0 mM-200 mM) for 4 h. Thereafter, 184 μL of the above solutions were 
introduced into a 96-well flat bottom microplate followed by the addition of 16 μL of 
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25.9 mM SPNA dissolved in ethanol, resulting in final concentrations of 3.2 μM for 
ChT, 1.6 μM for NPs and 2.0 mM for SPNA.  Activity was followed by monitoring the 
absorption changes at 405 nm with an Ultra Microplate Reader (EL808 Bio-Tek 
Instruments, Inc.).  The obtained activity was normalized to that of ChT without NPs at 
respective salt concentrations. Each sample was measured in triplicate and the average 
was reported. 
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3.4.5 Dynamic Light Scattering (DLS) 
 
Figure 3.13. The DLS analysis for the complexation of NP 1 with BSA at variable time 
scale.  
 
Gold nanoparticles were dissolved in 5 mM sodium phosphate buffer, pH 7.4 to 
make a 2 μM solution and their size was measured on a MALVERN Zetasizer Nano ZS 
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instrument. The similar experiment was repeated with the mixture of 2 μM nanoparticle 
and 6 μM BSA. Just after the addition of BSA the aggregation was started and the 
average diameter was 139 nm. After 15 minute the solution becomes cloudy and the 
measurement was not possible any more. After 2 hours we saw the complete 
precipitation of the protein nanoparticle conjugates. 
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CHAPTER 4 
 
SYNTHETIC “CHAPERONES”: NANOPARTICLE-MEDIATED REFOLDING 
OF THERMALLY DENATURED PROTEINS 
4.1 Introduction 
4.1.1 Molecular Chaperones in Protein Refolding  
One of the key hurdles in biotechnology is the rescue of misfolded proteins 
obtained by in vitro or bacterial expression.1, 2 The molecular chaperones play the role 
at this part by recognizing and selectively binding nonnative proteins to form relatively 
stable complexes.3 This complex help to refold the protein to its original active form 
then the complexes are dissociated by the binding and hydrolysis of ATP. In this 
context, chaperons are not only prevent irreversible aggregation of nonnative 
conformations and keep proteins on the productive folding pathway, but also maintain 
newly synthesized proteins in an unfolded conformation suitable for translocation across 
membranes and bind to nonnative proteins during cellular stress and other functions.4 
Now why chaperons are so important at cellular environment? It is well known that 
depending on amino acid sequence the unfolded or expressed proteins are folded to the 
native protein by a spontaneous process determine by the global free energy minimum. 
But for this process the key factors are time, concentrations and temperature which are 
unusual at physiological condition. In cellular environment the temperature is ambient 
(~37 °C), where the hydrophobic effect will be stronger and thus protein denaturation 
and aggregation will be bigger problem and the concentration with other proteins and 
metabolites is very high.5 Thus there is the need for additional factors for the successful 
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folding of many proteins in vivo with the following prerequisite: i) to prevent 
aggregation and misfolding during the folding of newly expressed proteins, ii) to 
prevent nonproductive interactions with other cell components, iii) to direct the 
assembly of larger proteins and multiprotein complexes and iv) after the proper folding 
the folded protein will be released without any surplus effects. 
Cells have solved the problem of misfolding and aggregation, to a considerable 
extent at least, through the participation of molecular chaperones in the in vivo folding 
process.6 Many investigations in the past few years have established the decisive role of 
molecular chaperones in protein folding, which predominantly involved the recognition 
of hydrophobic residues of newly expressed proteins.7, 8 This noncovalent interaction 
needs a large surface compare to the target protein. Hence based on the size the 
chaperones are classified as follows, 40-kDa heat shock protein (HSP40; the DnaJ 
family), 60-kDa heat shock protein [HSP60; including GroEL and the T-complex 
polypeptide 1 (TCP-1) ring complexes], 70-kDa heat shock protein (HSP70), and 90-
kDa heat shock protein (HSP90).9, 10 Although the fundamental mechanism is similar 
for all chaperones, but their activity is varied from each other. As example, the HSP70 
(DnaK in Escherichia coli) bind to nascent polypeptide chains on ribosomes, preventing 
their premature folding, misfolding, or aggregation, as well as to newly synthesized 
proteins in the process of translocation from the cytosol into the mitochondria and the 
endoplasmic reticulum (ER).11 The GroEL family of chaperones has been intensively 
studied, especially in the context of in vitro protein folding, yet it is not clear just how 
important a role this family play in the folding of most proteins in the cell. 
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Although the folding at cellular environment is not exactly similar to in vitro 
folding, but both in vivo and in vitro, proteins fold remarkably rapidly, indicating that 
the folding pathway is directed in some way. Many studies have revealed intermediates 
during in vitro protein folding experiments; it is not clear, and is very difficult to 
establish experimentally, whether these are on- or off-pathway species.12 Although it is 
becoming apparent that in some cases these may be off-pathway species,13 some appear 
to be true intermediates on the productive folding pathway.14 It was also evident that 
small proteins under appropriate conditions, fold to the native state within a few tens of 
milliseconds with no detectable intermediates.15 On the other hand, the presence of 
partially folded intermediates during folding was detected for larger proteins which take 
longer to achieve the native state (seconds or longer).16 
In general the protein folding processes can be summarized as described in 
Figure 4.1.  According to that the earliest stages of folding involve hydrophobic 
collapse to a relatively compact state and formation of metastable secondary structure. It 
is not clear if collapse or secondary structure occur simultaneously or if one precedes 
the other. It is most likely that both proceed concurrently. Following the metastable 
state, condensation will lead to one or more particularly stable intermediates; which 
consist of a core of nativelike structure with the remainder of the protein in varying 
degrees of disorder.17 Depending on the particular protein, the intermediate(s) will have 
regions of unique structure, especially in terms of the compactness, amount of 
secondary structure, and topology. It was also observed that the metastable and the 
equilibrium intermediates have high tendency to aggregate, particularly at high cellular 
concentration.18 It is likely that a significant factor in the formation of in vivo 
  117
aggregates, such as inclusion bodies, is a lack of available molecular chaperones, 
usually due to the rapid rate of protein synthesis, the formation of long-lived folding 
intermediates, or a combination of both. Either situation could lead to saturation of the 
available chaperones which inhibit the protein aggregation and allow proper folding. 
These folded proteins then release, which is mediated by a conformational change in the 
chaperone driven by ATP hydrolysis. 
 
Figure. 4.1. General outline of chaperone-mediated protein folding.  
4.1.2 Rescue of Misfolded Proteins Using Artificial ‘Chaperones’ 
Proper rescue of the misfolded protein can greatly widen the range of proteins 
available for medical and biotechnological applications. Of the issues associated with 
protein expression, aggregation is the main obstacle hindering proper folding of 
denatured proteins; self-association is often favorable relative to proper folding, 
resulting in significant losses in active protein yield. The importance of proper protein 
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folding has spurred research in developing artificial chaperones and other in vitro 
folding aids. The majority of these approaches proceed in a two-step manner: 
prevention of aggregation followed by proper folding. The most conventional methods 
include solubilization with either urea or guanidine HCl, relying on methods such as 
additives, pH and redox buffers to effect folding.19 Other simplified approaches include 
the addition of polyamines,20 amino acids,21 and polyetheylene glycol.22 
In the cellular environment, machinery in the form of molecular chaperones, 
such as the bacterial GroEL, are used to sequester unfolded proteins to hinder 
aggregation, allowing subsequent folding in a controlled manner.23 Grossly 
oversimplifying their mechanism of action, chaperonins such as GroEL use large 
hydrophobic patches in their interior to bind and unfold misfolded proteins. These 
proteins then refold upon release, which is mediated by a conformational change in the 
chaperone driven by ATP hydrolysis.24 The mechanism of action of molecular 
chaperones has spurred the design and implementation of a variety of biomimetic 
refolding strategies. Rozema and Gellman presented a two-step method using 
surfactants to prevent aggregation, followed by the addition of β-cyclodextrin to strip 
the surfactant and facilitate folding.25, 26 This approach can lead to successful protein 
refolding at concentrations below 1mg/mL, although this value was heavily dependent 
on the model protein used in the studies. Based on these initial reports, many groups 
have tested numerous surfactant and β-cyclodextrin combinations. For example, as 
reported by Cavalieri et. al., the hydrophobized nanoparticles assist carbonic anhydrase 
B (CAB) refolding in a manner similar to the mechanism of molecular chaperones. 
Irreversible CAB thermal denaturation is prevented by nanoparticle complexation and 
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recovery of almost 100% of enzymatic activity is triggered by the ability of β-
cyclodextrin to interact with the hydrophobic moieties (Figure 4.2).27 Other interesting 
modifications of this approach include using linear dextrins,28 hydrophobized 
carbohydrate nanogels,29 stimuli-responsive polymers,30 and liposomes.31 
 
Figure 4.2. Schematic illustration of hypothetical mechanism of nanoparticle induced 
refolding of CAB protein. The figure is adapted from reference no. 27. 
4.1.3 Reversible Binding and Folding of Protein Using Nanoparticles 
External control of the scaffold-protein interaction to either initiate or disrupt the 
binding event is a useful tool for both fundamental and applied biomedical 
investigations.32 Extension of this strategy to surface recognition extends the 
applicability of this methodology to a wide array of cellular processes. Previously, we 
demonstrated that noncovalent inhibition of chymotrypsin by nanoparticles is initially 
mediated by electrostatic complementarity between the cationic residues on ChT and 
the anionic surface of the carboxylate-functionalized nanoparticles. Given the unique 
characteristics of the nanoparticle monolayer we anticipated that the “irreversible” 
inhibition could be reversed through surface modification of the nanoparticle after 
enzyme inhibition has been accomplished. Cationic surfactant derivatives (Figure 4.3a) 
would be expected to bury their hydrophobic segments into the monolayer, exposing the 
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cationic head groups. As a result, the anionic surface charge of the monolayer would be 
attenuated, disrupting the electrostatic interaction between the nanoparticle and ChT 
and releasing the protein. 
 
Figure 4.3. a) Chemical structure of anionic nanoparticle and four cationic surfactants 
used for monolayer modification. b) Reactivation of ChT (3.2 μM) and MMPC (0.8 
μM) after preincubation for 16 hours at room temperature followed by surfactant. c) 
Proposed mechanism of ChT rescue by various surfactants as evident from 
hydrodynamic radius.  
 
For the inhibition of chymotrypsin on the nanoparticle surface, a buffered 
solution of ChT and anionic nanoparticle was incubated at room temperature for 16 
hours, at which time essentially complete inhibition was observed (Figure 4.3b).33 Four 
cationic surfactants were then added: C11 alkane S1, thiol S2, alcohol S3, and C6 
alkane S4 (Figure 4.3a). Addition of surfactants resulted in almost immediate 
restoration of enzyme activity. Long chain derivatives, however, were required for any 
substantial reactivation, with the shorter C6 alkane showing only marginal reactivation 
(Figure 4.3b). The strongest reactivation observed upon addition of the C11 alkane S1 
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was attributed to the formation of bilayer-type structures.34 Interestingly, the thiol 
chains show substantial reactivation at the lower concentration, suggesting that the 
favorable thiol-gold interaction augment the modification process. The formation of 
either bilayer or mixed monolayer was attributed from dynamic light scattering (DLS) 
study. 
We have also described previously that anionic nanoparticles without ethylene 
glycol spacer eventually denature the protein structure. The rescue of ChT activity by 
the addition of surfactants S1-S3, suggest that ChT is partially refold to regain the 
enzymatic activity. Further structural investigation by fluorescence analysis suggests 
that the released ChT from nanoparticle surface are partially refolded towards its native 
structure. 
4.2 Refolding of the Thermally Denatured Protein 
Most of the native proteins have a hydrophobic core and charged or polar group 
on the surface. The hydrophobic core helps to stabilize the tertiary structure of protein 
where the outer polar surfaces interact with the environment for the biological activity. 
Denatured proteins are responsible for numerous diseases such as Creutzfeldt-Jakob 
disease, Bovine spongiform encephalopathy (mad cow disease), and amyloid-related 
illnesses such as Alzheimer's diseases.35,36 Also various medical and biotechnological 
applications require the rescue of misfolded proteins produced by in vitro or in vivo 
genetic expression.37 Therefore, the requirements of proper protein folding have 
prompted research in developing artificial chaperones and other in vitro folding aids.  
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In the cellular environment, chaperone machinery, such as the bacterial GroEL 
and GroES, are used to stabilize unfolded proteins to hinder aggregation, allowing 
subsequent folding in a controlled manner. From the established mechanism of the 
molecular chaperone machinery, a variety of biomimetic refolding strategies are 
introduced. Rozema and Gellman presented a most popular method in protein refolding 
process in a two-step manner: (i) the capture step, in which denatured protein bind with 
ionic detergent to prevent aggregation and (ii) the releasing step, where detergents are 
removed from refolded proteins by some additives.26 The most conventional methods 
consider either urea or guanidine-HCl as an ionic detergent and relying on various 
additives, pH and redox buffers to effect folding. Additional interesting modifications 
of this approach include using linear dextrins, hydrophobized carbohydrate nanogels, 
stimuli-responsive polymers, and liposomes.28, 29 Alternative reported methods include 
the addition of polyamines, amino acids, and polyethylene glycol.20,38 
Recent advance in nanoparticle applications encouraged us to exploit these 
materials in protein refolding. In our previous studies we were able to denature α-
chymotrypsin (ChT) using anionic gold nanoparticles and then sequentially refolded 
and restored ChT activity by the addition of cationic surfactants as a releasing agent.33  
We have shown that 2-(10-mercapto-decyl)-malonic acid functionalized nanoparticle 
(NP_MA) (Figure 4.4a) can form strong complex with ChT and denature the protein 
and upon addition of NaCl it releases the protein with almost complete restoration of 
activity.39 Considering this effect, NP_MA can be used as a refolding agent by 
interacting with denatured cationic proteins, allowing to partial refolding and preventing 
the possible aggregation. After the partial refolding of the proteins, it will be released 
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from NP_MA by the increase of ionic strength of the solution by increasing the NaCl 
concentration since the electrostatic forces should be attenuated by the presence of 
competitive ions (Figure 4.4b).40 The partially refolded proteins will then be renatured 
to its native structure. To establish this idea we consider three cationic proteins, ChT, 
Lysozyme and Papain as model proteins (Figure 4.4c). 
 
Figure 4.4. a) Schematic representation of the structure of AuDA and b) thermal 
denaturation followed by NP mediated refolding of proteins. c) Surface structural 
features of three positively charged proteins used in the refolding study. Color scheme 
for the proteins: basic residues (blue), acidic residues (red) polar residues (green) and 
nonpolar residues (grey). 
4.2.1 Result and Discussion 
4.2.1.1 Rescue of Enzymatic Activity 
Protein can be denatured chemically in the presence of denaturing agents or 
thermally by heating or cooling. Here we denatured the protein solution in 5 mM 
sodium phosphate buffer (pH 7.4) by heating at suitable temperature. The NP_MA was 
prepared by Murray’s place exchange reaction. The detail procedure is described in 
experimental section. 
The enzymetic activity of the proteins are changed or diminished with the 
alteration of secondary structure of protein. As the ChT and papain are serine and 
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cysteine protease respectively, the enzymatic activity of denatured and refolded ChT 
and papain was studied to determine the extent of refolding. ChT and papain denatured 
by heating at 80°C for 30 min in 5mM sodium phosphate buffer at pH 7.4 while the 
lysozyme heated at 60°C for 30 min. For refolding the protein the NP_MA was added 
and the mixture was allowed to stand for one hour. 100 mM NaCl was then added to 
release the refolded protein by disrupting the electrostatic interaction. With this 
resultant solution the activity of ChT and papain was measured. The activity of ChT 
was monitored using N-succinyl-l-phenylalanine p-nitroanilide (SPNA) as a substrate in 
compare with native ChT in 5mM sodium phosphate buffer at 7.4 pH. The enzymatic 
activity of thermally denatured ChT and in the presence of NP_MA is also measured. 
The concentration of protein and nanoparticles ware fixed at 3.2μM and 0.8 μM 
respectively. As expected NP_MA exhibits inhibition on residual activity of denatured 
protein but upon release by 100mM NaCl solution highly efficient (~93%) restoration 
of activity was observed with NP_MA, while little activity restoration was observed in 
the absence of nanoparticle (Figure 4.5). The restoration of activity suggests that in 
presence of the nanoparticle, the thermally denatured ChT refolds. This refolding take 
place via binding with the nanoparticles with positively charged residues on the surface 
of the ChT and subsequent release by 100 mM NaCl which exposes its active site to the 
substrate. The similar enzymatic study was done with papin using Nα-benzoyl-L-
arginine p-nitroanilide (BAPNA) as a substrate in presence of β-mercaptoethanol as an 
activator. The concentration of nanoparticle and protein are same as the earlier at same 
buffer. Similar to ChT, the enzymatic activity of thermally denatured protein increases 
to ~97% in presence of  NP_MA compared to the native protein. 
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Figure 4.5. Enzymatic activity of thermally denatured ChT and papain (3.2μM) in the 
presence of NP_MA (0.8 μM) and 100 mM NaCl solution in 5 mM sodium phosphate 
buffer (pH = 7.4). 
4.2.1.2 Restoration of Secondary Structure  
The circular dichroism (CD) spectrum of a protein is particularly more potential 
for the characterization of secondary structure of a protein.41, 42 Hence to determine the 
degree of protein refolding we measure and compare the CD spectra of native, 
denatured and refolded proteins. CD spectra of protein with 100 mM NaCl could not be 
monitored at wavelengths shorter than 200 nm due to its high absorbance from the 
increased salt concentration. 
The CD spectrum of native ChT has two characteristic minimum at 202 nm and 
230 nm.43 This two minimum are lost or changed when ChT loses its native structure 
and hence the enzymatic activity.44 As expected, during the thermal denaturation the 
minimum at 230 nm completely disappears and the minimum at 202 nm enlarged and 
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shifted to 199 nm (Figure 4.6a). The addition of 100 mM NaCl does not show any 
spectral change but after the incubation with AuDA the minimum at 202 nm was 
regenerated. Although we didn’t see any minimum at 230 nm, but the spectra has high 
similarity with native one compared to thermally denatured ChT, which is consistent 
with the increased activity observed in activity assays. Also the calculation of secondary 
structures (Helices, strand, turn and random coil) using DICHROWEB suggests 
significant refolding of protein structure. According to the calculation, although the α-
helices are not entirely recovered, β-strand and turns increase with decrease of random 
coil compared to the native ChT which implies the extensive refolding of thermally 
denatured protein (Figure 4.6d). Similar experiment also performed with the other two 
cationic proteins, lysozyme and papain with consistent result. In case of lysozyme, the 
native protein has one minimum at 208 nm and one maximum at 192 nm primarily due 
to its high α-helix content.45 When lysozyme was thermally denatured the content of α-
helix decreases to ~6% from ~37% and the random coil increases accordingly. But in 
the presence of NP_MA the α-helicity increases and random coil decreases significantly 
which is similar to the native structure (Figure 4.6e). The removal of NP_MA by 
increasing ionic strength further improves the protein structure as we can see from 
figure 3b. In the similar way thermally denatured papain refolded to regenerate the two 
minimum at 208 nm and 222 nm, which is observed in native protein.46 The secondary 
structure analysis also suggests considerable refolding of denatured protein in the 
presence of NP_MA consistent with the enzymatic activity recovery (Figure 4.6c and 
f). 
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Figure 4.6. CD spectra of native, thermally denatured (5 μM) and denatured proteins 
with nanoparticles (NP) (1.25 μM) and in presence of 100 mM NaCl after 4h 
incubation. (a), (b) and (c) are CD spectra for α-chymotrypsin, lysozyme and papain 
respectively. (d-e) The percentage of secondary structure elements of native, thermally 
denatured and refolded proteins as estimated from far-UV CD spectra using CDSSTR 
method. 
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It was well known that the native structure has the hydrophilic residues present 
at the surface of the protein to prevent aggregation as it is hydrated. In our study the 
cationic proteins have positive residues (i.e. arginin and lysin) on the surface which 
prevent the protein aggregation by hydration and electrostatic repulsion. But during the 
thermal denaturation the hydrophobic inner core gets well exposed and causes the 
possible aggregation by intermolecular association of the hydrophobic core.47,48 But 
employment of negatively charged nanoparticles (NP_MA) prevents the aggregation by 
binding with unfolded proteins through the electrostatic interaction with positive 
residues and promotes correct refolding. The overall high negative charge of these 
complexes, as evident from the Zeta potential measurement (Table 4.2 in experimental 
section), prevents the aggregation, thereby promoting correct refolding (Figure 4.7). 
Thereby the nanoparticles preventing aggregation and misfolding act as an artificial 
chaperon. 
 
Figure 4.7. Illustration of the thermally induced protein unfolding process and the 
exposure of hydrophobic core followed by either aggregation in absence of nanoparticle 
or binding and refolding in presence of nanoparticle. 
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In presence of nanoparticle the charged residues are reorganized on the surface 
and hydrophobic part regenerate the inner core with probable secondary structure. Upon 
removal of negatively charged nanoparticle by increasing salt concentration the released 
partially refolded proteins are not further aggregated due to its hydrophilic surface 
becoming similar to native protein. After the rescue from nanoparticle surface the 
protein is refolded towards its native structure to minimize the potential energy. During 
this self refolding towards the native structure the protein passes through several 
intermediate structures which are already established by several studies such as NMR 
analysis,49 which is consistent with our experimental results. It was also reported that 
for some proteins one intermediate structure is present at equilibrium with other 
structures. In case of lysozyme an isosbestic point at 202 nm observed in CD study 
suggests clearly the equilibrium between the intermediate states. Although for the other 
two proteins this point is not prominent as lysozyme (212 nm and 201 nm for ChT and 
papain respectively). 
4.2.2 Conclusion 
In conclusion here we demonstrate the application of nanoparticles in protein 
refolding. In the present study we used highly charged negative particles, NP_MA for 
extensive refolding of thermally denatured cationic proteins. In this report we achieved 
considerable refolding of thermally denatured cationic proteins in presence of anionic 
nanoparticles. Also this perception opens the possibility of refolding the anionic 
proteins by using positively charged nanoparticles. This fundamental study offer 
promising opportunities in developing protein stabilization and refolding system for 
further application. 
  130
4.3 Experimental 
4.3.1 Materials 
All the reagents, α-Chymotrypsin (Type II from bovine pancreas, ChT), 
Lysozyme (from chicken egg white), Papain (from Carica papaya), N-succinyl-L-
phenylalanine p-nitroanilide (SPNA) and Nα-benzoyl-L-arginine p-nitroanilide 
(BAPNA) was purchased from Sigma and used as received. 
4.3.2 Synthesis of Ligand and Nanoparticle  
Synthesis of 2-(10-mercaptodecyl)-malonic acid (1) ligand and fabrication of 2 
nm gold particle was done according to the following procedure. In brief, 1,10-
dibromodecane was added to the solution of malonic diethyl ester and sodium ethoxide 
solution in ethanol. After the completion of the reaction, ethanol was evaporated and 
residues are redissolved in water-dichloromethane mixture. After the separation the 
crude product was purified using silica gel column chromatography to obtain 2-(10-
bromodecyl)-malonic acid diethyl ester (2). The compound 2 was refluxed with sodium 
thioacetate in ethanol for overnight for the thioacetate substitution followed by aqueous 
NaOH hydrolysis to produce the 2-(10-mercaptodecyl)- malonic acid (1) which was 
purified using silica gel column chromatography. 
Pentanethiol coated gold nanoparticles (d = 2 nm) were prepared according to 
the previously reported protocol.50 Place-exchange reactions51 were carried out to 
replace the 1-pentanethiol ligand on the nanoparticle surface with malonic acid 
functionalized ligand 1 to obtain the NP_MA nanoparticle. 
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Scheme 4.1. Synthesis of malonic acid derivative for NP_MA nanoparticle.  
4.3.3 Thermal Denaturation of Proteins 
Proteins were dissolved in aqueous 5 mM sodium phosphate buffer solution 
(Na2HPO4 / NaH2PO4), pH 7.4 to make a concentration of 10 μM. The protein solutions 
were thermally denatured by incubating at 60°C (for lysozyme) to 80°C (for α-
chymotrypsin and papain) for 30 min in airtight micro-centrifuge tubes. Following 
incubation, the proteins were transferred to an icewater bath to quench the denaturation 
process and the protein solution was used for activity assay and Circular dichroism 
study. 
4.3.4 Activity assay 
Activity assay of α-Chymotrypsin. Thermally denatured α-Chymotrypsin 
(3.48 μM) was incubated with AuDA (0.87 μM) in 5 mM sodium phosphate buffer (pH 
7.4) for 4h, then at 100 mM NaCl concentrations for 1h. Thereafter, 184 μL of the each 
solution were taken in a 96-well flat bottom microplate along with native and denatured 
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α-Chymotrypsin followed by the addition of 16 μL of 25.9 mM SPNA dissolved in 
ethanol, resulting in final concentrations of 3.2 μM for ChT, 0.8 μM for NPs and 2.0 
mM for SPNA.  Activity was followed by monitoring the absorption changes at 405 nm 
with an Ultra Microplate Reader (EL808 Bio-Tek Instruments, Inc.).  The obtained 
activity was normalized to that of ChT without NPs. Each sample was measured in 
triplicate and the average was reported. 
Activity assay of Papain. Papain enzyme activity was also assayed with the 
chromogenic reagent BAPNA. The enzyme was activated by incubating in 2-
mercaptoethanol at concentration of 142 mM. In this experiment thermally denatured 
papain was incubated with AuDA for 4h and then 1h with 100 mM NaCl at same 
concentration of ChT activity assay. Similarly 182 μL of each solution with 16 μL 
BAPNA and 2 μL mercaptoethanol was taken in a 96-well flat bottom microplate. The 
activity of papain on BAPNA was followed spectrophotometrically at 405 nm using 
same microplate reader. The obtained activity was normalized to that of native papain. 
Each sample was measured in triplicate and the average was reported. 
4.3.5 Circular Dichroism 
Far-UV circular dichroism (CD) spectra of ChT (3.2 μM) were measured on a 
JASCO J-720 spectropolarimeter with quartz cuvettes of 1 mm path length at 25 °C.  
The spectra were recorded from 190 to 250 nm as an average of 3 scans at a rate of 20 
nm/min.  The concentration of proteins is fixed at 5 μM and 0.8 μM for AuDA. The 
final spectra were obtained by subtracting the blank to eliminate background effects. 
The resultant CD spectra was fitted into secondary structure algorithm CDSSTR 
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(protein ref. set 7 comprising of 49 proteins) using DICHROWEB to determine the 
change in secondary structures (Table 4.1).  
Table 4.1. The percentage of secondary structure elements of native proteins and 
thermally denatured proteins in the absence and presence of gold nanoparticles as 
estimated from far-UV CD spectra using CDSSTR method.52 
 
Sample α−Helix β−Sheets β−Turn Random coil 
ChT 
DChT 
DChT-AuDA 
14.1 
6.5 
8.3 
23.1 
15.2 
26.4 
14.6 
14.7 
17.6 
48.1 
63.7 
47.7 
Lys 
DLys 
DLys-AuDA 
37.0 
6.1 
28.0 
16.2 
19.2 
25.3 
19.1 
14.2 
17.5 
27.3 
60.5 
28.2 
Pap 
DPap 
DPap-AuDA 
12.6 
4.1 
9.1 
27.6 
18.8 
30.1 
17.5 
18.6 
18.3 
42.3 
58.5 
42.4 
4.3.6 Zeta Potential 
AuDA gold nanoparticles were dissolved in 5 mM sodium phosphate buffer, pH 
7.4 to make a 1 μM solution and their zeta potentials were measured on a MALVERN 
Zetasizer Nano ZS instrument. The similar experiment was repeated with three 
denatured proteins at 4 μM concentration. Three rounds of assays of each solution have 
been performed and the average values were reported. 
Table 4.2. Zeta-potentials for AuDA nanoparticle and in presence of three denatured 
proteins in 5 mM sodium phosphate buffer, pH 7.4 at 25.0 °C 
 
Sample zeta-potential / mV 
AuDA −44.7±1.5 
AuDA + α-Chymotrypsin −42.8±1.4 
AuDA + Papain −30.6±2.5 
AuDA + Lysozyme −22.1±1.5 
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CHAPTER 5 
 
SENSING OF PROTEINS USING NANOPARTICLE-GREEN 
FLUORESCENCE PROTEIN CONJUGATES 
5.1 Introduction 
5.1.1 Protein Sensing 
 Protein sensors provide an important tool for the early diagnosis of diseases in 
biomedical research and practice,1, 2 as the presence of biomarker proteins or irregular 
protein concentrations is a consequence of cancer and other disease states.3, 4 Protein 
detection is however always a challenging target due to its structural and charge 
diversity and complexity, mainly to construct general sensor for multiple protein 
analyte. 
Current protein sensors are highly engineered detection systems that rely on 
highly specific and selective interactions between receptors and proteins, such as 
enzyme-linked immunosorbent assay (ELISA),5 artificial oligionucelotides (aptamers),6 
and protein chip technologies.7 In these systems receptors are immobilized onto a 
device surface and binding of the target protein induces either an optical or 
electrochemical signal.8, 9 As an example, So et. al. reported the real-time detection of 
protein using single-walled carbon nanotube field effect transistor (SWNT-FET) based 
biosensors consist of DNA aptamers as protein recognition elements (Figure 5.1).10 
Anti-thrombin aptamers that are highly specific to thrombin were immobilized on the 
sidewall of a SWNT-FET. The binding of thrombin aptamers to SWNT-FETs causes a 
rightward shift of the threshold gate voltages, whereas the addition of thrombin solution 
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causes an abrupt decrease in the conductance of the thrombin aptamer immobilized 
SWNT-FET. This change in voltage was used to detect the thrombin protein. The 
sensitivity of this system was saturated around protein concentrations of 300 nM. 
Although the lowest detection limit was around 10 nM. 
 
Figure 5.1. Binding and detection of thrombin on a SWNT-FET and aptamer based 
sensor. Carbodiimidazole-activated Tween 20 (CDI-Tween) was used to link the 
thrombin aptamer. Reprinted from reference no. 10. 
 
The advantage of this specific “lock and key” mechanism is a highly sensitive 
detection system that can eliminate false positives. Affinity and catalytic-based protein 
sensors relying on antibodies as the recognition elements dominate commercial 
biosensor markets.11 These protein detection systems are effective, however high 
production costs for antibodies, protein stability on surfaces, and extensive sample 
preparation has encouraged the demand for other multi-protein array detection system. 
5.1.2 Chemical tongue/nose sensors 
In biology most biomolecular interaction takes place by specific recognitions. 
Mimicking that interaction various sensor systems are reported, which are limited to 
specific analyte sensing. Other sensory processes such as taste and smell use 
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“differential” binding where the receptors bind to their analytes by different binding 
characteristics that are selective rather then specific.12 These arrays, also known as 
“electronic tongues”13 and “nose”14 provide highly versatile sensors. For instance,  
Greene and Shimizu reported a colorimetric sensor array composed of seven 
molecularly imprinted polymers to identify seven different aromatic amines (Figure 
5.2).15 Using the colorimetric response they systematically identified the amines using 
linear discriminant analysis with 94% classification accuracy.  
 
Figure 5.2. A Representative Scheme of an MIP Sensor Array that Uses a Dye-
Displacement Strategy to Give an Easily Visualized and Unique Colorimetric Response 
Pattern for Each Analyte. 
 
This method also has been used to sense calcium and metal ions, pH levels, 
sugars as well as cholesterol levels in blood, cocaine in urine, and toxins in water.16, 17 
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A variety of other analytes such as including metal ions,18 volatile agents,19 aromatic 
amines and nitrates,15, 20 amino acids,21, 22 and carbohydrates23 have also been 
successfully identified using this approach.  
5.1.3 Protein sensing using chemical noses 
The emergences of abnormal proteins and/or irregular protein concentrations are 
indicative of cancers and diseases.24 Therefore, sensitive, convenient, and precise 
protein sensing methods are required to obtain early diagnosis of diseases and 
successful treatment of patients. Currently, the most extensively used detection method 
for proteins is enzyme-linked immunosorbent array (ELISA).25 In this system, the 
capture antibodies immobilized onto surfaces bind the antigen through a “lock-key” 
approach and another enzyme-coupled antibody is combined to react with chromogenic 
or fluorogenic substrates to generate detectable signals. Despite of the high sensitivity, 
the application of this method is restricted due to its high production cost, instability, 
and challenges for quantification. On the other hand, synthetic agents with high affinity 
and specificity for proteins are scarcely available although they possess better chemical 
and thermal stability.  
Recently, the “chemical nose/tongue” approach has been applied to protein 
sensing. Hamilton’s group has used eight tetra-meso-carboxylphenyl-porphyrins 
carrying peripheral amino acid functionalities to identify four metal and nonmetal-
containing proteins, with a detection limit between 7.5 ~ 15 μM (Figure 5.3a).26, 27 
Anslyn et al. have employed 29 boronic acid-containing oligopeptide functionalized 
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resin beads to differentiate 5 proteins and glycoproteins through an indicator-uptake 
colorimetric analysis, with a limit of detection of 355 μM (Figure 5.3b).28 
 
Figure 5.3. a) A library of tetra-meso-carboxylphenylporphyrin (TCPPs) conjugated 
with amino acids or amino acid derivatives used for protein sensing by Hamilton’s 
group (reprinted from reference no. 26, 27). b) Structure of receptors which 
incorporates one of 19 natural amino acids at each of three sites that are biased towards 
particular analyte classes. Bromopyrogallol red is used for the indicator-uptake 
colorimetric analysis (reprinted from reference no. 28).  
 
It has more recently been shown that non-selective electrostatic interaction in 
combination with covalently or non-covalently bound fluorophores are sufficient to 
differentiate between a numbers of biological relevant metalloproteins. Thayumanavan 
et al. exploited eight different fluorescence dye molecules non-covalently bound to the 
  142
micellar interiors of an amphiphilic homopolymer to generate a pattern and differentiate 
four different metalloproteins, with limits of detection between 1-200 μM.29, 30 
5.1.4 Protein sensing using particle-polymer complexes 
Based on pattern based sensing our group also created a sensor array which 
contains six structurally related cationic gold nanoparticles (NP 1-NP 6) as noncovalent 
protein receptors to create protein sensors (Figure 5.4a).31 The nanoparticle end groups 
carry additional hydrophobic, aromatic or hydrogen-bonding functionality to tune the 
interaction between nanoparticles and proteins.  For the signal transduction element, 
highly fluorescent poly(p-phenyleneethynylene) (PPE)32, 33 derivative, PPE-CO2,34 
was used a as a fluorescence indicator (Figure 5.4a). To establish the efficiency of this 
sensor, seven proteins with diverse structural features (Mw, pI) with variable 
concentrations levels were used as the target analytes.   
As the PPE-CO2 backbone is anionic in nature, in presence of cationic 
nanoparticles the polymer fluorescence is quenched by gold nanoparticles. But in 
presence of analyte proteins, due to the competitive interaction between polymer and 
protein, disrupted the nanoparticle-polymer interaction, producing distinct fluorescence 
response patterns. These patterns were highly reproducible and characteristic for 
individual proteins, depending on the size and charge of the corresponding protein 
(Figure 5.4b). As all proteins vary their charge and size, they can be distinguished by 
this pattern. Also the response pattern fluctuates with the concentration of the analyte 
proteins but the reproducibility was observed even at nanomolar concentration. 
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Figure 5.4. a) Structure of cationic gold nanoparticles (NP 1-NP 6) and anionic 
fluorescent polymer PPE-CO2 (n~12). b) Fluorescence response (ΔI) patterns of the NP-
PPE sensor array (NP 1 – NP 6) against various proteins (5 μM). 
 
The raw data obtained were subjected to linear discriminant analysis (LDA) to 
differentiate the fluorescence response patterns of the nanoparticle-PPE systems against 
the different protein targets.  LDA can maximize the ratio of between-class variance to 
the within-class variance in any particular data set thereby enabling maximal 
reparability. 
The response patterns obtained from LDA for 5 μM proteins ware giving 100% 
separation accuracy (Figure 5.5a). Furthermore, another 56 protein samples were 
prepared randomly and used as unknowns in a “blind” experiment, i.e. the individual 
performing the analysis did not know the identity of the solutions. Out of 56 cases, 54 
were correctly classified, affording an identification accuracy of 96.4%. But the 
detection and identification of proteins with both unknown identity and concentration is 
necessary for real world application. To make possible the detection of unknown 
proteins, a protocol was designed with the combination of LDA and UV measurements.  
In this approach, a set of fluorescence response patterns were generated at protein 
concentrations with an identical UV absorption value at 280 nm (A280 = 0.005) which is 
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the lowest concentration to get the substantial difference in responses. Using this 
protocol this sensor system were able to identify and quantify proteins at unknown 
concentrations with LDA classification accuracy of 97.6% (41 out of 42), according to 
the Jackknifed classification matrix (Figure 5.5b). This measurement also successfully 
used to identify and quantify 52 unknown proteins with an accuracy of 94.2% with 
concentrations within ±5-10%. 
 
Figure 5.5. Canonical score plot as calculated by LDA for the identification of seven 
proteins, with 95% confidence for a) 5 μM proteins and b) proteins with identical 
absorption values of A = 0.005 at 280 nm. 
5.2 Protein Detection using Nanoparticle-GFP Conjugates 
In gold nanoparticle-fluorescent conjugated polymer based array array we used 
six different functionalized cationic nanoparticles and a fluorescent polymer to detect 
seven target proteins at detection limit of 4 nM for β-galactosidase (β-gal) with the 
accuracy of 94%.31 Alternative to that system we also construct a biomolecules-based 
chemical nose approach that provides lowered limits of detection coupled with 
enhanced biocompatibility. In this approach an array of green fluorescent protein 
(GFP)-nanoparticle complexes was fashioned and used for the identification of proteins. 
The biocompatibility of the nanoparticles and GFP allows us to use this conjugated 
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system without any effect on target protein conformation during their detection.35, 36 
GFP is a beta barrel shaped marker protein that is negatively charged at physiological 
conditions (3.0 x 4.0 nm, MW = 27 KDa, pH 7.4, pI = 5.92),37, 38 with an excitation 
peak at 490 nm and emission peak at 510 nm (Figure 5.6a). Due to its negative charge, 
GFP forms complexes with cationic gold nanoparticles, quenching GFP fluorescence. 
We hypothesized that displacement of the GFP from the particle by analyte proteins 
would regenerate GFP fluorescence.  
Figure 5.6. a) Structure, absorbance and fluorescence spectra of GFP in 5 mM sodium 
phosphate buffer, pH 7.40. b) Chemical structure of cationic gold nanoparticles (NP1-
NP14). The nanoparticles highlited with green and blue color are used for low and high 
detection limit and red are used for both. c) Schematic illustration of the competitive 
binding between protein and quenched nanoparticle-GFP complexes leading to the 
fluorescence light-up. 
 
To test this hypothesis, fourteen cationic gold nanoparticles (NP1–NP14) were 
synthesized and used to sense proteins. In addition to their cationic charges, these 
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nanoparticles varied hydrophobicity, aromaticity, and hydrogen bonding functionality 
(Figure 5.6b). We expected that in the presence of protein targets, GFP-nanoparticle 
interactions would be disrupted and generating distinct fluorescent signal patterns. 
Based on the affinity between protein target and GFP-nanoparticle adducts that could 
then be used to identify proteins (Figure 5.6c) 
5.2.1 Result and Discussion 
5.2.1.1 Fluorescence titration and Sensor Design 
To optimize the binding ratio between GFP and nanoparticles for sensing, 
fluorescence titration was first conducted to assess the complexation between anionic 
GFP and cationic gold nanoparticles NP1-NP6. The intrinsic fluorescence of GFP was 
significantly quenched upon addition of all nanoparticles (Figure 5.7). The absorption 
effect of gold cores was obtained through control experiments using neutral particles39, 
40 and the normalized fluorescence intensities of GFP at 510 nm were subsequently 
plotted versus the ratio of nanoparticle to GFP. The complex stability constants (KS) and 
association stoichiometries (n) were obtained through nonlinear least-squares curve-
fitting analysis (Table 5.1).41 Complex stabilities vary within ca. one order of 
magnitude (ΔΔG ~ 15 kJ mol-1), while the binding stoichiometry varies from ~2 to ~10.  
The observation indicates that the subtle structural changes of nanoparticle end groups 
significantly affect their affinity for the protein surface. It is noteworthy that all particle-
GFP conjugates were optically transparent over the concentration range studied.  
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Figure 5.7. Fluorescence titration curves for the complexation of GFP with cationic 
gold nanoparticles NP 7. The changes of fluorescence intensity at 510 nm were 
measured following the addition of cationic nanoparticles (0-100 nM) with an excitation 
wavelength of 475 nm. The red solid lines represent the best curve fitting using the 
model of single set of identical binding sites. 
 
Table 5.1. Binding constants (KS), Gibbs free energy changes (−ΔG) and binding 
stoichiometries (n) between GFP and various cationic nanoparticles (NP1–NP14) as 
determined from fluorescence titration. 
 
Nanoparticle Ks (109 
M-1) 
-ΔG (kJ 
mol-1) 
n 
NP1 22.7 59.11 3.9 
NP2 2.6 53.74 2.8 
NP3 51.3 61.13 2.2 
NP4 15.9 58.23 3.6 
NP5 30.7 59.86 4.1 
NP6 9.4 56.93 1.8 
NP7 0.5 49.65 4.7 
NP8 1.1 51.61 7.9 
NP9 0.2 47.38 1.6 
NP10 0.5 49.65 9.7 
NP11 9.3 56.90 4.4 
NP12 83.9 62.35 3.3 
NP13 0.1 45.66 6.2 
NP14 0.2 47.38 3.3 
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5.2.1.2 Proteins Identification and Determination of the Detection Limit 
Once the optimal binding ratios were determined, eleven target proteins with 
diverse sizes and charges were used to test the efficacy of the method (Table 1). Once 
the different binding characteristics of GFP with NP1-NP14 were established, the 
optimal binding ratios were determined. According to that, nanoparticle-GFP 
conjugates were used to sense eleven proteins. The proteins were chosen to display a 
variety of sizes and charges: the isoelectric points (pI) of the eleven proteins vary from 
4.6 to 10.7 and molecular weights range from 12.3 to 540 kDa (Table 5.2).  Within this 
set there are several pairs of proteins that have comparable molecular weights and/or pI 
values, providing a challenging testbed for protein discrimination. In the initial sensing 
study, 200 μL of GFP (100 nM) and stoichiometric nanoparticles NP1-NP14 (the 
stoichiometric values were taken from Table 5.1) were respectively loaded onto 96-well 
plates for recording the initial fluorescence intensities at 510 nm.  Under these 
conditions, it is estimated that > 80% of polymer is bound to the nanoparticles based on 
the binding constants listed in Table 5.1, allowing fluorescent enhancement via 
subsequent displacement. 
Table 5.2.Analyte proteins and concentrations used in study 
 
Conc. (nM)  
Proteins 
MW 
(kDa) 
pI ε280 
(M-1 cm-1) A280 0.005 A280 0.0005 
Bovine serum alb. (BSA) 66.3 4.8 46860 107 10.7 
Acid phosphatase  (PhosA) 110 5.2 257980 19 1.9 
α-amylase (α-Am) 50 5.0 130000 38 3.8 
β-galactosidase ( β-Gal) 540 4.6 1128600 4 0.4 
Subtilisin A (SubA) 30.3 9.4 26030 192 19.2 
Hemoglobin (Hem) 64.5 6.8 125000 40 4.0 
Human serum alb. (HSA) 69.4 5.2 37800 132 13.2 
Alk. phosphatase (PhosB) 140 5.7 62780 80 8.0 
Myoglobin  (Myo) 17.0 7.2 13940 359 35.9 
Lipase (Lip) 58 5.6 54350 92 9.2 
Histone (His) 21.5 10.8 3840 1302 130 
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Following the previous protocol we can identify the unknown protein with 
unknown concentrations. The protocol is based on the combination of LDA and UV 
measurements. In brief, according to this protocol, a set of fluorescence response 
patterns were generated at analyte protein concentrations that generated a standard UV 
absorption value at 280 nm. We will determine the lowest absorbance that the proteins 
could be substantially differentiated using the given sensor array followed by LDA.  
Therefore, the absorbance followed by the corresponding protein concentration (can be 
obtained from ε280) could also be treated as the detection limit of this assay. Another 
part is the identification of unknown protein with unidentified concentration. According 
to our protocol, the A280 value of the protein will be determined, and an aliquot 
subsequently diluted to A280 for recording the fluorescence response pattern against the 
nanoparticle-GFP sensing array. Once the identity of the protein was established by 
LDA, its initial concentration could be determined from the initial A280 value and 
corresponding molar extinction coefficient (ε280) according to Beer-Lambert Law. 
To determine the feasibility and efficiency of this system we first started with 
A280 = 0.005, which was the detection limit for the previous nanoparticle-polymer 
system. Using that concentration of all eleven analyte proteins we generated its 
fluorescence response against the corresponding GFP-nanoparticle complexes (GFP-
NP1 to NP14) using six duplicates. 
In the first matrix set, addition of proteins into GFP-nanoparticle complexes at 
the same absorbance value (A280 = 0.005) resulted in unique fluorescence response 
patterns, as the affinity between the analyte proteins and nanoparticles differs depending 
on the surface characteristics of protein. At A280 = 0.005 we found maximum 
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classification accuracy of single nanoparticle-GFP conjugate was 80% (NP14 and 
NP2). We also found that at A280 = 0.005 three GFP-nanoparticle complexes (NP7, 
NP9, NP12) afford an optimal classification of 100% accuracy (3 factors x 11 proteins 
x 6 replicates, Jackknifed classification matrix = 100%) (Figure 5.8a, b). This efficiency 
was mirrored in our unknown studies, where 48 unknown protein samples from the 11 
target analytes were randomly prepared and identified with 100% identification 
accuracy. 
 
Figure 5.8. a) Fluorescence response (ΔI) patterns of the nanoparticle-GFP conjugate 
(NP7, NP12 and NP14) in the presence of various proteins at identical absorbance value 
of 0.005. Each value is an average of six parallel measurements. b) Canonical score plot 
for the fluorescence patterns as obtained from LDA against 11 protein analytes at fixed 
absorbance values A280 = 0.005. The 95% confidence ellipses for the individual proteins 
are also shown. 
 
After getting the better efficiency in protein detection using nanoparticle-GFP 
conjugates, the next step will be the determination of the detection limit of this system. 
For that we run the trial at various lower absorbances of those eleven proteins. We 
found out that the lowest absorbance, where we can generate reproducible response 
pattern is A280 = 0.0005. The fluorescence response patterns where the protein 
concentration is A280 = 0.0005 are distinctly different from those generated from A280 = 
0.005, but retain a high degree of reproducibility. In the case of A280 = 0.0005, the 
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biosensor accuracy was reduced to 70% using the above three nanoparticles. We found 
that accuracy was restored using six GFP-nanoparticle complexes (NP1, NP2, NP4, 
NP7, NP12, NP14), obtaining 98% accuracy (6 factors x 11 proteins x 6 replicates, 
Jackknifed classification matrix = 98%) (Figure 5.9).The canonical fluorescence 
response patterns display excellent separation, except for a minor overlap between 
hemoglobin and subtilisin A. 
A series of unknown protein solutions were subsequently used for quantitative 
detection. For this set, 45 out of 48 unknown samples were correctly identified, 
affording an identification accuracy of 94 % with a detection limit as low as 400 
picomolar for β-gal. This result unambiguously manifests that our sensor array holds 
substantial promise for both the identification and quantification of protein analytes. 
 
Figure 5.9. a) Fluorescence response (ΔI) patterns of the nanoparticle-GFP conjugate 
(NP1, NP2, NP4, NP7, NP9 and NP12) in the presence of various proteins at identical 
absorbance value of 0.0005. Each value is an average of six parallel measurements. b) 
LDA analysis of the fluorescence patterns as obtained from 11 protein analytes at fixed 
absorbance values A280 = 0.005. The little overlap between SubA and Hem was 
observed. 
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5.2.2 Conclusion 
In summary, we have demonstrated that GFP-nanoparticle conjugates can effectively 
identify the wide range of proteins at nano/picomolar concentrations (400 pM for β-
Gal). In this approach the competitive complexation between GFP and analyte proteins 
with nanoparticles make this system comparable to natural protein-protein interaction. 
Moreover the use of GFP and gold nanoparticle make this system biocompatible which 
can detect protein without any possible chance of protein deconformation. Hence these 
efficient characteristics of this system make it extremely promising in detection of 
proteins for biomedical diagnostics.  
5.3 Detection of Serum Protein in Human Serum 
Personalized medicine42, 43 requires personalized diagnostics to achieve 
personalized treatment of specific diseases. While treatment with personalized drugs is 
the final goal, a necessary prerequisite is the early determination of the disease status 
and causes. It was evident that the most acute and chronic disease states will result in 
subtle or dramatic changes in the relative composition of a person’s blood serum.44, 45 
This hypothesis has strong support from regular clinical tools, where simple 
electrophoresis of plasma leads to the identification and semiquantitative 
“fingerprinting” of proteins that are abundant in blood serum. The presence of specific 
electrophoresis patterns can interpreted by physicians to diagnose a significant number 
of disorders.46 Changes in protein electrophoresis patterns are diagnostic for liver and 
renal failure, as well to states of massive malnutrition, systemic shock or other large 
scale inflammatory events. Simple one-dimensional agarose electrophoresis of protein 
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serum is an effective but slow and insensitive tool for the detection of gross protein 
imbalances. The reason of the difficulty for the detection of protein composition in 
serum is arising from its complex composition. Human blood serum contains >20,000 
different proteins, some of which are present in concentrations > 50 gL-1 such as 
albumin, down to specific disease markers including cardiac troponin or natriuretic 
peptide that are found after a myocardial infarct or in patients with congestive heart 
failure respectively in concentrations of 2-9 μgL-1 and 0.6-1.4 μgL-1 respective. Besides 
albumin, the other proteins found in plasma at high concentrations are prealbumin (0.2-
0.4 gL-1), antitrypsin (a protease inhibitor 0.5 gL-1), macroglobulin (1.5-3.5 gL-1),  
lipoprotein (3-7 gL-1),  transferrin (2-4 gL-1), and immunoglobulins A, D, E, G (8-17 
gL-1).  About 20 proteins constitute 99 weight% of all of the serum protein content. 
Table 5.3 displays the isoelectric point, molecular weight and approximate 
concentrations of the 20 most common proteins in human serum. Most of the serum 
proteins are negatively charged, but their molecular weights vary from 28 to 900 kDa. It 
is important to note that some of these proteins such as transferrin display a quite 
significant range in concentration.  
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Table 5.3. Approximate Weight Content of High Abundant Proteins in Serum/Plasma 
for a healthy adult.46, 47 
Protein gL-1 Mwa PIb 
Albumin 50 65 5.2 
IgG 10 150 7.5-7.8 
Transferrin 2-4 80 5.6 
Fibrinogen 2 340 5.6 
IgA Total 1.5 350 4.9 
α-Macroglobulin 1.5 750 5.3-6.3 
IgM 0.5 900 5-7 
α-Antitrypsin 0.5 52 5.4 
C3-Complement 0.5 180 5.8 
Haptoglobin 0.2 41 5.1-7 
Apolipoprotein A1 0.2 28 5.4-5.6 
Apolipoprotein B 0.2 515 5.0-5.3 
α-1-acid glycoprotein 0.2 40 2.7 
Lipoprotein(a) 0.1 400-700 ? 
Factor H 0.2 139 ? 
Ceruloplasmin 0.2 135 4.4 
C4-Complement 0.2 200 6 
Complement B 0.2 100 5.9-6.1 
Prealbumin  0.2 60 ? 
C9-Complement 0.1 71 5.60 
a) molecular weight in kDa. b) isoelectric point. 
 
The plasma protein composition can change for various reasons48 such as, i) 
inter- and intradaily changes in serum composition, ii) age related changes in serum 
composition, iii) nutritional status, iv) differences in serum composition for each 
individual and v) disease related changes in serum composition. 
The detection of the vast number of proteins acquired with proteomic techniques 
such as surface-enhanced laser desorption/ionization (SELDI)49, 50 technique allows the 
determination of patterns of protein distribution that in comparison with normal sera 
  155
may allow to find specific protein signatures for specific diseases. But here the 
instrumentation is expensive, the throughput is low and the dynamic range is limited. If 
specific fractions of proteins are removed from the serum, then mass spectrometry is 
more sensitive and a tool for the discovery of hitherto unknown serum proteins. 
However mass spectrometry is at the moment not well suited as a high throughput tool 
for the economical screening of large numbers of serum samples, and is certainly 
unrealistic as a tool for personalized diagnostics.  
With 2-D-SDS-PAGE electrophoresis, the specific proteins identified may also 
be sequenced.51 Isoelectric focusing allows separation of proteins according to their 
charge, while in the second dimension the proteins are separable according to their 
molecular weight. This technique has led to the discovery of signature protein patterns 
in patients with ovarian carcinomas and in patients with inflammatory bowel disease.52, 
53 But these chromatograms are examined by eye and therefore only significant changes 
in serum composition are recognized. Plasma proteins that are present in much smaller 
amounts are specifically detected by monoclonal antibodies, with enhanced troponin or 
myoglobin levels being used to diagnose myocardial infarcts and increased PSA antigen 
used to detect prostate cancers.54 
The third group is composed of specific disease markers that are present in small 
quantities to signal the early stage of a specific disease or a group of disorders. In such a 
case the gross plasma composition may be changed either significantly or subtly.  
Classic examples for such markers include those for neoplastic diseases, where the 
debris produced by the large number of dead and therefore lysed cells significantly 
increases the DNA content of the plasma.55  While the use of monoclonal antibodies is 
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powerful, each monoclonal antibody has to be raised and can only detect one specific 
protein. Moreover, the technical difficulties as regards to quantification are 
significant.56 We pose the hypothesis that most disease states will leave their 
“fingerprint” in the overall plasma composition, leading to an altered serum content of 
specific proteins or protein groups. The development of generalized and easy access 
“serum sensors” should give fast, reliable, and accurate readings of a person’s health 
status. 
Considering the high sensitivity of the nanoparticle-GFP conjugates as a sensor, 
we hypothesized that in presence of different composition of proteins the binding 
equilibrium between GFP and nanoparticle would be altered due to competitive binding, 
which will affect the fluorescence response. We are also expecting that those 
fluroscence responses will be reproducible to detect the particular composition. For that 
purpose, we consider some human serum protein. According to commercial availability 
we choose five serum proteins: albumin, IgG, transferrin, fibrinogen and α-antitrypsin. 
Table 5.3 displays the isoelectric point, molecular weight and approximate 
concentrations of the five proteins in healthy adult human serum. We spiked these 
proteins in commercially available human serum and differentiate those spiked serum 
from each other by LDA analysis. 
5.3.1 Result and Discussion 
5.3.1.1 Nanoparticle-GFP Complexation in Human Serum 
Sensing of proteins in human serum is different than detection of single protein 
in buffer. As expected, the rate fluorescence quenching is not similar to buffer solution. 
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Due the opacity of pure human serum the required concentration of GFP to get 
sufficient response is higher than the previous study and the suitable concentration we 
found was 250 nM (in buffer solution we need 100 nM). According to the titration 
curve (Figure 5.10) we observed we did not reach the saturation in fluorescence 
quenching even in presence of 2 μM nanoparticles. This behavior can easily explain by 
the presence of several other proteins from human serum which are always competing 
with GFP to bind with nanoparticle. Also due to the existence of this multiple 
equilibrium constant it is very difficult to determine the binding characteristics of GFP 
with nanoparticles in serum. For our study we choose the middle point of the curve (500 
nm of nanoparticles) as an optimum point.  
 
Figure 5.10. The changes of fluorescence intensity of GFP (250 nM) at 510 nm were 
measured following the addition of cationic nanoparticle NP7 (0-2 μM) with an 
excitation wavelength of 475 nm. Inset shows the change of Fluorescence intensity of 
GFP (100 nM) at 510 nm upon addition of NP7 in 5 mM sodium phosphate buffer. 
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5.3.1.2 Sensing of Protein in Human Serum 
Similar to fluorescence titration, in serum we need to detect the protein in 
presence of several other proteins with variable concentration. In case of human serum 
solution the only albumin concentration is around 769 μM and total protein 
concentration is ~1mM. To detect the change of concentration of particular protein at 
certain level we ware considered the nanoparticles that showed the maximum selectivity 
in serum protein detection according to the result obtained from previous section. To 
determine the efficiency and detection limit of this system in serum we will spike the 
human serum with five proteins (Table 5.3) with various concentrations to generate a 
training matrix. We will then run the experiment with those spiked serum for multiple 
times (6 runs/ protein) and the results will be subjected to linear discriminate analysis 
(LDA).57 Based on “jackknife classification analysis”,58  if we get a sufficient degree of 
separation accuracy (~>90%) then we will use that concentration as our detection limit 
and will use unknown identification as a proof of our concept. The minimum 
concentration we fond to get reproducible and well separable protein pattern is 500 nM 
using five nanoparticle-GFP conjugates ( NP1, NP3, NP7, NP8 and NP14). Hence we 
spiked the commercial human serum with additional protein with final concentration 
500 nM and were used to create training matrix (5 nanoparticle-GFP conjugates × 5 
proteins × 6 replicates) with various nanoparticle-GFP conjugates. The fluorescence 
response patterns of proteins are distinctly different from those generated from 25 nM 
in buffer solution, but each protein generates a distinguishable response pattern and 
retain the reproducibility (Figure 5.11a). As before, these patterns were further 
subjected to LDA analysis, providing a 97% of accuracy as α-antitrypsin slightly 
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overlap with IgG. Similar to the previous analysis the four canonical factors are 76.9%, 
20.3%, 2.7%, 0.1% and the plot of the first two factors with 95% confidence ellipses as 
presented in Figure 4b. A series of unknown protein solutions were subsequently used 
to validate this system and out of 30 samples 28 samples were correctly identified 
affording 93.3% identification accuracy. This result indicate that we were able to 
identify target proteins in the complex serum matrix at the sub-micromolar range, 
corresponding to ~0.05% of the analyte by molarity relative to the total serum proteins. 
Successful identification of those proteins when spiked into this commercially available 
human serum demonstrates the superb sensitivity of this sensory system, which is able 
to detect subtle concentration changes (500 nM) in this complex matrix containing a 
significant quantity of other proteins. 
 
Figure 5.11. a) Fluorescence response (ΔI) pattern of the five nanoparticle-GFP adducts 
in the presence of serum proteins spiked in human serum at 500 nM concentration 
(average of six measurements). b)Canonical score plot for the fluorescence patterns as 
obtained from LDA against five protein analytes at fixed concentration 500 nM, with 
95% confidence ellipses. 
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5.3.2 Conclusion 
In conclusion, we have demonstrated a nanoparticle-GFP array based biosensor 
that can effectively identify most abundant serum proteins rang at very low 
concentration with higher efficiency. We also successfully extend this efficiency in 
detection of proteins in highly complex system i.e., human serum which is composed of 
several proteins with variable concentrations. This result indicate that the simple 
nanoparticle-GFP array can efficiently recognize biological analyst in serum simply and 
instantaneously with reliable fashion. In this approach the competitive complexation 
between GFP and analyte proteins with nanoparticles makes this system comparable to 
natural protein-protein interaction, providing potential for further optimization via 
engineering of both the synthetic and biological components. We also believe that 
optimization of this methodology potentially modernize the medical diagnostics, both in 
the clinic and as a tool for personalized diagnostics.   
5.4 Experimental 
5.4.1 Materials 
Green fluorescence protein (GFP) was expressed according to the known 
procedure. In brief, Starter cultures from a glycerol stock of GFP in BL21(DE3) was 
grown overnight in 50 ml culture media at 37 oC. The following day, 5 ml of the starter 
cultures was added to a Fernbach flask containing 1 L culture media and shaken until 
the OD600 = 0.6 - 0.7.  The culture was then induced by adding isopropyl-β-D-
thiogalactopyranoside (IPTG) (1 mM final concentration) and shaken at 28 oC.  After 
three hours, the cells were harvested by centrifugation and the pellet was then 
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resuspended in lysis buffer. Once lysed, the solution was pelleted and the supernatant 
was further purified using HisPur Cobalt columns. The Mw and pI of the expressed 
GFP is 26.9KDa and 5.92 respectively. The maximum λex and λem are 490 nm and 510 
nm (Figure S1).  
The analyte proteins, bovine serum albumin (BSA), acid phosphatase (PhosA, 
frompotato), α-amylase (α-Am, from Bacillus Licheniformis), lipase (Lip, from 
Candida Rugosa, type VII), β-galactosidase (β-Gal, from Escherichia Coli), Subtilisin 
A (SubA, from Bacillus Licheniformis), hemoglobin (Hem, from human), human serum 
albumin (HAS), alkaline phosphatase (PhosB, from bovine intestinal mucosa), Histone 
(His, from calf thymus, type III-S) and myoglobin (Myo, from equine heart) for sensing 
of common proteins in clear buffer solution were purchased from Sigma-Aldrich and 
used as received. For sensing in serum, the analyte proteins, serum albumin (HSA), 
immunoglobulins (IgG), transferrin, fibrinogen and α-antitrypsin all from human serum 
were purchased from the same supplier. 
Cationic nanoparticles NP1–NP6,31 were synthesized according to the reported 
procedure and NP7–NP14 were prepared according to the similar procedure as 
described below. 
5.4.2 Synthesis of ligand and nanoparticles 
General procedure for L1-L13. Compound 2 bearing ammonium end groups 
were synthesized through the reaction of 1,1,1-triphenyl-14,17,20,23-tetraoxa-2- 
thiapentacosan-25-yl methanesulphonate (1) with corresponding substituted N,N-
dimethylamines during 48 h at ~35 oC. The trityl protected thiol ligand (2) was 
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dissolved in dry DiChloroMethane (Methylene Chloride, DCM) and an excess of 
trifluoroacetic acid (TFA, ~ 20 equivalents) was added. The color of the solution was 
turned to yellow immediately. Subsequently, triisopropylsilane (TIPS, ~ 1.2 
equivalents) was added to the reaction mixture. The reaction mixture was stirred for ~5 
h under Ar condition at room temperature. The solvent and most TFA and TIPS were 
distilled off under reduced pressure. The pale yellow residue was further dried in high 
vacuum. The product (L) formation was quantitative and their structure was confirmed 
by NMR. The yields were >95%.  
 
Scheme 5.1. Synthesis of ligands (L1-L13).  
 
General procedure for L14. Compound 4 bearing L-Phe group was 
synthesized through the reaction of 26-mercapto-3,6,9,12,15-pentaoxahexacosan-1-oic 
acid (3) with corresponding 2-amino-N-(2-(dimethylamino)ethyl)-3-
phenylpropanamide. The reaction was done in a mixture of DiChloroMethane 
(Methylene Chloride, DCM) and N, N-Dimethylformamide (DMF). After 2 days, the 
solution was poured into ethyl acetate (EtOAc) and water. The organic layer was 
collected and washed with bride, and dried with Na2SO4. After removal of the solvent, 
the residue was charged in SiO2 column for purification. EtOAc/MeOH (90:10) and 
EtOAc/MeOH/NH4OH (90:10:1) were used as gradient eluent. Compound 5 was 
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obtained through nucleophilic substitution of compound 4 with bromothane.  The trityl 
protected thiol ligand (5) was dissolved in dry DCM and an excess of trifluoroacetic 
acid (TFA, ~ 20 equivalents) was added. The color of the solution was turned to yellow 
immediately. Subsequently, triisopropylsilane (TIPS, ~ 1.2 equivalents) was added to 
the reaction mixture. The reaction mixture was stirred for ~5 h under Ar condition at 
room temperature. The solvent and most TFA and TIPS were distilled off under reduced 
pressure. The pale yellow residue was further dried in high vacuum. The product L14 
(5-benzyl-N-ethyl-32-mercapto-N,N-dimethyl-4,7-dioxo-9,12,15,18,21-pentaoxa-3,6-
diazadotriacontan-1-aminium) formation was quantitative and their structure was 
confirmed by NMR. The yields were >93%. 
 
 
 
 
Scheme 5.2. Synthesis of ligand L14. 
 
General procedure: 1-Pentanethiol coated gold nanoparticles (d = ~2 nm) were 
prepared according to the previously reported protocol.59  Place-exchange reaction60 of 
compound Ls dissolved in DCM with pentanethiol-coated gold nanoparticles (d~2 nm) 
was carried out for 3 days at environmental temperature. Then, DCM was evaporated 
under reduced pressure. The residue was dissolved in a small amount of distilled water 
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and dialyzed (membrane MWCO = 1,000) to remove excess ligands, acetic acid and the 
other salts present with the nanoparticles. After dialysis, the particles were lyophilized 
to afford a brownish solid. The nanoparticles are redispersed in water and/or ionized 
water (18 MΩ-cm). 1H NMR spectra in D2O showed substantial broadening of the 
proton signals and no free ligands were observed. 
 
Scheme 5.3. Fabrication of cationic gold nanoparticles by place exchange method. 
5.4.3 Fluorescence Titration 
In the fluorescence titration between nanoparticles and GFP, the change of 
fluorescence intensity at 510 nm was measured with an excitation wavelength of 475 
nm at various concentrations of nanoparticles from 0 to 100 nM on a Molecular Devices 
SpectaMax M5 microplate reader at 25 οC in 5 mM sodium phosphate buffer. The 
change of fluorescence intensity against increasing nanoparticle concentrations was 
plotted, using a non-interacting gold nanoparticle (e.g. PEG-NP) as a control to 
compensate for particle absorption. Nonlinear least-squares curve-fitting analysis was 
employed to estimate the binding constant (Ks) and association stoichiometry (n) using 
the model in which the nanoparticle is assumed to possess n equivalent of independent 
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binding sites. In case of human serum, similar procedure was followed, but the only 
modification was the concentration of GFP (250 nM) and the nanoparticles (0-2 μM). 
5.4.4 Training Matrix 
To create the training matrix, GFP and nanoparticles are mixed in the ratio 
obtained from fluorescence titration. In case of 5 mM sodium phosphate buffer solution 
the final concentration of nanoparticle and GFP were 100 nM each. On the other hand, 
in serum solution study the final concentration of nanoparticle and GFP were 500 nM 
and 250 nM respectively. After 30 min of incubation 200 μL of each solution was 
loaded into a well on a 96-well plate (300 μL Whatman black bottom micropalte) and 
the fluorescence intensity at 510 nm recorded using fluorescence microplate reader 
(Molecular Devices SpectraMax M5). Subsequently, 10 μL of protein solution of two 
different concentrations with absorbance value at 280 nm was added. In case of sensing 
in serum 10.5 μM of protein solution, was added so that the final concentrations were 
500 nM. After incubation for 30 min the fluorescence intensity at 510 nm was recorded 
again. The difference between the two intensities before and after addition of proteins 
was considered as the fluorescence response. This process was repeated for five serum 
proteins with five selective cationic nanoparticles in six replicates. This data was used 
to generate the 6 × 5 × 5 (6 replicates × 5 proteins × 5 nanoparticles) training matrix. 
This training matrix was used for classical linear discriminant analysis (LDA) in 
SYSTAT (version 11.0). 
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5.4.5 Unknown Detection 
For the unknown detection, we prepared the protein solutions out of the eleven 
common protein or five serum proteins according to buffer or serum study. From this 
prepared solution we randomly choose 48 or 30 samples for each system (buffer or 
serum) and the same method was followed using the nanoparticle-GFP motif. We 
replicated each unknown samples three times instead of six for preparing training 
matrix. We considered the average response of three replicates for a single unknown 
sample and analyzed with known proteins in LDA analysis. 
5.5 References
 
1 Kingsmore, S. F., Nat. Rev. Drug Discovery 2006, 5, 310-320. 
 
2 Sawyers, C. L., Nature 2008, 452, 548-552. 
 
3 Daniels, M. J.; Wang, Y. M.; Lee, M. Y.; Venkitaraman, A. R., Science 2004, 306, 
876-879. 
 
4 Meyer-Luehmann, M.; Spires-Jones, T. L.; Prada, C.; Garcia-Alloza, M.; de Calignon, 
A.; Rozkalne, A.; Koenigsknecht-Talboo, J.; Holtzman, D. M.; Bacskai, B. J.; Hyman, 
B. T., Nature 2008, 451, 720-U5. 
 
5 MacBeath, G., Nat. Genet. 2002, 32, 526-532. 
 
6 Mairal, T.; Ozalp, V. C.; Sanchez, P. L.; Mir, M.; Katakis, I.; O'Sullivan, C. K., Anal. 
Bioanal. Chem. 2008, 390, 989-1007. 
 
7 Henares, T. G.; Mizutani, F.; Hisamoto, H., Anal. Chim. Acta 2008, 611, 17-30. 
 
8 Siwy, Z.; Trofin, L.; Kohli, P.; Baker, L. A.; Trautmann, C.; Martin, C. R., J. Am. 
Chem. Soc. 2005, 127, 5000-5001. 
 
9 Meiring, J. E.; Schmid, M. J.; Grayson, S. M.; Rathsack, B. M.; Johnson, D. M.; 
Kirby, R.; Kannappan, R.; Manthiram, K.; Hsia, B.; Hogan, Z. L.; Ellington, A. D.; 
Pishko, M. V.; Willson, C. G., Chem. Mater. 2004, 16, 5574-5580. 
 
  167
 
10 So, H. M.; Won, K.; Kim, Y. H.; Kim, B. K.; Ryu, B. H.; Na, P. S.; Kim, H.; Lee, J. 
O., J. Am. Chem. Soc. 2005, 127, 11906-11907. 
 
11 Rich, R. L.; Myszka, D. G., J. Mol. Recognit. 2008, 21, 355-400. 
 
12 Lavigne, J. J.; Anslyn, E. V., Angew. Chem., Int. Ed. 2001, 40, 3119-3130. 
 
13 Ciosek, P.; Wroblewski, W., Analyst 2007, 132, 963-978. 
 
14 Gardner, J. W.; Bartlett, P. N., Electronic Noses. Principles and Applications. 
Oxford University Press, USA: 1999. 
 
15 Greene, N. T.; Shimizu, K. D., J. Am. Chem. Soc. 2005, 127, 5695-5700. 
 
16 Wiskur, S. L.; Floriano, P. N.; Anslyn, E. V.; McDevitt, J. T., Angew. Chem., Int. 
Ed. 2003, 42, 2070-2072. 
 
17 Lavigne, J. J.; Savoy, S.; Clevenger, M. B.; Ritchie, J. E.; McDoniel, B.; Yoo, S. J.; 
Anslyn, E. V.; McDevitt, J. T.; Shear, J. B.; Neikirk, D., J. Am. Chem. Soc. 1998, 120, 
6429-6430. 
 
18 Lee, J. W.; Lee, J. S.; Kang, M.; Su, A. I.; Chang, Y. T., Chem.Eur. J. 2006, 12, 
5691-5696. 
 
19 Rakow, N. A.; Suslick, K. S., Nature 2000, 406, 710-713. 
 
20 Hughes, A. D.; Glenn, I. C.; Patrick, A. D.; Ellington, A.; Anslyn, E. V., Chem.Eur. 
J. 2008, 14, 1822-1827. 
 
21 Folmer-Andersen, J. F.; Kitamura, M.; Anslyn, E. V., J. Am. Chem. Soc. 2006, 128, 
5652-5653. 
 
22 Leung, D.; Folmer-Andersen, J. F.; Lynch, V. M.; Anslyn, E. V., J. Am. Chem. Soc. 
2008, 130, 12318-12327. 
 
23 Wright, A. T.; Anslyn, E. V., Chem. Soc. Rev. 2006, 35, 14-28. 
 
24 Anderson, N. L.; Anderson, N. G., Molecular & Cellular Proteomics 2002, 1, 845-
867. 
  
25 Haab, B. B., Curr. Opin. Biotechnol. 2006, 17, 415-421. 
 
26 Baldini, L.; Wilson, A. J.; Hong, J.; Hamilton, A. D., J. Am. Chem. Soc. 2004, 126, 
5656-5657. 
 
  168
 
27 Zhou, H. C.; Baldini, L.; Hong, J.; Wilson, A. J.; Hamilton, A. D., J. Am. Chem. Soc. 
2006, 128, 2421-2425. 
 
28 Wright, A. T.; Griffin, M. J.; Zhong, Z. L.; McCleskey, S. C.; Anslyn, E. V.; 
McDevitt, J. T., Angew. Chem., Int. Ed. 2005, 44, 6375-6378. 
 
29 Sandanaraj, B. S.; Demont, R.; Aathimanikandan, S. V.; Savariar, E. N.; 
Thayumanavan, S., J. Am. Chem. Soc. 2006, 128, 10686-10687. 
 
30 Sandanaraj, B. S.; Demont, R.; Thayumanavan, S., J. Am. Chem. Soc. 2007, 129, 
3506-+. 
 
31 You, C. C.; Miranda, O. R.; Gider, B.; Ghosh, P. S.; Kim, I. B.; Erdogan, B.; Krovi, 
S. A.; Bunz, U. H. F.; Rotello, V. M., Nature Nanotechnology 2007, 2, 318-323. 
 
32 Bunz, U. H. F., Synthesis and structure of PAEs. In Poly(Arylene Ethynylene)S: from 
Synthesis to Application, 2005; Vol. 177, pp 1-52. 
 
33 Juan, Z.; Swager, T. M., Poly(arylene ethynylene)s in chemosensing and biosensing. 
In Poly(Arylene Ethynylene)S: from Synthesis to Application, 2005; Vol. 177, pp 151-
179. 
 
34 Kim, I. B.; Dunkhorst, A.; Gilbert, J.; Bunz, U. H. F., Macromolecules 2005, 38, 
4560-4562. 
 
35 De, M.; You, C. C.; Srivastava, S.; Rotello, V. M., J. Am. Chem. Soc. 2007, 129, 
10747-10753. 
 
36 Hong, R.; Fischer, N. O.; Verma, A.; Goodman, C. M.; Emrick, T.; Rotello, V. M., 
J. Am. Chem. Soc. 2004, 126, 739-743. 
 
37 Tsien, R. Y., Annu. Rev. Biochem. 1998, 67, 509-544. 
 
38 Chalfie, M.; KainIn, S. R., Green Fluorescent Protein: Properties, Applications, and 
Protocols. Wiley-Interscience: Hoboken, N.J., 2006. 
 
39 Aguila, A.; Murray, R. W., Langmuir 2000, 16, 5949-5954. 
 
40 Zhang, F.; Skoda, M. W. A.; Jacobs, R. M. J.; Zorn, S.; Martin, R. A.; Martin, C. M.; 
Clark, G. F.; Goerigk, G.; Schreiber, F., J. Phys. Chem. A 2007, 111, 12229-12237. 
 
41 You, C. C.; De, M.; Han, G.; Rotello, V. M., J. Am. Chem. Soc. 2005, 127, 12873-
12881. 
 
42 Hood, L.; Heath, J. R.; Phelps, M. E.; Lin, B. Y., Science 2004, 306, 640-643. 
  169
 
 
43 Ginsburg, G. S.; McCarthy, J. J., Trends Biotechnol. 2001, 19, 491-496. 
 
44 Issaq, H. J.; Xiao, Z.; Veenstra, T. D., Chem. Rev. 2007, 107, 3601-3620. 
 
45 Pieper, R.; Gatlin, C. L.; Makusky, A. J.; Russo, P. S.; Schatz, C. R.; Miller, S. S.; 
Su, Q.; McGrath, A. M.; Estock, M. A.; Parmar, P. P.; Zhao, M.; Huang, S. T.; Zhou, J.; 
Wang, F.; Esquer-Blasco, R.; Anderson, N. L.; Taylor, J.; Steiner, S., Proteomics 2003, 
3, 1345-1364. 
  
46 McPherson, R. A.; Pincus, M. R., Henry’s Clinical Diagnosis and Manangement by 
Laboratory Methods. 21st ed.; Saunders-Elsevier: 2007; Vol. Chapter 19. 
 
47 Anderson, N. L.; Anderson, N. G., Molecular & Cellular Proteomics 2002, 1, 845-
867. 
 
48 Steil, L.; Thiele, T.; Hammer, E.; Bux, J.; Kalus, M.; Volker, U.; Greinacher, A., 
Transfusion 2008, 48, 2356-2363. 
 
49 Hu, Y.; Zhang, S. Z.; Yu, J. K.; Liu, J.; Zheng, S., Breast 2005, 14, 250-255. 
 
50 Li, J. N.; Zhang, Z.; Rosenzweig, J.; Wang, Y. Y.; Chan, D. W., Clinical Chemistry 
2002, 48, 1296-1304. 
 
51 Adam, B. L.; Vlahou, A.; Semmes, O. J.; Wright, G. L., Proteomics 2001, 1, 1264-
1270. 
 
52 Petricoin, E. F.; Ardekani, A. M.; Hitt, B. A.; Levine, P. J.; Fusaro, V. A.; Steinberg, 
S. M.; Mills, G. B.; Simone, C.; Fishman, D. A.; Kohn, E. C.; Liotta, L. A., Lancet 
2002, 359, 572-577. 
 
53 Fiocchi, C., Gastroenterology 1998, 115, 182-205. 
 
54 Wu, G. H.; Datar, R. H.; Hansen, K. M.; Thundat, T.; Cote, R. J.; Majumdar, A., 
Nat. Biotechnol. 2001, 19, 856-860. 
 
55 Bastian, P. J.; Ellinger, J.; Wittkamp, V.; Albers, P.; von Rucker, A.; Muller, S. C., 
Journal of Urology 2008, 179, 272-272. 
 
56 Milam, R. A.; Milam, M. R.; Iyer, R. B., Journal of Clinical Oncology 2007, 25, 
5657-5658. 
 
57 Massart, D. L.; Kaufman, L., The Interpretation of Analytical Chemical Data by the 
Use of Cluster Analysis. John Wiley and Sons: New York, 1983. 
 
  170
 
58 Gong, G., Journal of the American Statistical Association 1986, 81, 108-113. 
 
59 Brust, M.; Walker, M.; Bethell, D.; Schiffrin, D. J.; Whyman, R., J. Chem. Soc., 
Chem. Commun. 1994, 801-802. 
 
60 Hostetler, M. J.; Wingate, J. E.; Zhong, C. J.; Harris, J. E.; Vachet, R. W.; Clark, M. 
R.; Londono, J. D.; Green, S. J.; Stokes, J. J.; Wignall, G. D.; Glish, G. L.; Porter, M. 
D.; Evans, N. D.; Murray, R. W., Langmuir 1998, 14, 17-30. 
 
  171
APPENDIX 
ENTHALPY-ENTROPY CORRELATION PLOTS 
 
 
 
Figure A.1. Plots of entropy (TΔS) versus enthalpy (ΔH) for the protein-ligand 
(nonpeptide) interactions from Table A.2. 
 
 
 
Figure A.2. Plots of entropy (TΔS) versus enthalpy (ΔH) for the protein-peptide 
interactions from Table A.3.
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Table A.1. Thermodynamic Parameters for Some Protein-Protein Interactions (continues on the next page). 
 
Complex Solvent T / 
°C 
ΔG / 
kJ mol-1 
ΔH / 
kJ mol-1 
TΔS / 
kJ mol-1 
Ref. 
Trypsin/soybean inhibitor 200 mM KCl, 50 mM CaCl2, pH 5.0 25.0 -51.5 36.0 87.1 1 
Trypsin/cleaved soybean inhibitor 200 mM KCl, 50 mM CaCl2, pH 5.0 25.0 -45.2 52.7 98.0 1 
Trypsin/ovomucoid 200 mM KCl, 50 mM CaCl2, pH 5.0 25.0 -42.7 23.4 66.2 1 
Trypsin/lima bean inhibitor 200 mM KCl, 50 mM CaCl2, pH 5.0 25.0 -53.1 8.8 62.0 1 
Chymotrypsin/bovine pancreatic trypsin inhibitor 50 mM Tris/HCl, 20 mM CaCl2, 0.005% Triton X-100, pH 8.2 22.0 -44.8 10.5 55.2 2 
Chymotrypsin/subtilisin inhibitor 25 mM potassium phosphate, ionic strength = 100 mM with KCl, pH 7.0 25.0 -29.9 18.7 47.7 3 
Chymotrypsin/OMTKY3 50 mM acetic acid/sodium acetate, 20 mM NaCl, pH 4.5 25.0 -39.3 52.3 91.6 4 
Subtilisin/subtilisin inhibitor 25 mM potassium phosphate, ionic strength = 100 mM with KCl, pH 7.0 25.0 -57.9 -19.8 38.1 5 
Calmodulin Ca2+/myosin light chain kinase 50 mM Pipes/NaOH, 150 mM NaCl, 0.5 mM CaCl2, pH 7.5 25.0 -48.1 -84.9 -36.4 6 
Calmodulin Ca2+/seminal plasmin 50 mM Pipes/NaOH, 150 mM NaCl, 0.5 mM CaCl2, pH 7.5 25.0 -50.2 -50.2 0 6 
Calmodulin/myosin light chain kinase 50 mM Pipes/NaOH, 150 mM NaCl, pH 7.5 25.0 -30.1 0 30.1 6 
Calmodulin/seminal plasmin 50 mM Pipes/NaOH, 150 mM NaCl, pH 7.5 25.0 -33.9 0 33.9 6 
Ch4D5 Fab/p185HER2-ECD 20 mM sodium phosphate, 100 mM NaCl, pH 7.5 25.0 -56.5 -72.0 -15.0 7 
HyHEL-5/hen egg lysozyme 10 mM sodium phosphate, pH 8.0 25.0 -60.7 -94.6 -33.9 8 
HyHEL-10/hen egg lysozyme 50 mM phosphate, 200 mM NaCl, pH 7.2 30.0 -50.2 -91.6 -41.4 9 
HyHEL-10/hen egg lysozyme 50 mM phosphate, 200 mM NaCl, pH 7.2 30.0 -51.7 -99.7 -47.9 10 
Fv D1.3/hen egg lysozyme 10 mM sodium phosphate, 150 mM NaCl, pH 7.1 49.8 -42.6 -129.0 -86.0 11 
mAb D1.3/hen egg lysozyme 10 mM sodium phosphate, 150 mM NaCl, pH 7.1 24.2 -48.0 -90.8 -42.8 11 
F9.13.7/hen egg lysozyme 10 mM sodium phosphate, 150 mM NaCl, pH 7.1 23.9 -50.2 -46.4 4.1 12 
D44.1/hen egg lysozyme 10 mM sodium phosphate, 150 mM NaCl, pH 7.1 24.2 -40.6 -43.1 -2.9 12 
D11.15/hen egg lysozyme 10 mM sodium phosphate, 150 mM NaCl, pH 7.1 24.9 -50.6 -79.5 -28.7 12 
D1.3/E5.2 10 mM sodium phosphate, 150 mM NaCl, pH 7.1 25.0 -43.5 -279.1 -235.0 13 
D1.3/E225 10 mM sodium phosphate, 150 mM NaCl, pH 7.1 28.3 -30.5 7.5 38.3 13 
Ferredoxin/ferredoxin :NADP+reductase 50 mM Tris/HCl, pH 7.5 27.0 -39.1 -1.3 37.8 14 
Colicin N/OmpF 20 mM Tris, 300 mM NaCl, 1% octyl-polyoxyethylene, pH 7.4 25.0 -32.4 -51.5 -19.1 15 
Colicin N/OmpC 20 mM Tris, 300 mM NaCl, 1% octyl-polyoxyethylene, pH 7.4 25.0 -29.5 -15.5 14.0 15 
Colicin N/PhoE 20 mM Tris, 300 mM NaCl, 1% octyl-polyoxyethylene, pH 7.4 25.0 -30.8 -25.0 5.9 15 
Barstar/barnase 50 mM Pipes, pH 7.0 25.0 -73.2 -58.0 15.2 16 
Human tissue factor/coagulation factor VII 20 mM Tris/HCl, 100 mM NaCl, 5 mM CaCl2, pH 7.5 25.0 -46.9 -133.9 -87.3 17 
Cytochrome c/cytochrome c peroxidase 50 mM ionic strength, potessium phosphate/KNO3, pH 6.0 26.0 -29.1 9.6 38.8 18 
Cytochrome c/cytochrome c peroxidase 50 mM DMG, pH 6.0 25.0 -32.2 -9.6 22.2 19 
Cytochrome c/cytochrome c peroxidase, site 1 50 mM DMG, 200 mM melezitose, pH 6.0 25.0 -41.8 -15.5 26.3 19 
Cytochrome c/cytochrome c peroxidase, site 2 50 mM DMG, 200 mM melezitose, pH 6.0 25.0 -33.5 -2.5 31.0 19 
Cytochrome c/cytochrome b5 2 mM Tris/HCl, pH 7.4 25.0 -38.1 4.2 42.3 20 
Cytochrome c/Ab E3 20 mM sodium/potassium phosphate, 0.8% NaCl, 0.02% KCl, pH 7.2 25.0 -40.6 -30.5 11.0 21 
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Cytochrome c/Ab E8 20 mM sodium/potassium phosphate, 0.8% NaCl, 0.02% KCl, pH 7.2 25.0 -39.7 -39.7 0.4 21 
Cytochrome c/MAb 2B5 100 mM sodium phosphate, pH 7.0 25.0 -52.7 -87.9 -35.2 22 
Cytochrome c/MAb 5F8 100 mM sodium phosphate, pH 7.0 25.0 -58.2 -90.8 -32.8 22 
CheY/CheA1-233 20 mM sodium phosphate, 20 mM NaCl, 1 mM EDTA, 1 mM 
PMSF, 10% (v/v) glycerol, pH 7.4 
28.0 -33.9 -51.9 -18.1 23 
CheB/CheA1-233 20 mM sodium phosphate, 20 mM NaCl, 1 mM EDTA, 1 mM 
PMSF, 10% (v/v) glycerol, pH 7.4 
28.0 -31.4 -42.3 -11.0 23 
Interleukin 5-IL5 receptor α subunit 20 mM potassium phosphate, 150 mM NaCl, pH 7.4 25.0 -48.5 -47.7 0.8 24 
Erythropoietin/EPO receptor site 1 Dulbecco’s phosphate buffered saline, pH 7.0 25.0 -49.0 -6.3 42.7 25 
Erythropoietin/EPO receptor site 2 Dulbecco’s phosphate buffered saline, pH 7.0 25.0 -35.1 -14.2 21.0 25 
Human growth hormone G120R/hGHbp 10 mM sodium phosphate, 137 mM NaCl, 2.7 mM KCl, pH 7.2 26.2 -49.0 -39.3 9.6 26 
Phosphocarrier protein/enzyme I N-domain 10 mM potassium phosphate, 100 mM KCl, 1 mM EDTA, pH 7.5 25 -29.3 36.7 66.0 27 
Stem cell factor/Kit extracellular domain Phosphate buffered  saline 25 -37.7 -54.4 -16.7 28 
Hck SH3 domain/HIV-1 Nef 50 mM HEPES, 150 mM NaCl, 3.4 mM EDTA, 2 mM DTT, pH 7.4 25 -38.5 -53.6 -15.0 29 
Fyn SH3 domain/PI3-Kinase p85 subunit 10 mM phosphate, pH 6.0 30 -31.8 44.4 76.4 30 
Elastase/ovomucoid third domain 50 mM imidazole chloride, pH 7.0 25 -60.7 -4.2 56.5 31 
Chaperonin GroEL/reduced α-lactalbumin 25 mM Tris/HCl, 200 mM KCl, 1 mM DTT, 1 mM EDTA, pH 7.8 10.0 -28.4 49.7 78.1 32 
Chaperonin GroEL/reduced α-lactalbumin 25 mM Tris/HCl, 1 mM DTT, 1 mM EDTA, pH 7.8 10.5 -31.6 82.2 113.8 32 
Champeronin GroEL/denatured pepsin 25 mM Tris/HCl, 200 mM KCl, 1 mM DTT, 1 mM EDTA, pH 7.8 25.1 -32.1 47.4 79.6 32 
Glycoprotein gp120/CD4 3 mM sodium phosphate, 100 mM NaCl, pH 7.4 37.0 -49.4 -263.6 -214.2 33 
Dihydrolipoyl dehydrogenase/PSBD of E2 10 mM HEPES, 150 mM NaCl, 3.4 mM EDTA, pH 7.4 25.0 -52.7 9.2 61.9 34 
Human factor X/NAPc2 20 mM HEPES, 150 mM NaCl, 2 mM Ca2+, pH 7.4 25.0 -51.7 -57.8 -6.1 35 
Human factor Xa/NAPc2 20 mM HEPES, 150 mM NaCl, 2 mM Ca2+, pH 7.4 25.0 -52.0 -71.5 -19.5 35 
CBFβ protein/Runx 1 Runt domain ------- 30.0 -42.2 -18.9 23.3 36 
CBFβ-SMMHC47 protein/Runx 1 Runt domain ------- 30.0 -47.0 -16.9 30.1 36 
A. niger xylanase/xylanase-inhibiting protein I McIlvaine buffer, pH 5.5 25.0 -42.1 -48.5 -6.3 37 
α-Hemoglobin stabilizing protein/α-globin 20 mM sodium phosphate buffer, 150 mM NaCl, pH 7.0 20.0 -39.3 -36.6 2.7 38 
β-Lactoglobulin/pectin, site 1 5 mM sodium phosphate, pH 4.0 22.0 -43.5 -52.7 -10.5 39 
β-Lactoglobulin/pectin, site 2 5 mM sodium phosphate, pH 4.0 22.0 -38.1 -23.0 14.6 39 
α-Amylase 2/BASI 40 mM HEPES, 200 mM NaCl, 5 mM CaCl2, pH 6.8 25.0 -45.0 -98.0 -53.0 40 
α-Amylase 2/BASI 40 mM sodium acetate, 5 mM CaCl2, pH 5.5 27.0 -43.5 -69.0 -26.0 40 
Thrombin/monoclonal antibody 25 mM potassium phosphate, 150 mM NaCl, pH 6.5 25.0 -44.8 -34.3 10.5 41 
Xanthine oxidase/Cu, Zn-SOD 10 mM HEPES, 150 mM NaCl, 1 mM EDTA, pH 7.4 25.0 -34.0 -201.1 -161.1 42 
Human growth hormone/hGHR ECD1 20 mM HEPES, 150 mM NaCl, pH 7.4 25.0 -51.0 -37.6 13.4 43 
E colicin DNase E2/immunity protein Im2 50 mM Mops, 200 mM NaCl, pH 7.0 25.0 -82.2 -161.7 -79.5 44 
E colicin DNase E7/immunity protein Im9 50 mM Mops, 200 mM NaCl, pH 7.0 25.0 -82.8 -237.4 -154.4 44 
E colicin DNase E9/immunity protein Im9 50 mM Mops, 200 mM NaCl, pH 7.0 25.0 -77.7 -79.5 -1.8 44 
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Table A.2. Thermodynamic Parameters for Some Protein-Ligand (nonpeptide) Interactions (continues on the next page). 
 
Complex Solvent T / 
°C 
ΔG / 
kJ mol-1 
ΔH / 
kJ mol-1 
TΔS / 
kJ mol-1 
Ref. 
AAC(6’)-Iy/kanamycin B 50 mM Tris,  50 mM NaCl, 0.1% HS(CH2)2OH, 0.01% Tween-80, pH 7.5 27 -29.3 -54.4 -25.1 45 
AAC(6’)-Iy/tobramycin  50 mM Tris,  50 mM NaCl, 0.1% HS(CH2)2OH, 0.01% Tween-80, pH 7.5 27 -30.5 -50.6 -20.1 45 
AAC(6’)-Iy/dibekacin  50 mM Tris,  50 mM NaCl, 0.1% HS(CH2)2OH, 0.01% Tween-80, pH 7.5 27 -31.0 -53.6 -22.6 45 
AAC(6’)-Iy/gentamicin C  50 mM Tris,  50 mM NaCl, 0.1% HS(CH2)2OH, 0.01% Tween-80, pH 7.5 27 -26.8 -33.9 -7.1 45 
AAC(6’)-Iy/kanamycin A  50 mM Tris,  50 mM NaCl, 0.1% HS(CH2)2OH, 0.01% Tween-80, pH 7.5 27 -27.6 -40.2 -13.8 45 
AAC(6’)-Iy/amikacin  50 mM Tris,  50 mM NaCl, 0.1% HS(CH2)2OH, 0.01% Tween-80, pH 7.5 27 -27.6 -23.8 3.8 45 
AAC(6’)-Iy/sisomicin  50 mM Tris,  50 mM NaCl, 0.1% HS(CH2)2OH, 0.01% Tween-80, pH 7.5 27 -30.1 -37.2 -7.1 45 
AAC(6’)-Iy/netilmicin  50 mM Tris,  50 mM NaCl, 0.1% HS(CH2)2OH, 0.01% Tween-80, pH 7.5 27 -30.5 -25.1 5.4 45 
AAC(6’)-Iy/ribostamycin  50 mM Tris,  50 mM NaCl, 0.1% HS(CH2)2OH, 0.01% Tween-80, pH 7.5 27 -34.7 -83.3 -48.5 45 
AAC(6’)-Iy/butirosin  50 mM Tris,  50 mM NaCl, 0.1% HS(CH2)2OH, 0.01% Tween-80, pH 7.5 27 -33.9 -52.7 -18.8 45 
AAC(6’)-Iy/neomycin B  50 mM Tris,  50 mM NaCl, 0.1% HS(CH2)2OH, 0.01% Tween-80, pH 7.5 27 -31.4 -61.5 -30.1 45 
AAC(6’)-Iy/paromomycin  50 mM Tris,  50 mM NaCl, 0.1% HS(CH2)2OH, 0.01% Tween-80, pH 7.5 27 -28.5 -31.4 -2.9 45 
AAC(6’)-Iy/lividomycin A  50 mM Tris,  50 mM NaCl, 0.1% HS(CH2)2OH, 0.01% Tween-80, pH 7.5 27 -30.5 -44.4 -8.8 45 
Epoxyalkane:CoM transferase/CoM 50 mM Tris-HCl, pH 8.0 30 -31.4 -102.9 -71.5 46 
Epoxyalkane:CoM transferase/ethanethiol 50 mM Tris-HCl, pH 8.0 30 -20.1 -2.5 -17.6 46 
Epoxyalkane:CoM transferase/ethanesulfonate 50 mM Tris-HCl, pH 8.0 30 -13.8 -15.1 -1.3 46 
Epoxyalkane:CoM transferase/propanethiol 50 mM Tris-HCl, pH 8.0 30 -23.4 -0.8 22.6 46 
Biotin holoenzyme synthetase/biotin 10 mM Tris-HCl, 200 mM KCl, 2.5 mM MgCl2, pH 7.5 20 -41.4 -39.3 2.1 47 
Biotin holoenzyme synthetase/bio-5’-AMP 10 mM Tris-HCl, 200 mM KCl, 2.5 mM MgCl2, pH 7.5 20 -58.6 -24.3 33.9 47 
Adenosine deaminase/inosine 50 mM sodium phosphate, pH 7.5 27 -22.1 -32.0 -9.9 48 
YajQ/ATP 50 mM Tris-HCl, pH 7.4 25 -22.8 1.5 24.4 49 
DNA gyrase/clorobiocin 20 mM Tris, 1 mM EDTA, pH 7.5 25 -51.0 -39.6 11.4 50 
DNA gyrase/RU 64135 20 mM Tris, 1 mM EDTA, pH 7.5 25 -40.3 -18.9 21.4 50 
DNA gyrase/RU 64136 20 mM Tris, 1 mM EDTA, pH 7.5 25 -35.1 -18.0 17.1 50 
DNA gyrase/novobiocin 20 mM Tris, 1 mM EDTA, pH 7.5 25 -42.7 -51.8 -9.1 50 
HIV-1 protease/TMC-126 10 mM sodium acetate, 2% DMSO, pH 5 25 -65.3 -50.2 15.1 51 
HIV-1 protease/amprenavir 10 mM sodium acetate, 2% DMSO, pH 5 25 -55.2 -28.9 26.4 51 
Peanut agglutinin/ Galactose 20 mM citrate buffer, pH 7.4 25 -17.0 -23.0 -6.0 52 
Peanut agglutinin/ GalEMA 20 mM citrate buffer, pH 7.4 25 -21.4 -39.4 -18 52 
Peanut agglutinin/ pGalEMA-A 20 mM citrate buffer, pH 7.4 25 -26.6 -5.8 20.8 52 
Peanut agglutinin/ pGalEMA-B 20 mM citrate buffer, pH 7.4 25 -22.7 -19.8 2.8 52 
Peanut agglutinin/ Galactosec 20 mM citrate buffer, 150 mM NaCl, pH 7.4 25 -16.5 -23.9 -7.4 52 
Peanut agglutinin/ pGalEMA-A 20 mM citrate buffer, 150 mM NaCl, pH 7.4 25 -21.7 -10.8 10.9 52 
Peanut agglutinin/ pGalEMA-B 20 mM citrate buffer, 150 mM NaCl, pH 7.4 25 -21.2 -8.3 12.9 52 
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Peanut agglutinin/ pGalEMA-A 20 mM citrate buffer, 150 mM NaCl, pH 7.4, heats of dilution subtracted 25 -20.6 -6.4 14.2 52 
Peanut agglutinin/ pGalEMA-A 50 mM Tris-HCl buffer, 500mM MgCl2, 1mM MnCl2, 1mM CaCl2, pH 
6.9 
25 -17.9 -15.8 2.1 52 
Peanut agglutinin/ pGalEMA-A 50 mM Tris-HCl buffer, 500mM MgCl2, 1mM MnCl2, 1mM CaCl2, pH 
6.9, heats of dilution subtracted 
25 -18.6 -42.6 -24.0 52 
Wild-Type MUP/ IBMP PBS, pH 7.4 35 -38.5 -47.9 -9.4 53 
Y120F MUP/ IBMP PBS, pH 7.4 15 -34.9 -25.8 9.1 53 
Y120F MUP/ IBMP PBS, pH 7.4 25 -35.3 -31.4 3.9 53 
Y120F MUP/ IBMP PBS, pH 7.4 35 -33.6 -35.9 -2.3 53 
Rho/ Bicyclomycin 40 mM Tris HCl 400 mM KCl, 0.1 mM EDTA, and 0.1 mM DTT, pH 7.9 26 -25.1 -3.3 21.8 54 
Rho/ Bicyclomycin analogue 40 mM Tris HCl 400 mM KCl, 0.1 mM EDTA, and 0.1 mM DTT, pH 7.9 26 -32.2 -11.5 20.7 54 
BirA/ Biotin 10 mM Tris-HCl, 200 mM KCl, 2.5 mM MgCl2, pH 7.50  20 -41.4 -80.3 -38.9 55 
BirA/ Btn-SA 10 mM Tris-HCl, 200 mM KCl, 2.5 mM MgCl2, pH 7.50  20 -40.6 -83.3 -42.7 55 
BirA/ BtnOH-AMP 10 mM Tris-HCl, 200 mM KCl, 2.5 mM MgCl2, pH 7.50  20 -49.5 -41.4 7.9 55 
BirA/ Bio-5’-AMP 10 mM Tris-HCl, 200 mM KCl, 2.5 mM MgCl2, pH 7.50  20 -58.2 -51.5 6.7 55 
ConA/methyl α-D-mannopyranoside 0.1 M sodium acetate, 0.1 M NaCl, 5 mM each CaCl2 and MnCl2, pH 5.2  27 -23.4 -35.1 -11.7 56 
ConA/ Bivalant sugar derivative 1 0.1 M sodium acetate, 0.1 M NaCl, 5 mM each CaCl2 and MnCl2, pH 5.2 27 -25.1 -46.9 -21.8 56 
ConA/ Bivalant sugar derivative 2 0.1 M sodium acetate, 0.1 M NaCl, 5 mM each CaCl2 and MnCl2, pH 5.2 27 -25.1 -59.0 -33.9 56 
ConA/ Bivalant sugar derivative 3 0.1 M sodium acetate, 0.1 M NaCl, 5 mM each CaCl2 and MnCl2, pH 5.2  27 -24.7 -53.1 -28.0 56 
ConA/ Bivalant sugar derivative 4 0.1 M sodium acetate, 0.1 M NaCl, 5 mM each CaCl2 and MnCl2, pH 5.2 27 -25.1 -47.7 -22.6 56 
ConA/ Bivalant sugar derivative 5 0.1 M sodium acetate, 0.1 M NaCl, 5 mM each CaCl2 and MnCl2, pH 5.2 27 -26.4 -43.1 -16.7 56 
ConA/ Bivalant sugar derivative 6 0.1 M sodium acetate, 0.1 M NaCl, 5 mM each CaCl2 and MnCl2, pH 5.2  27 -26.8 -56.1 -29.3 56 
ConA/ Bivalant sugar derivative 7 0.1 M sodium acetate, 0.1 M NaCl, 5 mM each CaCl2 and MnCl2, pH 5.2 27 -26.8 -61.5 -34.7 56 
ConA/ Bivalant sugar derivative 8 0.1 M sodium acetate, 0.1 M NaCl, 5 mM each CaCl2 and MnCl2, pH 5.2 27 -27.2 -63.6 -36.4 56 
ConA/ Bivalant sugar derivative 9 0.1 M sodium acetate, 0.1 M NaCl, 5 mM each CaCl2 and MnCl2, pH 5.2  27 -26.8 -71.1 -44.4 56 
ConA/ Bivalant sugar derivative 10 0.1 M sodium acetate, 0.1 M NaCl, 5 mM each CaCl2 and MnCl2, pH 5.2 27 -27.2 -69.5 -42.3 56 
ConA/ Bivalant sugar derivative 11 0.1 M sodium acetate, 0.1 M NaCl, 5 mM each CaCl2 and MnCl2, pH 5.2 27 -27.6 -64.4 -36.8 56 
ConA/ Bivalant sugar derivative 12 0.1 M sodium acetate, 0.1 M NaCl, 5 mM each CaCl2 and MnCl2, pH 5.2  27 -27.6 -59.8 -32.2 56 
ConA/ Bivalant sugar derivative 13 0.1 M sodium acetate, 0.1 M NaCl, 5 mM each CaCl2 and MnCl2, pH 5.2 27 -27.2 -66.5 -39.3 56 
DGL/methyl α-D-mannopyranoside 0.1 M sodium acetate, 0.1 M NaCl, 5 mM each CaCl2 and MnCl2, pH 5.2 27 -20.5 -34.3 -13.8 56 
DGL/ Bivalant sugar derivative 1 0.1 M sodium acetate, 0.1 M NaCl, 5 mM each CaCl2 and MnCl2, pH 5.2  27 -24.3 -42.3 -18.0 56 
DGL/ Bivalant sugar derivative 2 0.1 M sodium acetate, 0.1 M NaCl, 5 mM each CaCl2 and MnCl2, pH 5.2 27 -24.7 -45.2 -20.5 56 
DGL/ Bivalant sugar derivative 3 0.1 M sodium acetate, 0.1 M NaCl, 5 mM each CaCl2 and MnCl2, pH 5.2 27 -24.7 -46.9 -22.2 56 
DGL/ Bivalant sugar derivative 4 0.1 M sodium acetate, 0.1 M NaCl, 5 mM each CaCl2 and MnCl2, pH 5.2  27 -23.8 -46.0 -22.2 56 
DGL/ Bivalant sugar derivative 5 0.1 M sodium acetate, 0.1 M NaCl, 5 mM each CaCl2 and MnCl2, pH 5.2 27 -26.4 -43.5 -17.2 56 
DGL/ Bivalant sugar derivative 6 0.1 M sodium acetate, 0.1 M NaCl, 5 mM each CaCl2 and MnCl2, pH 5.2 27 -27.2 -48.5 -21.3 56 
DGL/ Bivalant sugar derivative 7 0.1 M sodium acetate, 0.1 M NaCl, 5 mM each CaCl2 and MnCl2, pH 5.2  27 -28.0 -54.0 -25.9 56 
DGL/ Bivalant sugar derivative 8 0.1 M sodium acetate, 0.1 M NaCl, 5 mM each CaCl2 and MnCl2, pH 5.2 27 -28.9 -61.9 -33.0 56 
DGL/ Bivalant sugar derivative 9 0.1 M sodium acetate, 0.1 M NaCl, 5 mM each CaCl2 and MnCl2, pH 5.2 27 -23.8 -59.8 -36.0 56 
DGL/ Bivalant sugar derivative 10 0.1 M sodium acetate, 0.1 M NaCl, 5 mM each CaCl2 and MnCl2, pH 5.2  27 -25.1 -61.9 -36.8 56 
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DGL/ Bivalant sugar derivative 11 0.1 M sodium acetate, 0.1 M NaCl, 5 mM each CaCl2 and MnCl2, pH 5.2 27 -26.8 -65.3 -38.5 56 
DGL/ Bivalant sugar derivative 12 0.1 M sodium acetate, 0.1 M NaCl, 5 mM each CaCl2 and MnCl2, pH 5.2 27 -25.9 -50.2 -24.3 56 
DGL/ Bivalant sugar derivative 13 0.1 M sodium acetate, 0.1 M NaCl, 5 mM each CaCl2 and MnCl2, pH 5.2 27 -25.1 -64.0 -38.9 56 
BSA/ Naproxen 50 mM sodium phosphate buffer, pH 7.4. 25 -44.8 -50.7 -5.8 57 
TtgV/ 1-Naphthol 25mM Tris-HOAc,8mM Mg(OAc)2,1mM KCl,1mM dithiothreitol,pH 8.0 30 -31.4 -36.0 -4.6 58 
TtgV-DNA complex/ 1-Naphthol 25mM Tris-HOAc,8mM Mg(OAc)2,1mM KCl,1mM dithiothreitol,pH 8.0 30 -30.5 -21.8 8.8 58 
TtgV/ 2,3-Dihydroxynaphthalene 25mM Tris-HOAc,8mM Mg(OAc)2,1mM KCl,1mM dithiothreitol,pH 8.0 30 -32.2 -3.4 28.9 58 
TtgV/ 4-Nitrotoluene 25mM Tris-HOAc,8mM Mg(OAc)2,1mM KCl,1mM dithiothreitol,pH 8.0 30 -26.8 -62.3 -35.6 58 
TtgV/ Benzonitrile 25mM Tris-HOAc,8mM Mg(OAc)2,1mM KCl,1mM dithiothreitol,pH 8.0 30 -24.3 -52.3 -28.0 58 
TtgV/ Indole 25mM Tris-HOAc,8mM Mg(OAc)2,1mM KCl,1mM dithiothreitol,pH 8.0 30 -23.8 -54.4 -30.5 58 
TtgV/ Tolune 25mM Tris-HOAc,8mM Mg(OAc)2,1mM KCl,1mM dithiothreitol,pH 8.0 30 -22.6 -26.4 -3.8 58 
TtgV/ 1-Hexanol 25mM Tris-HOAc,8mM Mg(OAc)2,1mM KCl,1mM dithiothreitol,pH 8.0 30 -17.2 -62.3 -45.2 58 
Porcine odorant binding protein/ Halothane 130 mm NaCl, 20 mm sodium phosphate, pH 7.0 20 -23.0 -5.9 17.2 59 
Porcine odorant binding protein/ Isoflurane 130 mm NaCl, 20 mm sodium phosphate, pH 7.0 20 -22.6 -10.0 12.6 59 
Tetracycline Repressor/ Tetracycline 10 mM Tris, 150 mM NaCl, and 2 mM DTT with 1 mM EDTA, pH 8.0 25 -27.7 -32.9 -5.3 60 
Tetracycline Repressor/ Tetracycline with Mg2+ 10 mM Tris, 150 mM NaCl, and 2 mM DTT with 10 mM MgCl2, pH 8.0 25 -39.7 -51.5 -11.6 60 
β-trypsin/ Benzamidine/ Glycine-0.00 50 mM Tris buffer, with 25 mM CaCl2, at pH 8.0 25 -26.8 -15.2 11.6 61 
β-trypsin/ Benzamidine/ Glycine-0.25 50 mM Tris buffer, with 25 mM CaCl2, at pH 8.0 25 -26.8 -12.5 14.3 61 
β-trypsin/ Benzamidine/ Glycine-0.50 50 mM Tris buffer, with 25 mM CaCl2, at pH 8.0 25 -26.1 -7.1 19.1 61 
β-trypsin/ Benzamidine/ Glycine-1.00 50 mM Tris buffer, with 25 mM CaCl2, at pH 8.0 25 -25.7 -6.5 19.2 61 
β-trypsin/ Benzamidine/ Glucose-0.00 50 mM Tris buffer, with 25 mM CaCl2, at pH 8.0 25 -26.8 -15.2 11.6 61 
β-trypsin/ Benzamidine/ Glucose-0.38 50 mM Tris buffer, with 25 mM CaCl2, at pH 8.0 25 -26.7 -15.2 11.6 61 
β-trypsin/ Benzamidine/ Glucose-0.75 50 mM Tris buffer, with 25 mM CaCl2, at pH 8.0 25 -26.2 -11.4 14.7 61 
β-trypsin/ Berenil/ Glycine-0.00 50 mM Tris buffer, with 25 mM CaCl2, at pH 8.0 25 -33.0 -17.2 15.8 61 
β-trypsin/ Berenil/ Glycine-0.38 50 mM Tris buffer, with 25 mM CaCl2, at pH 8.0 25 -32.8 -12.3 20.5 61 
β-trypsin/ Berenil/ Glycine-0.75 50 mM Tris buffer, with 25 mM CaCl2, at pH 8.0 25 -32.2 -12.3 19.9 61 
β-trypsin/ Berenil/ Glycine-1.00 50 mM Tris buffer, with 25 mM CaCl2, at pH 8.0 25 -32.2 -10.0 22.2 61 
β-trypsin/ Berenil/ Glucose-0.00 50 mM Tris buffer, with 25 mM CaCl2, at pH 8.0 25 -33.0 -17.2 15.8 61 
β-trypsin/ Berenil/ Glucose-0.25 50 mM Tris buffer, with 25 mM CaCl2, at pH 8.0 25 -32.2 -18.3 13.9 61 
β-trypsin/ Berenil/ Glucose-0.50 50 mM Tris buffer, with 25 mM CaCl2, at pH 8.0 25 -32.0 -14.1 17.9 61 
β-trypsin/ Berenil/ Glucose-1.00 50 mM Tris buffer, with 25 mM CaCl2, at pH 8.0 25 -32.2 -10.5 21.7 61 
MUP-I-wild type/SBT 10 mM phosphate, 0.02% NaN3, pH 6.3 30 -34.7 -45.6 -10.9 62 
MUP-I-wild type/HMH 10 mM phosphate, 0.02% NaN3, pH 6.3 30 -25.1 -54.4 -29.3 62 
MUP-I/ IPMP PBS, pH 7.4 35 -33.9 -44.5 -10.6 63 
MUP-I/IBMP PBS, pH 7.4 35 -38.5 -47.9 -9.4 63 
Integrin I-domain/ inhibitor 1 20 mM Tris base, 150 mM NaCl, and 1 mM MgCl2, 2% DMSO, pH 7.5 30 -44.9 -32.2 12.7 64 
GH1 β-glucosidase/Aza sugar glycosidase 
inhibitor 6 
100 mM sodium citrate buffer, pH 5.8 27 -41.2 -28.5 12.9 65 
GH1 β-glucosidase/Aza sugar glycosidase 
inhibitor 1 
100 mM sodium citrate buffer, pH 5.8 27 -36.3 -46.7 -10.5 65 
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GH1 β-glucosidase/Aza sugar glycosidase 
inhibitor 5 
100 mM sodium citrate buffer, pH 5.8 27 -29.0 -33.2 -3.9 65 
Cellobiohydrolase I / (S)-alprenolol sodium acetate buffer, pH 5.5 25 -24.1 17.6 42.4 66 
Cellobiohydrolase I / (S)-alprenolol sodium acetate buffer, pH 5.8 25 -25.2 20.5 44.9 66 
Cellobiohydrolase I / (S)-alprenolol sodium acetate buffer, pH 6.8 25 -26.9 38.9 66.1 66 
Cellobiohydrolase I / (R)-alprenolol sodium acetate buffer, pH 6.8 25 -21.3 8.4 29.9 66 
HIV protease 1/ APV 10mM Na acetate, 2%DMSO, 2mM Tris(2-carboxyethyl)phosphine, pH 5 20 -52.7 -30.5 22.2 67 
HIV protease 1/ TMC114 10mM Na acetate, 2%DMSO, 2mM Tris(2-carboxyethyl)phosphine, pH 5 20 -63.6 -50.6 13.0 67 
hGSTA1-1_High-affinity site/ BSP sodium phosphate, 150 mM NaCl , pH 6.5 20 -38.9 -23.5 15.5 68 
hGSTA1-1_Low-affinity site/ BSP sodium phosphate, 150 mM NaCl , pH 6.5 20 -28.3 -7.2 19.7 68 
HAS/ Halothane (variable n) 20 mM Sodium phosphate buffer, 130 mM NaCl, pH 7.0 20 -15.6 -5.5 10.2 69 
HAS/ Halothane (fixed n) 20 mM Sodium phosphate buffer, 130 mM NaCl, pH 7.0 20 -15.6 -6.0 9.6 69 
HAS/ Propofol 20 mM Sodium phosphate buffer, 130 mM NaCl, pH 7.0 20 -23.5 -21.8 1.7 69 
APH(3’)-IIIa (Binary Complex)/ kanamycine A 50 mM Tris buffer, 100 mM KCl, pH 7.5 37 -31.0 -138.1 -107.1 70 
APH(3’)-IIIa (Binary Complex)/ kanamycine A 50 mM Bicine buffer, 100 mM KCl, pH 7.5 37 -31.4 -160.2 -128.9 70 
APH(3’)-IIIa (Binary Complex)/ kanamycine B 50 mM Tris buffer, 100 mM KCl, pH 7.5 37 -38.5 -93.7 -55.2 70 
APH(3’)-IIIa (Binary Complex)/ kanamycine B 50 mM Bicine buffer, 100 mM KCl, pH 7.5 37 -37.7 -128.9 -91.2 70 
APH(3’)-IIIa (Binary Complex)/ tobramycin 50 mM Tris buffer, 100 mM KCl, pH 7.5 37 -36.4 -122.2 -85.8 70 
APH(3’)-IIIa (Binary Complex)/ tobramycin 50 mM Bicine buffer, 100 mM KCl, pH 7.5 37 -36.8 -155.2 -118.4 70 
APH(3’)-IIIa (Binary Complex)/ amikacin 50 mM Tris buffer, 100 mM KCl, pH 7.5 37 -23.8 -81.6 -57.7 70 
APH(3’)-IIIa (Binary Complex)/ amikacin 50 mM Bicine buffer, 100 mM KCl, pH 7.5 37 -25.9 -78.7 -52.7 70 
APH(3’)-IIIa (Binary Complex)/ ribostamycin 50 mM Tris buffer, 100 mM KCl, pH 7.5 37 -33.9 -125.9 -92.0 70 
APH(3’)-IIIa (Binary Complex)/ ribostamycin 50 mM Bicine buffer, 100 mM KCl, pH 7.5 37 -33.9 -117.6 -83.7 70 
APH(3’)-IIIa (Binary Complex)/ meomycine B 50 mM Tris buffer, 100 mM KCl, pH 7.5 37 -38.9 -139.7 -100.8 70 
APH(3’)-IIIa (Binary Complex)/ meomycine B 50 mM Bicine buffer, 100 mM KCl, pH 7.5 37 -38.9 -181.2 -142.3 70 
APH(3’)-IIIa (Binary Complex)/ paromomycine I 50 mM Tris buffer, 100 mM KCl, pH 7.5 37 -37.7 -127.2 -89.5 70 
APH(3’)-IIIa (Binary Complex)/ paromomycine I 50 mM Bicine buffer, 100 mM KCl, pH 7.5 37 -38.9 -152.3 -113.4 70 
APH(3’)-IIIa (Binary Complex)/ lividomycine A 50 mM Tris buffer, 100 mM KCl, pH 7.5 37 -36.0 -140.6 -104.6 70 
APH(3’)-IIIa (Binary Complex)/ lividomycine A 50 mM Bicine buffer, 100 mM KCl, pH 7.5 37 -36.8 -184.5 -147.7 70 
APH(3’)-IIIa (Ternery Complex)/ kanamycine A 50 mM Tris buffer, 100 mM KCl, pH 7.5 37 -35.6 -39.3 -3.8 70 
APH(3’)-IIIa (Ternery Complex)/ kanamycine A 50 mM Bicine buffer, 100 mM KCl, pH 7.5 37 -34.7 -79.5 -44.8 70 
APH(3’)-IIIa (Ternery Complex)/ kanamycine B 50 mM Tris buffer, 100 mM KCl, pH 7.5 37 -39.3 -34.3 5.0 70 
APH(3’)-IIIa (Ternery Complex)/ kanamycine B 50 mM Bicine buffer, 100 mM KCl, pH 7.5 37 -38.1 -73.2 -35.1 70 
APH(3’)-IIIa (Ternery Complex)/ tobramycin 50 mM Tris buffer, 100 mM KCl, pH 7.5 37 -39.3 -38.1 1.3 70 
APH(3’)-IIIa (Ternery Complex)/ tobramycin 50 mM Bicine buffer, 100 mM KCl, pH 7.5 37 -37.2 -78.2 -41.0 70 
APH(3’)-IIIa (Ternery Complex)/ amikacin 50 mM Tris buffer, 100 mM KCl, pH 7.5 37 -26.4 -20.1 6.3 70 
APH(3’)-IIIa (Ternery Complex)/ amikacin 50 mM Bicine buffer, 100 mM KCl, pH 7.5 37 -27.2 -63.2 -36.0 70 
APH(3’)-IIIa (Ternery Complex)/ ribostamycin 50 mM Tris buffer, 100 mM KCl, pH 7.5 37 -38.9 -48.5 -9.6 70 
APH(3’)-IIIa (Ternery Complex)/ ribostamycin 50 mM Bicine buffer, 100 mM KCl, pH 7.5 37 -37.2 -54.0 -16.7 70 
APH(3’)-IIIa (Ternery Complex)/ meomycine B 50 mM Tris buffer, 100 mM KCl, pH 7.5 37 -41.0 -51.0 -10.0 70 
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APH(3’)-IIIa (Ternery Complex)/ meomycine B 50 mM Bicine buffer, 100 mM KCl, pH 7.5 37 -38.9 -95.8 -56.9 70 
APH(3’)-IIIa (Ternery Complex)/ paromomycine I 50 mM Tris buffer, 100 mM KCl, pH 7.5 37 -40.6 -48.1 -7.5 70 
APH(3’)-IIIa (Ternery Complex)/ paromomycine I 50 mM Bicine buffer, 100 mM KCl, pH 7.5 37 -41.0 -78.7 -37.7 70 
APH(3’)-IIIa (Ternery Complex)/ lividomycine A 50 mM Tris buffer, 100 mM KCl, pH 7.5 37 -36.4 -43.9 -7.5 70 
APH(3’)-IIIa (Ternery Complex)/ lividomycine A 50 mM Bicine buffer, 100 mM KCl, pH 7.5 37 -37.2 -92.5 -55.2 70 
APH(3’)-IIIa (Ternery Complex)/ kanamycine A 50 mM Tris buffer, 100 mM KCl, pH 8.5 37 -27.2 -15.5 11.7 70 
APH(3’)-IIIa (Ternery Complex)/ kanamycine A 50 mM Bicine buffer, 100 mM KCl, pH 8.5 37 -27.2 -72.0 -44.8 70 
APH(3’)-IIIa (Ternery Complex)/ kanamycine B 50 mM Tris buffer, 100 mM KCl, pH 8.5 37 -29.7 -35.6 -5.4 70 
APH(3’)-IIIa (Ternery Complex)/ kanamycine B 50 mM Bicine buffer, 100 mM KCl, pH 8.5 37 -31.8 -109.6 -77.8 70 
APH(3’)-IIIa (Ternery Complex)/ tobramycin 50 mM Tris buffer, 100 mM KCl, pH 8.5 37 -29.3 -29.3 -0.4 70 
APH(3’)-IIIa (Ternery Complex)/ tobramycin 50 mM Bicine buffer, 100 mM KCl, pH 8.5 37 -31.0 -106.3 -75.3 70 
APH(3’)-IIIa (Ternery Complex)/ meomycine B 50 mM Tris buffer, 100 mM KCl, pH 8.5 37 -37.2 -46.4 -9.2 70 
APH(3’)-IIIa (Ternery Complex)/ meomycine B 50 mM Bicine buffer, 100 mM KCl, pH 8.5 37 -40.2 -129.3 -89.1 70 
APH(3’)-IIIa (Ternery Complex)/ paromomycine I 50 mM Tris buffer, 100 mM KCl, pH 8.5 37 -32.6 -45.6 -13.0 70 
APH(3’)-IIIa (Ternery Complex)/ paromomycine I 50 mM Bicine buffer, 100 mM KCl, pH 8.5 37 -33.9 -116.3 -82.4 70 
Tetrameric human PAH/ BH4 20 mM NaHepes, 0.2 M NaCl, pH 7.0 5 -33.1 -23.8 9.1 71 
Tetrameric human PAH/ BH4 20 mM NaHepes, 0.2 M NaCl, pH 7.0 15 -34.5 -33.8 0.8 71 
Tetrameric human PAH/ BH4 20 mM NaHepes, 0.2 M NaCl, pH 7.0 25 -35.0 -49.3 -14.3 71 
Tetrameric human PAH/ BH4 20 mM NaHepes, 0.2 M NaCl, pH 7.0 35 -35.2 -68.8 -33.6 71 
Tetrameric human PAH/ 6M-PH4 20 mM NaHepes, 0.2 M NaCl, pH 7.0 10 -28.2 -9.0 19.1 71 
Tetrameric human PAH/ 6M-PH4 20 mM NaHepes, 0.2 M NaCl, pH 7.0 25 -27.3 -14.0 13.3 71 
Tetrameric human PAH/ 6M-PH4 20 mM NaHepes, 0.2 M NaCl, pH 7.0 35 -28.7 -15.5 13.2 71 
Tetrameric human PAH/ BH4 20 mM MES, 0.2 M NaCl, pH 6.0 25 -29.4 -40.8 -11.8 71 
Tetrameric human PAH/ BH4 20 mM NaPhosphate, 0.2 M NaCl, pH 6.5 25 -33.8 -42.8 -8.9 71 
Tetrameric human PAH/ BH4 20 mM NaHepes, 0.2 M NaCl, pH 7.5 25 -33.9 -41.3 -7.4 71 
Tetrameric human PAH/ BH4 20 mM NaHepes, 0.2 M NaCl, pH 8.0 25 -35.7 -43.9 -8.1 71 
Tetrameric human PAH/ 6M-PH4 20 mM NaHepes, 0.2 M NaCl, pH 8.0 25 -27.8 -12.7 15.1 71 
Tetrameric human PAH/ BH4 20 mM Hepes, 200 mM NaCl, pH 7.0, 1 mM L-Phe 25 -31.8 -27.7 4.1 71 
Tetrameric human PAH/ 6M-PH4 20 mM Hepes, 200 mM NaCl, pH 7.0, 1mM L-Phe 25 -27.6 -7.7 19.8 71 
wt FabI/ PD048890 10 mM Na-phosphate Buffer, 2% DMSO, 1 mM EDTA, and 1% 
Glycerol, 0.5 mM NAD+,  pH 7.5 
15 -41.7 -42.5 -0.7 72 
wt FabI/ PD048890 10 mM Na-phosphate Buffer, 2% DMSO, 1 mM EDTA, and 1% 
Glycerol, 0.5 mM NAD+,  pH 7.5 
20 -40.8 -56.9 -15.9 72 
wt FabI/ PD048890 10 mM Na-phosphate Buffer, 2% DMSO, 1 mM EDTA, and 1% 
Glycerol, 0.5 mM NAD+,  pH 7.5 
25 -39.0 -84.9 -45.8 72 
wt FabI/ PD048890 10 mM Na-phosphate Buffer, 2% DMSO, 1 mM EDTA, and 1% 
Glycerol, 0.5 mM NAD+,  pH 7.5 
30 -40.5 -95.0 -54.5 72 
wt FabI/ PD0200828 10 mM Na-phosphate Buffer, 2% DMSO, 1 mM EDTA, and 1% 
Glycerol, 0.5 mM NAD+,  pH 7.5 
 
20 -46.6 -72.8 -26.1 72 
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wt FabI/ PD200828 10 mM Na-phosphate Buffer, 2% DMSO, 1 mM EDTA, and 1% 
Glycerol, 0.5 mM NAD+,  pH 7.5 
25 -45.8 -81.2 -35.4 72 
wt FabI/ PD200828 10 mM Na-phosphate Buffer, 2% DMSO, 1 mM EDTA, and 1% 
Glycerol, 0.5 mM NAD+,  pH 7.5 
30 -46.5 -106.3 -59.8 72 
wt FabI/ PD2002165 10 mM Na-phosphate Buffer, 2% DMSO, 1 mM EDTA, and 1% 
Glycerol, 0.5 mM NAD+,  pH 7.5 
25 -50.2 -73.2 -23.1 72 
wt FabI/ PD2002165 10 mM Na-phosphate Buffer, 2% DMSO, 1 mM EDTA, and 1% 
Glycerol, 0.5 mM NAD+,  pH 7.5 
27.5 -49.5 -88.3 -38.8 72 
wt FabI/ PD2002165 10 mM Na-phosphate Buffer, 2% DMSO, 1 mM EDTA, and 1% 
Glycerol, 0.5 mM NAD+,  pH 7.5 
30 -48.2 -98.3 -50.1 72 
wt FabI/ PD205405 10 mM Na-phosphate Buffer, 2% DMSO, 1 mM EDTA, and 1% 
Glycerol, 0.5 mM NAD+,  pH 7.5 
25 -49.0 -68.7 -19.8 72 
wt FabI/ PD205405 10 mM Na-phosphate Buffer, 2% DMSO, 1 mM EDTA, and 1% 
Glycerol, 0.5 mM NAD+,  pH 7.5 
27.5 -46.0 -81.6 -35.6 72 
wt FabI/ PD205405 10 mM Na-phosphate Buffer, 2% DMSO, 1 mM EDTA, and 1% 
Glycerol, 0.5 mM NAD+,  pH 7.5 
30 -48.8 -93.3 -44.5 72 
BSA/ desflurane 150 mM NaCl and 10 mM HEPES at pH 7.2 20 -19.3 -12.7 6.6 73 
BSA/ isoflurane 150 mM NaCl and 10 mM HEPES at pH 7.2 20 -17.5 -16.5 1.0 73 
BSA/ enflurane 150 mM NaCl and 10 mM HEPES at pH 7.2 20 -16.6 -25.0 -8.4 73 
BSA/halothane 150 mM NaCl and 10 mM HEPES at pH 7.2 20 -14.6 -26.1 -11.5 73 
BSA/sevoflurane 150 mM NaCl and 10 mM HEPES at pH 7.2 20 -13.6 -18.0 -4.4 73 
HSA/ desflurane 150 mM NaCl and 10 mM HEPES at pH 7.2 20 -20.0 -15.4 4.6 73 
HSA/ isoflurane 150 mM NaCl and 10 mM HEPES at pH 7.2 20 -18.5 -15.6 2.9 73 
HSA/ enflurane 150 mM NaCl and 10 mM HEPES at pH 7.2 20 -17.8 -22.0 -4.2 73 
HSA/halothane 150 mM NaCl and 10 mM HEPES at pH 7.2 20 -14.9 -20.4 -5.5 73 
HSA/sevoflurane 150 mM NaCl and 10 mM HEPES at pH 7.2 20 -15.1 -7.1 7.9 73 
Disabled-1 PTB native/ PI-4,5P2 20 mM PIPES buffer, 150 mM NaCl,  0.2 mM DTT, pH 7.0 25 -33.8 -80.3 -46.4 74 
Disabled-1 PTB mutant H81A/ PI-4,5P2 20 mM PIPES buffer, 150 mM NaCl,  0.2 mM DTT, pH 7.0 25 -26.4 -46.9 -19.2 74 
Disabled-1 PTB mutant H81Q/ PI-4,5P2 20 mM PIPES buffer, 150 mM NaCl,  0.2 mM DTT, pH 7.0 25 -27.1 -41.0 -14.2 74 
Disabled-1 PTB mutant S114Y/ PI-4,5P2 20 mM PIPES buffer, 150 mM NaCl,  0.2 mM DTT, pH 7.0 25 -33.8 -102.1 -68.2 74 
Disabled-1 PTB mutant F158V/ PI-4,5P2 20 mM PIPES buffer, 150 mM NaCl,  0.2 mM DTT, pH 7.0 25 -35.5 -75.7 -40.2 74 
HAS/ Sodium Penicillins Cloxacillin, first binding Aqueous Buffered Solutions, pH 4.5 25 -21.7 -0.4 21.3 75 
HAS/ Sodium Penicillins Cloxacillin, second 
binding 
Aqueous Buffered Solutions, pH 4.5 25 -19.1 -0.1 19.0 75 
HSA/ Sodium Penicillins Cloxacillin, first binding Aqueous Buffered Solutions, pH 7.4 25 -20.5 -0.1 20.4 75 
HSA/ Sodium Penicillins Cloxacillin, second 
binding 
Aqueous Buffered Solutions, pH 7.4 25 -16.6 -0.1 16.5 75 
HSA/ Sodium Penicillins Dicloxacillin, first 
binding 
Aqueous Buffered Solutions, pH 4.5 25 -22.3 -0.3 22.0 75 
HSA/ Sodium Penicillins Dicloxacillin, 2nd bindin Aqueous Buffered Solutions, pH 4.5 25 -19.5 -0.1 19.4 75 
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HSA/ Sodium Penicillins Dicloxacillin, first 
binding 
Aqueous Buffered Solutions, pH 7.4 25 -21.0 -0.1 20.9 75 
HSA/ Sodium Penicillins Dicloxacillin, second 
binding 
Aqueous Buffered Solutions, pH 7.4 25 -17.5 -0.1 17.4 75 
S. japonicum-GST/ ANS Standard phosphate buffer, pH 6.5 25 -20.0 -52.4 -32.4 76 
S. japonicum-GST/ ANS Standard phosphate buffer, pH 6.5 30 -19.9 -57.2 -37.2 76 
S. japonicum-GST/ ANS Standard phosphate buffer, pH 6.5 35 -20.0 -64.8 -44.8 76 
S. japonicum-GST/ ANS Standard phosphate buffer, pH 6.5 40 -20.2 -70.3 -50.1 76 
S. japonicum-GST/ BS Standard phosphate buffer, pH 6.5 25 -30.2 -12.0 18.2 76 
S. japonicum-GST/ BS Standard phosphate buffer, pH 6.5 30 -29.5 -29.1 0.5 76 
S. japonicum-GST/ BS Standard phosphate buffer, pH 6.5 35 -30.7 -38.7 -8.1 76 
S. japonicum-GST/ BS Standard phosphate buffer, pH 6.5 40 -33.5 -49.0 -15.6 76 
Wild-Type HasASM/ Heme Sodium Phosphate Buffer, pH 7.3 25 -61.1 -105.4 -44.3 77 
H32A Mutated HasASM/ Heme Sodium Phosphate Buffer, pH 7.3 25 -57.1 -72.2 -15.1 77 
Y75A Mutated HasASM/ Heme Sodium Phosphate Buffer, pH 7.3 25 -46.4 -74.4 -28.0 77 
H83A Mutated HasASM/ Heme Sodium Phosphate Buffer, pH 7.3 25 -47.3 -62.2 -14.9 77 
H83Q Mutated HasASM/ Heme Sodium Phosphate Buffer, pH 7.3 25 -48.7 -89.1 -40.4 77 
H32A-Y75A Mutated HasASM/ Heme Sodium Phosphate Buffer, pH 7.3 25 -27.2 -25.8 -1.4 77 
H32A-H83A Mutated HasASM/ Heme Sodium Phosphate Buffer, pH 7.3 25 -42.0 -41.1 -0.9 77 
H32A-H83Q Mutated HasASM/ Heme Sodium Phosphate Buffer, pH 7.3 25 -42.3 -29.2 13.1 77 
Y75A-H83A Mutated HasASM/ Heme Sodium Phosphate Buffer, pH 7.3 25 -35.7 -35.0 0.6 77 
Y75A-H83Q Mutated HasASM/ Heme Sodium Phosphate Buffer, pH 7.3 25 -36.9 -54.0 -17.0 77 
Glycyl-tRNA Synthetase/ ATP 20 mM HEPES-KOH, 5 mM MgCl2, 0.5 mM DTT, 50 mM NaCl, pH 7.2 25 -30.6 -72.0 -36.9 78 
Glycyl-tRNA Synthetase/ AMPPNP 20 mM HEPES-KOH, 5 mM MgCl2, 0.5 mM DTT, 50 mM NaCl, pH 7.2 25 -31.7 -68.0 -38.9 78 
Glycyl-tRNA Synthetase/ AMPPCP 20 mM HEPES-KOH, 5 mM MgCl2, 0.5 mM DTT, 50 mM NaCl, pH 7.2 25 -36.3 -70.7 -31.7 78 
Glycyl-tRNA Synthetase/ GSAd 20 mM HEPES-KOH, 5 mM MgCl2, 0.5 mM DTT, 50 mM NaCl, pH 7.2 25 -37.4 -187 -149 78 
MAP2C/ DHEA 50 mM MES, pH 6.8 25 -42.0 -34.0 8.0 79 
MAP2C/ DHEA 50 mM phosphate buffer, pH 7.5 25 -40.0 -10.0 30.0 79 
Human AAG/ Indinavir 10 mM sodium acetate, 2% DMSO, pH 5.0 35 -26.9 -7.5 19.4 80 
Human AAG/Saquinavir 10 mM sodium acetate, 2% DMSO, pH 5.0 25 -30.7 -60.7 -30.0 80 
Human AAG/ KNI-764 10 mM sodium acetate, 2% DMSO, pH 5.0 25 -33.3 -28.9 4.4 80 
Human AAG/ Nelfinavir 10 mM sodium acetate, 2% DMSO, pH 5.0 25 -33.4 -22.2 11.2 80 
Human AAG/ Ritonavir 10 mM sodium acetate, 2% DMSO, pH 5.0 25 -34.9 -24.7 10.2 80 
Trypsin/ p-Alkylbenzamidinium Chlorides 50 mM Tris, 10 mM CaCl2 buffer at pH 8.0 20 -26.9 -17.0 9.9 81 
Trypsin/ p-Alkylbenzamidinium Chlorides 50 mM Tris, 10 mM CaCl2 buffer at pH 8.0 37 -26.7 -23.7 3.0 81 
Trypsin/Me- p-Alkylbenzamidinium Chlorides 50 mM Tris, 10 mM CaCl2 buffer at pH 8.0 20 -27.5 -16.7 10.8 81 
Trypsin/Me- p-Alkylbenzamidinium Chlorides 50 mM Tris, 10 mM CaCl2 buffer at pH 8.0 37 -27.4 -23.8 3.6 81 
Trypsin/Et- p-Alkylbenzamidinium Chlorides 50 mM Tris, 10 mM CaCl2 buffer at pH 8.0 20 -25.5 -10.6 14.9 81 
Trypsin/ Et-p-Alkylbenzamidinium Chlorides 50 mM Tris, 10 mM CaCl2 buffer at pH 8.0 37 -25.6 -22.4 3.2 81 
Trypsin/ nPr-p-Alkylbenzamidinium Chlorides 50 mM Tris, 10 mM CaCl2 buffer at pH 8.0 20 -25.7 -9.7 16.0 81 
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Trypsin/ nPr-p-Alkylbenzamidinium Chlorides 50 mM Tris, 10 mM CaCl2 buffer at pH 8.0 37 -25.6 -19.9 5.7 81 
Trypsin/ iPr-p-Alkylbenzamidinium Chlorides 50 mM Tris, 10 mM CaCl2 buffer at pH 8.0 20 -22.6 -4.9 18 81 
Trypsin/ i-Pr-p-Alkylbenzamidinium Chlorides 50 mM Tris, 10 mM CaCl2 buffer at pH 8.0 37 -22.7 -12.0 11 81 
Trypsin/ nBu-p-Alkylbenzamidinium Chlorides 50 mM Tris, 10 mM CaCl2 buffer at pH 8.0 20 -26.2 -6.1 20.1 81 
Trypsin/ nBu-p-Alkylbenzamidinium Chlorides 50 mM Tris, 10 mM CaCl2 buffer at pH 8.0 37 -26.3 -18.5 7.8 81 
Trypsin/ nPent- p-Alkylbenzamidinium Chlorides 50 mM Tris, 10 mM CaCl2 buffer at pH 8.0 20 -26.8 -6.6 20.3 81 
Trypsin/ nPent-p-Alkylbenzamidinium Chlorides 50 mM Tris, 10 mM CaCl2 buffer at pH 8.0 37 -27.9 -17.5 10.4 81 
Trypsin/ nHex-p-Alkylbenzamidinium Chlorides 50 mM Tris, 10 mM CaCl2 buffer at pH 8.0 20 -28.9 -6.6 22.2 81 
Trypsin/ nHex-p-Alkylbenzamidinium Chlorides 50 mM Tris, 10 mM CaCl2 buffer at pH 8.0 37 -29.7 -21.0 8.7 81 
Anti-NP antibody N1G9/NP-Cap 5 mM sodium phosphate buffer, 200 mM NaCl, pH 8.0 25.5 -31.0 -46.9 -15.7 82 
Anti-NP antibody N1G9/NP-Cap 5 mM sodium phosphate buffer, 200 mM NaCl, pH 8.0 30 -31.3 -56.1 -24.5 82 
Anti-NP antibody N1G9/NP-Cap 5 mM sodium phosphate buffer, 200 mM NaCl, pH 8.0 34.7 -29.9 -61.5 -31.5 82 
Anti-NP antibody N1G9/NP-Cap 5 mM sodium phosphate buffer, 200 mM NaCl, pH 8.0 37.5 -29.8 -64.4 -34.9 82 
Anti-NP antibody N1G9/NP-Cap 5 mM sodium phosphate buffer, 200 mM NaCl, pH 8.0 41 -29.7 -70.3 -40.7 82 
Anti-NP antibody N1G9/NP-Cap 5 mM sodium phosphate buffer, 200 mM NaCl, pH 8.0 45.2 -29.5 -72.4 -42.9 82 
Anti-NP antibody 3B44/NP-Cap 5 mM sodium phosphate buffer, 200 mM NaCl, pH 8.0 25.5 -39.4 -69.0 -29.6 82 
Anti-NP antibody 3B44/NP-Cap 5 mM sodium phosphate buffer, 200 mM NaCl, pH 8.0 30 -39.7 -77.0 -37.6 82 
Anti-NP antibody 3B44/NP-Cap 5 mM sodium phosphate buffer, 200 mM NaCl, pH 8.0 33.1 -39.1 -81.6 -42.0 82 
Anti-NP antibody 3B44/NP-Cap 5 mM sodium phosphate buffer, 200 mM NaCl, pH 8.0 37.2 -38.2 -87.4 -49.3 82 
Anti-NP antibody 3B44/NP-Cap 5 mM sodium phosphate buffer, 200 mM NaCl, pH 8.0 40.3 -35.6 -90.8 -55.4 82 
Anti-NP antibody 3B44/NP-Cap 5 mM sodium phosphate buffer, 200 mM NaCl, pH 8.0 45.2 -34.1 -100.0 -65.6 82 
Anti-NP antibody 3B62/NP-Cap 5 mM sodium phosphate buffer, 200 mM NaCl, pH 8.0 25.2 -41.5 -76.6 -34.8 82 
Anti-NP antibody 3B62/NP-Cap 5 mM sodium phosphate buffer, 200 mM NaCl, pH 8.0 30 -40.1 -84.9 -45.0 82 
Anti-NP antibody 3B62/NP-Cap 5 mM sodium phosphate buffer, 200 mM NaCl, pH 8.0 33 -39.6 -88.7 -48.9 82 
Anti-NP antibody 3B62/NP-Cap 5 mM sodium phosphate buffer, 200 mM NaCl, pH 8.0 36.8 -39.9 -96.7 -56.9 82 
Anti-NP antibody 3B62/NP-Cap 5 mM sodium phosphate buffer, 200 mM NaCl, pH 8.0 39.8 -39.3 -102.5 -63.2 82 
Anti-NP antibody 3B62/NP-Cap 5 mM sodium phosphate buffer, 200 mM NaCl, pH 8.0 44.6 -39.6 -109.6 -70.2 82 
 
 
 
Table A.3. Thermodynamic Parameters for Some Protein-Peptide Interactions (continues on the next page). 
 
Complex Solvent T / 
°C 
ΔG / 
kJ mol-1 
ΔH / 
kJ mol-1 
TΔS / 
kJ mol-1 
Ref. 
nGLP1R/GLP-1 0.25 M L-arginine, 50 mM phosphate, 1 mM EDTA, pH 7.3 20 -38.4 -102.5 -64.1 83 
Fibrinogen/S-nitrosoglutathione Phosphate buffered saline, pH 7.4 25 -31.3 46.9 79.5 84 
Nematode anticoagulant protein c2/factor X 20 mM hepes, 0.15 M NaCl, 2.0 mM Ca2+, pH 7.4 25 -51.7 -57.8 -6.1 85 
Nematode anticoagulant protein c2/factor X 20 mM hepes, 0.15 M NaCl, pH 7.4 25 -50.2 -57.1 -6.9 85 
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Nematode anticoagulant protein c2/factor Xa 20 mM hepes, 0.15 M NaCl, 2.0 mM Ca2+, pH 7.4 25 -52.0 -71.5 -65.6 85 
Calmodulin/nitric oxide synthase I peptide 10 mM hepes, 150 mM NaCl, 10 mM MgCl2, 3 mM CaCl2, 2 mM EGTA, 
0.005% Tween 20, pH 7.4 
25 -41.1 -30.4 10.8 86 
Src homology 2/phosphotyrosyl peptide inhibitor 20 mM hepes, 1 mM HS(CH2)2OH, 1 mM EDTA, 100 mM NaCl, pH 7.3 25 -37.7 -25.4 12.3 87 
Src homology 2/phosphotyrosyl peptide inhibitor 20 mM hepes, 1 mM HS(CH2)2OH, 1 mM EDTA, 100 mM NaCl, pH 7.3 25 -40 -24.7 21.2 87 
Src homology 2/phosphotyrosyl peptide inhibitor 20 mM hepes, 1 mM HS(CH2)2OH, 1 mM EDTA, 100 mM NaCl, pH 7.3 25 -41 -30.7 10.4 87 
Src homology 2/phosphotyrosyl peptide inhibitor 20 mM hepes, 1 mM HS(CH2)2OH, 1 mM EDTA, 100 mM NaCl, pH 7.3 25 -38.7 -21 17.8 87 
Src homology 2/phosphotyrosyl peptide inhibitor 20 mM hepes, 1 mM HS(CH2)2OH, 1 mM EDTA, 100 mM NaCl, pH 7.3 25 -40.7 -29 11.7 87 
Human protein S100P/melittin 50 mM Tris, 0.2 mM EDTA, 1.5 mM TCEP, pH 7.5 25 -21.4 63 84.4 88 
Dihydrolipoyl dehydrogenase/PSBD of 
dihydrolipoyl acetyltransferase 
10 mM Hepes, 150 mM NaCl, 3.4 mM EDAT, pH 7.4 25 -52.7 9.2 61.9 89 
Pyruvate decarboxylase/ PSBD of dihydrolipoyl 
acetyltransferase 
10 mM Hepes, 150 mM NaCl, 3.4 mM EDAT, pH 7.4 25 -54.0 -35.1 18.8 89 
FRS2α PTB domain/FGFR1 peptide 20 mM Tris-HCl, pH 8.0 25 -27.6 -5.0 22.6 90 
FRS2α PTB domain/FGFR1 peptide 50mM phosphate,200mM NaCl,1 mM EDTA,5 mM HS(CH2)2OH,pH 7.0 25 -28.5 -7.5 20.9 90 
FRS2α PTB domain/TRKB, pY61 peptide 20 mM Tris-HCl, pH 8.0 25 -28.9 -20.1 8.8 90 
FRS2α PTB domain/TRKB, pY61 peptide 50mM phosphate,200mM NaCl,1 mM EDTA,5 mM HS(CH2)2OH,pH 7.0 25 -30.1 -33.5 -3.3 90 
FRS2α PTB domain/TRKA, pY490 peptide 20 mM Tris-HCl, pH 8.0 25 -27.2 -20.9 6.3 90 
FRS2α PTB domain/TRKA, pY490 peptide 50mM phosphate,200mM NaCl,1 mM EDTA,5 mM HS(CH2)2OH,pH 7.0 25 -29.3 -27.2 2.1 90 
FRS2α PTB domain/TRKA (A-5) peptide 20 mM Tris-HCl, pH 8.0 25 -25.5 -19.7 5.4 90 
FRS2α PTB domain/TRKA (A-5) peptide 50mM phosphate,200mM NaCl,1 mM EDTA,5 mM HS(CH2)2OH,pH 7.0 25 -26.4 -23.0 3.3 90 
FRS2α PTB domain/IL-4R, pY497 peptide 20 mM Tris-HCl, pH 8.0 25 -34.3 -43.1 -8.8 90 
SOCS3(Δ101–133)/ gp130 peptide 50 mm NaCl, 50 mm arginine, 50 mm glutamate, 5 mm 2-
mercaptoethanol, pH 6.7 
25 -40.6 -27.0 13.6 91 
Wild type SOCS3/ gp130 peptide 50 mm NaCl, 50 mm arginine, 50 mm glutamate, 5 mm 2-
mercaptoethanol, pH 6.7 
25 -38.7 -25.9 12.7 91 
Hemextin AB complex/ FVIIα 50 mM Tris-HCl buffer and 10 mM CaCl2, pH 7.4 37 -33.3 -33.2 -1.6 92 
Tetratricopeptide repeat domain/ MEEVD peptide 50 mM Mes, 5 mM DTT, pH 6.0 10 -40.6 -33.0 7.6 93 
Tetratricopeptide repeat domain/ MEEVD peptide 50 mM Mes, 5 mM DTT, pH 6.0 15 -40.3 -52.9 -12.7 93 
Tetratricopeptide repeat domain/ MEEVD peptide 50 mM Mes, 5 mM DTT, pH 6.0 17.5 -39.3 -63.4 -24.1 93 
Tetratricopeptide repeat domain/ MEEVD peptide 50 mM Mes, 5 mM DTT, pH 6.0 20 -41.2 -84.9 -43.7 93 
Tetratricopeptide repeat domain/ MEEVD peptide 50 mM Mes, 5 mM DTT, pH 6.0 22.5 -41.7 -90.9 -49.1 93 
Tetratricopeptide repeat domain/ MEEVD peptide 50 mM Mes, 5 mM DTT, pH 6.0 25 -41.4 -144.7 -73.3 93 
Tetratricopeptide repeat domain/ MEEVD peptide 50 mM Mes, 5 mM DTT, pH 6.0 25 -40.3 -119.0 -78.6 93 
Tetratricopeptide repeat domain/ MEEVD peptide 50 mM Mes, 5 mM DTT, pH 6.0 27.5 -42.2 -123.7 -81.4 93 
Tetratricopeptide repeat domain/ MEEVD peptide 50 mM Mes, 5 mM DTT, pH 6.0 30 -42.6 -173.2 -130.5 93 
Tetratricopeptide repeat domain/ MEEVD peptide 50 mM Mes, 5 mM DTT, pH 6.0 32 -39.8 -177.7 -137.9 93 
Tetratricopeptide repeat domain/ MEEVD peptide 50 mM Mes, 5 mM DTT, pH 6.0 34 -42.8 -202.8 -161.0 93 
Tetratricopeptide repeat domain/ MEEVD peptide 50 mM Mes, 5 mM DTT, pH 6.0 36 -41.1 -219.9 -178.8 93 
SjGST(Y7F)/ S-methyl-GSH 20 mM MES, 2 mM DTT, and 1 mM EDTA, pH 6.5 25 -26.2 -19.2 7.0 94 
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SjGST(Y7F)/ S-methyl-GSH 20 mM MES, 2 mM DTT, and 1 mM EDTA, pH 6.5 30 -25.5 -26.5 -1.0 94 
SjGST(Y7F)/ S-methyl-GSH 20 mM MES, 2 mM DTT, and 1 mM EDTA, pH 6.5 35 -24.5 -32.4 -7.9 94 
SjGST(Y7F)/ S-hexyl-GSH 20 mM MES, 2 mM DTT, and 1 mM EDTA, pH 6.5 25 -30.1 -31.3 -1.1 94 
SjGST(Y7F)/ S-hexyl-GSH 20 mM MES, 2 mM DTT, and 1 mM EDTA, pH 6.5 30 -30.1 -36.9 -6.7 94 
SjGST(Y7F)/ S-hexyl-GSH 20 mM MES, 2 mM DTT, and 1 mM EDTA, pH 6.5 35 -30.7 -42.4 -11.7 94 
SjGST(Y7F)/ S-octyl-GSH 20 mM MES, 2 mM DTT, and 1 mM EDTA, pH 6.5 20 -32.2 -27.9 4.3 94 
SjGST(Y7F)/ S-octyl-GSH 20 mM MES, 2 mM DTT, and 1 mM EDTA, pH 6.5 25 -32.5 -30.4 2.1 94 
SjGST(Y7F)/ S-octyl-GSH 20 mM MES, 2 mM DTT, and 1 mM EDTA, pH 6.5 30 -32.8 -33.5 -0.7 94 
SjGST(Y7F)/ S-octyl-GSH 20 mM MES, 2 mM DTT, and 1 mM EDTA, pH 6.5 35 -32.5 -38.1 -5.6 94 
FadR protein- E. coli/ Leoyl-CoA 
 
20mM Tris-HCl, 50mM NaCl, 1 mM EDTA, 0.1 mM Tris(2-
carboxyethyl)phosphine hydrochloride), pH 7.0 
30 -41.4 -82.9 -41.5 95 
FadR protein- S. enterica/ Leoyl-CoA 
 
20mM Tris-HCl, 50mM NaCl, 1 mM EDTA, 0.1 mM Tris(2-
carboxyethyl)phosphine hydrochloride), pH 7.0 
30 -39.7 -80.8 -41.0 95 
FadR protein- V. cholerae/ Leoyl-CoA 20mM Tris-HCl, 50mM NaCl, 1 mM EDTA, 0.1 mM Tris(2-
carboxyethyl)phosphine hydrochloride), pH 7.0 
30 -44.0 -49.0 -5.0 95 
FadR protein- P. multocida/ Leoyl-CoA 20mM Tris-HCl, 50mM NaCl, 1 mM EDTA, 0.1 mM Tris(2-
carboxyethyl)phosphine hydrochloride), pH 7.0 
30 -32.7 -36.0 -3.3 95 
FadR protein- H. influenzae/ Leoyl-CoA 20mM Tris-HCl, 50mM NaCl, 1 mM EDTA, 0.1 mM Tris(2-
carboxyethyl)phosphine hydrochloride), pH 7.0 
30 -32.2 -34.3 -2.1 95 
Grb7-SH2/ erbB2 peptide pY1139 50 mM sodium acetate, 100 mM NaCl, 5 mM DTT, 1 mM NaN3, and 1 
mM EDTA, pH 6.6 
25 -32.2 -19.5 12.7 96 
Molecular Chaperone, ClpA6/ SsrA peptide 50 mM Tris, 0.1 M KCl, 10% glycerol, 10 mM MgCl2, 2 mM ATPγS, 
7.5 
4 -26.4 83.7 110.0 97 
Molecular Chaperone, ClpA6/ SsrA peptide 50 mM Tris, 0.1 M KCl, 10% glycerol, 10 mM MgCl2, 2 mM ATPγS, 
7.5 
10 -33.1 75.3 108.4 97 
Molecular Chaperone, ClpA6/ SsrA peptide 50 mM Tris, 0.1 M KCl, 10% glycerol, 10 mM MgCl2, 2 mM ATPγS, 
7.5 
15 -34.7 25.1 59.8 97 
Molecular Chaperone, ClpA6/ SsrA peptide 50 mM Tris, 0.1 M KCl, 10% glycerol, 10 mM MgCl2, 2 mM ATPγS, 
7.5 
20 -38.1 -16.7 21.3 97 
Molecular Chaperone, ClpA6/ SsrA peptide 50 mM Tris, 0.1 M KCl, 10% glycerol, 10 mM MgCl2, 2 mM ATPγS, 
7.5 
28 -38.9 -20.9 18.0 97 
Molecular Chaperone, ClpA6/ SsrA peptide 20mM MOPS, 0.1M KCl, 10% glycerol, 10mM MgCl2, 2mM ATPγS, 
7.5 
10 -38.9 12.6 51.5 97 
Molecular Chaperone, ClpA6/ SsrA peptide 20mM MOPS, 0.1M KCl, 10% glycerol, 10mM MgCl2, 2mM ATPγS, 
7.5 
28 -83.7 -2.9 80.8 97 
Molecular Chaperone, ClpA6/ DNS-SsrA peptide 50 mM Tris, 0.1 M KCl, 10% glycerol, 10 mM MgCl2, 2 mM ATPγS, 
7.5 
12 -38.5 16.7 55.2 97 
Molecular Chaperone, ClpA6/ DNS-SsrA peptide 50 mM Tris, 0.1 M KCl, 10% glycerol, 10 mM MgCl2, 2 mM ATPγS, 
7.5 
28 -40.6 -8.4 32.2 97 
Molecular Chaperone, ClpA6/ αSsrA peptide 50 mM Tris, 0.1 M KCl, 10% glycerol, 10 mM MgCl2, 2 mM ATPγS, 75 6 -38.1 184.1 222.2 97 
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Molecular Chaperone, ClpA6/ αSsrA peptide 50 mM Tris, 0.1 M KCl, 10% glycerol, 10 mM MgCl2, 2 mM ATPγS, 
7.5 
10 -38.5 133.9 172.4 97 
Molecular Chaperone, ClpA6/ αSsrA peptide 50 mM Tris, 0.1 M KCl, 10% glycerol, 10 mM MgCl2, 2 mM ATPγS, 
7.5 
18 -38.9 25.1 64.0 97 
CaM/ RS20 peptide 50 mM Hepes, 2 mM CaCl2, pH 7.5 25 -43.3 -55.3 -11.8 98 
CaMox/ RS20 peptide 50 mM Hepes, 2 mM CaCl2, pH 7.5 25 -36.3 -32.4 3.9 98 
CaMox + MsrA/ RS20 peptide 50 mM Hepes, 2 mM CaCl2, pH 7.5 25 -42.8 -56.3 -13.5 98 
CaMox + MsrB/ RS20 peptide 50 mM Hepes, 2 mM CaCl2, pH 7.5 25 -37.8 -54.7 -17.7 98 
CaMox + MsrAB/ RS20 peptide 50 mM Hepes, 2 mM CaCl2, pH 7.5 25 -41.9 -58.1 -16.2 98 
PDZ3 from PSD-95/ peptide 1 20 mM MES, 10 mM NaCl, pH 6.0 25 -27.6 -7.7 19.8 99 
PDZ3 from PSD-95/ peptide 2 20 mM MES, 10 mM NaCl, pH 6.0 25 -29.4 -14.4 15.0 99 
PDZ3 from PSD-95/ peptide 3 20 mM MES, 10 mM NaCl, pH 6.0 25 -30.3 -16.2 14.1 99 
PDZ3 from PSD-95/ peptide 4 20 mM MES, 10 mM NaCl, pH 6.0 25 -31.0 -7.8 23.1 99 
PDZ3 from PSD-95/ peptide 5 20 mM MES, 10 mM NaCl, pH 6.0 25 -31.0 -7.7 23.2 99 
PDZ3 from PSD-95/ peptide 6 20 mM MES, 10 mM NaCl, pH 6.0 25 -29.7 -14.6 15.1 99 
PDZ3 from PSD-95/ peptide 7 20 mM MES, 10 mM NaCl, pH 6.0 25 -27.5 -11.1 16.4 99 
PDZ3 from PSD-95/ peptide 8 20 mM MES, 10 mM NaCl, pH 6.0 25 -27.6 -13.9 13.7 99 
src homology 3 (SH3)/ peptide p1 10 mM phosphate buffer, pH 7.5 25 -17.8 -4.7 13.1 100 
src homology 3 (SH3)/ peptide p2 10 mM phosphate buffer, pH 7.5 25 -7.6 3.8 11.4 100 
ApoCaM/ NOS-II V511K peptide 10 mM HEPES, 150 mM NaCl, 2 mM MgCl2, 10 mM EGTA, and 
0.005% (v/v) Tween 20,  pH 7.4 
25 -34.8 25.9 60.7 101 
ApoCaM/ NOS-II F517K peptide 10 mM HEPES, 150 mM NaCl, 2 mM MgCl2, 10 mM EGTA, and 
0.005% (v/v) Tween 20,  pH 7.4 
25 -37.9 31.2 69.1 101 
ApoCaM/ NOS-II M521K peptide 10 mM HEPES, 150 mM NaCl, 2 mM MgCl2, 10 mM EGTA, and 
0.005% (v/v) Tween 20,  pH 7.4 
25 -41.3 11.9 53.2 101 
ApoCaM/ NOS-II 3K peptide 10 mM HEPES, 150 mM NaCl, 2 mM MgCl2, 10 mM EGTA, and 
0.005% (v/v) Tween 20,  pH 7.4 
25 -33.0 33.3 66.3 101 
ApoCaM/ NOS-II E3K peptide 10 mM HEPES, 150 mM NaCl, 2 mM MgCl2, 10 mM EGTA, and 
0.005% (v/v) Tween 20,  pH 7.4 
25 -33.7 27.0 60.8 101 
Ab1-SH3/ RP1 peptide 20 mM phosphate buffer, pH 7.0 25 -25.8 -63.2 -37.6 102 
Ab1-SH3/ APR-RP1 peptide 20 mM phosphate buffer, pH 7.0 25 -23.0 -61.5 -38.5 102 
Native IL-8/ CXCR1N 50 mM NaCl, 50 mM HEPES, pH 8.0 25 -30.5 -29.3 1.3 103 
Native IL-8 monomer/ CXCR1N 50 mM NaCl, 50 mM HEPES, pH 8.0 25 -29.7 -43.9 -14.2 103 
Sem-5 C-SH3/ SosY I 20 mM Tris and 200 mM NaCl, pH 9.0 25.1 -25.5 -39.3 -13.80 104 
Sem-5 C-SH3/ SosY I 20 mM Tris and 200 mM NaCl, pH 8.5 25.1 -25.1 -36.0 -10.9 104 
Sem-5 C-SH3/ SosY I 20 mM Tris and 200 mM NaCl, pH 8.0 25.1 -25.1 -38.1 -13.0 104 
Sem-5 C-SH3/ SosY III 20 mM Tris and 200 mM NaCl, pH 7.5 15.2 -25.1 -27.6 -2.5 104 
Sem-5 C-SH3/ SosY III 20 mM Tris and 200 mM NaCl, pH 7.5 20.2 -25.1 -31.4 -6.3 104 
Sem-5 C-SH3/ SosY III 20 mM Tris and 200 mM NaCl, pH 7.5 35.2 -25.1 -34.7 -9.6 104 
Sem-5 C-SH3/ SosY III 20 mM Tris and 200 mM NaCl, pH 7.5 25.1 -25.1 -37.7 -12.6 104 
  
185 
Sem-5 C-SH3/ SosY III 20 mM Tris and 200 mM NaCl, pH 7.5 25.1 -24.7 -41.8 -17.2 104 
Sem-5 C-SH3/ SosY II 20 mM Tris and 200 mM NaCl, pH 7.5 25.1 -25.1 -38.1 -13.0 104 
Sem-5 C-SH3/ SosY II 20 mM imidazole and 200 mM NaCl, pH 7.5 25.1 -25.1 -33.9 -8.8 104 
Sem-5 C-SH3/ SosY II 20 mM Hepes and 200 mM NaCl, pH 7.5 25.1 -25.1 -31.8 -6.7 104 
Sem-5 C-SH3/ SosY II 20 mM phosphate and 200 mM NaCl, pH 7.5 25.1 -25.1 -33.5 -8.4 104 
Sem-5 C-SH3/ SosY III 20 mM imidazole and 200 mM NaCl, pH 7.0 25.1 -24.7 -35.1 -10.5 104 
Sem-5 C-SH3/ SosY III 20 mM imidazole and 200 mM NaCl, pH 6.5 25.1 -24.3 -38.9 -14.6 104 
Sem-5 C-SH3/ SosY III 50 mM sodium acetate, 100 mM NaCl and 10 mM CaCl2. pH 4.8 25.1 -20.1 -28.0 -7.9 104 
Wild type FAT/ LD2 peptide (Helix 1,4 site) 50 mM HEPES, 100 mM NaCl, and 2 mM NaN3 at pH 7.0 26 -28.9 -30.1 -1.3 105 
E949A/K956A/R963A/ LD2 peptide (Helix 1,4 
site) 
50 mM HEPES, 100 mM NaCl, and 2 mM NaN3 at pH 7.0 26 -30.7 -23.0 7.5 105 
Pyk2/ LD2 peptide (Helix 1,4 site) 50 mM HEPES, 100 mM NaCl, and 2 mM NaN3 at pH 7.0 26 -24.9 -41.8 -16.7 105 
Wild type FAT/ LD2 peptide (Helix 2,3 site) 50 mM HEPES, 100 mM NaCl, and 2 mM NaN3 at pH 7.0 26 -28.3 4.6 32.6 105 
1937A/ LD2 peptide (Helix 2,3 site) 50 mM HEPES, 100 mM NaCl, and 2 mM NaN3 at pH 7.0 26 -27.9 1.3 28.9 105 
Pyk2/ LD2 peptide (Helix 2,3 site) 50 mM HEPES, 100 mM NaCl, and 2 mM NaN3 at pH 7.0 26 -26.8 1.3 28.0 105 
C3/ V4W/H9A peptide PBS, pH 7.4 15 -39.5 -61.1 -21.8 106 
C3/ V4W/H9A peptide PBS, pH 7.4 20 -39.9 -70.7 -31.0 106 
C3/ V4W/H9A peptide PBS, pH 7.4 25 -39.3 -75.9 -36.8 106 
C3/ V4W/H9A peptide PBS, pH 7.4 37 -37.9 -99.6 -61.9 106 
C3/ V4W/H9A peptide Tris, pH 7.4 25 -40.3 -61.5 -21.5 106 
C3/ V4W/H9A peptide MOPS, pH 7.4 25 -39.6 -66.2 -26.8 106 
C3/ V4W/H9A peptide PBS, pH 6.7 25 -40.4 -75.0 -34.7 106 
C3/ V4W/H9A peptide Tris, pH 6.7 25 -40.8 -54.0 -13.4 106 
C3/ V4W/H9A peptide MOPS, pH 6.7 25 -40.4 -65.3 -25.0 106 
C3/ V4W/H9A peptide PB, pH 7.4 25 -39.9 -66.5 -26.8 106 
C3/ V4W/H9A peptide PBS, 0.5 M glycerol, pH 7.4 25 -39.7 -126.8 -91.6 106 
C3/ V4W/H9A peptide PBS, 1 M glycerol, pH 7.4 25 -38.7 -92.5 -54.0 106 
C3/ V4H9 peptide PBS, pH 7.4 15 -34.6 -39.7 -5.3 106 
C3/ V4H9 peptide PBS, pH 7.4 20 -32.6 -46.5 -14.1 106 
C3/ V4H9 peptide PBS, pH 7.4 25 -33.8 -50.7 -17.1 106 
C3/ V4H9 peptide PBS, pH 7.4 37 -31.2 -58.5 -27.4 106 
C3/ V4H9 peptide Tris, pH 7.4 25 -33.8 -66.9 -33.4 106 
C3/ V4H9 peptide MOPS, pH 7.4 25 -31.6 -62.8 -31.4 106 
C3/ V4H9 peptide PBS, pH 6.7 25 -34.6 -53.7 -19.2 106 
C3/ V4H9 peptide Tris, pH 6.7 25 -32.9 -57.3 -24.6 106 
C3/ V4H9 peptide MOPS, pH 6.7 25 -33.8 -49.7 -16.1 106 
C3/ V4H9 peptide PB, pH 7.4 25 -34.2 -52.6 -18.6 106 
C3/ V4H9 peptide PBS, 0.5 M glycerol, pH 7.4 25 -33.5 -46.6 -13.2 106 
C3/ V4H9 peptide PBS, 1 M glycerol, pH 7.4 25 -32.8 -76.8 -44.2 106 
PDZ3 fromPSD-95/ peptide ligand 2 20 mM MES, pH 6.0 25 -24.0 -8.6 15.4 107 
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PDZ3 fromPSD-95/ peptide ligand 4 20 mM MES, pH 6.0 25 -23.9 -5.1 18.7 107 
PDZ3 fromPSD-95/ peptide ligand 5 20 mM MES, pH 6.0 25 -27.0 -10.3 16.7 107 
PDZ3 fromPSD-95/ peptide ligand 6 20 mM MES, pH 6.0 25 -25.8 -12.3 13.5 107 
PDZ3 fromPSD-95/ peptide ligand 7 20 mM MES, pH 6.0 25 -25.4 -10.3 15.2 107 
PDZ3 fromPSD-95/ peptide ligand 8 20 mM MES, pH 6.0 25 -30.5 -9.6 21.0 107 
PDZ3 fromPSD-95/ peptide ligand 9 20 mM MES, pH 6.0 25 -28.7 -11.5 17.3 107 
PDZ3 fromPSD-95/ peptide ligand 10 20 mM MES, pH 6.0 25 -26.8 -5.9 21.0 107 
PDZ3 fromPSD-95/ peptide ligand 11 20 mM MES, pH 6.0 25 -29.7 -14.2 15.6 107 
PDZ3 fromPSD-95/ peptide ligand 12 20 mM MES, pH 6.0 25 -30.0 -20.0 10.0 107 
PDZ3 fromPSD-95/ peptide ligand 13 20 mM MES, pH 6.0 25 -24.9 -5.8 19.1 107 
PDZ3 fromPSD-95/ peptide ligand 14 20 mM MES, pH 6.0 25 -24.4 -6.8 17.7 107 
PDZ3 fromPSD-95/ peptide ligand 15 20 mM MES, pH 6.0 25 -30.2 -12.9 17.4 107 
Abl-SH3 domain/ p41 20 mM sodium phosphate, pH 7.0 25 -32.2 -91.6 -59.4 108 
Abl-SH3 domain/ p41 20 mM sodium phosphate, pH 7.0 25 -32.2 -88.3 -56.1 108 
Abl-SH3 domain/ p40 20 mM sodium phosphate, pH 7.0 25 -31.8 -76.6 -44.8 108 
Abl-SH3 domain/ p7 20 mM sodium phosphate, pH 7.0 25 -28.9 -73.2 -44.4 108 
Abl-SH3 domain/ p0 20 mM sodium phosphate, pH 7.0 25 -28.9 -71.1 -42.3 108 
Abl-SH3 domain/ 3BP1 20 mM sodium phosphate, pH 7.0 25 -25.5 -69.9 -44.4 108 
PDZ3 from PSD-95/ KKETEX (X=Ala, Me) 20 mM MES, 10 mM NaCl, pH 6.0 25 -23.1 -19.1 4.0 109 
PDZ3 from PSD-95/ KKETEX (X=Aib, Me,Me) 20 mM MES, 10 mM NaCl, pH 6.0 25 -22.5 -4.3 18.2 109 
PDZ3 from PSD-95/ KKETEX (X=Abu, Et) 20 mM MES, 10 mM NaCl, pH 6.0 25 -30.6 -31.8 -1.3 109 
PDZ3 from PSD-95/ KKETEX (X=Val, i-Pr) 20 mM MES, 10 mM NaCl, pH 6.0 25 -32.6 -26.1 6.6 109 
PDZ3 from PSD-95/ KKETEX (X=Ape, nPr) 20 mM MES, 10 mM NaCl, pH 6.0 25 -34.2 -31.0 3.2 109 
PDZ3 from PSD-95/ KKETEX (X=Tle, t-Bu) 20 mM MES, 10 mM NaCl, pH 6.0 25 -31.0 -18.7 12.3 109 
PDZ3 from PSD-95/ KKETEX (X=Ile, s-Bu) 20 mM MES, 10 mM NaCl, pH 6.0 25 -29.2 -18.0 11.2 109 
PDZ3 from PSD-95/ KKETEX (X=Leu, i-Bu) 20 mM MES, 10 mM NaCl, pH 6.0 25 -29.2 -17.2 11.9 109 
PDZ3 from PSD-95/ KKETEX (X=Ahx, n-Bu) 20 mM MES, 10 mM NaCl, pH 6.0 25 -29.4 -26.9 2.6 109 
Disabled-1 PTB native/ ApoER2 Peptide 20 mM PIPES buffer, 150 mM NaCl,  0.2 mM DTT, pH 7.0 25 -32.2 -40.2 -7.9 74 
Disabled-1 PTB mutant H81Q/ ApoER2 Peptide 20 mM PIPES buffer, 150 mM NaCl,  0.2 mM DTT, pH 7.0 25 -33.1 -45.2 -12.1 74 
Disabled-1 PTB mutant K45A/ ApoER2 Peptide 20 mM PIPES buffer, 150 mM NaCl,  0.2 mM DTT, pH 7.0 25 -32.2 -42.3 -10.0 74 
Disabled-1 PTB mutant K45Q/ ApoER2 Peptide 20 mM PIPES buffer, 150 mM NaCl,  0.2 mM DTT, pH 7.0 25 -31.6 -33.9 -2.5 74 
Disabled-1 PTB mutant K45E/ ApoER2 Peptide 20 mM PIPES buffer, 150 mM NaCl,  0.2 mM DTT, pH 7.0 25 -32.3 -44.4 -12.1 74 
Disabled-1 PTB mutant K82A/ ApoER2 Peptide 20 mM PIPES buffer, 150 mM NaCl,  0.2 mM DTT, pH 7.0 25 -33.4 -46.0 -12.6 74 
Disabled-1 PTB mutant K82Q/ ApoER2 Peptide 20 mM PIPES buffer, 150 mM NaCl,  0.2 mM DTT, pH 7.0 25 -32.9 -60.7 -27.6 74 
Disabled-1 PTB mutant K45A/K82A/ ApoER2 
Peptide 
20 mM PIPES buffer, 150 mM NaCl,  0.2 mM DTT, pH 7.0 25 -31.5 -36.8 -5.4 74 
Disabled-1 PTB mutant K45Q/K82Q/ ApoER2 
Peptide 
20 mM PIPES buffer, 150 mM NaCl,  0.2 mM DTT, pH 7.0 25 -31.8 -38.9 -7.1 74 
Disabled-1 PTB mutant K45E/K82Q/ ApoER2 
Peptide 
20 mM PIPES buffer, 150 mM NaCl,  0.2 mM DTT, pH 7.0 25 -32.4 -42.7 -10.5 74 
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Cob B/ H4-11 peptide 20 mM Hepes, 100 mM NaCl, 10 mM DTT, pH 7.5 15 -35.1 -38.0 -2.9 110 
Cob B/ p53-11 peptide 20 mM Hepes, 100 mM NaCl, 10 mM DTT, pH 7.5 15 -32.0 -16.0 15.5 110 
Cob B/ Acs-11 peptide 20 mM Hepes, 100 mM NaCl, 10 mM DTT, pH 7.5 15 -31.6 -8.8 23.2 110 
Cob B/ Acs-15 peptide 20 mM Hepes, 100 mM NaCl, 10 mM DTT, pH 7.5 15 -30.0 -7.0 23.1 110 
SjGST-Y7F/ GSH 20mM phosphate, 2mM DTT, 1mM EDTA, pH 6.5 16 -28.0 -17.2 10.8 111 
SjGST-Y7F/ GSH 20mM phosphate, 2mM DTT, 1mM EDTA, pH 6.5 20 -28.1 -22.0 6.1 111 
SjGST-Y7F/ GSH 20mM phosphate, 2mM DTT, 1mM EDTA, pH 6.5 25 -28.2 -28.7 0.5 111 
SjGST-Y7F/ GSH 20mM phosphate, 2mM DTT, 1mM EDTA, pH 6.5 30 -28.1 -34.9 -6.8 111 
WT Human GSH Transferase/ GSH 5 mM NaCl, 0.1 mM EDTA, 1 mM DTT, 50 mM Na phosphate, pH 6.5 25 -23.1 -46.9 -23.6 112 
Y49F mutant Human GSH Transferase/ GSH 5 mM NaCl, 0.1 mM EDTA, 1 mM DTT, 50 mM Na phosphate, pH 6.5 25 -20.4 -54.6 -38.4 112 
WT Human GSH Transferase/ S-hexyl-GSH 5 mM NaCl, 0.1 mM EDTA, 1 mM DTT, 50 mM Na phosphate, pH 6.5 25 -33.6 -67.5 -33.6 112 
Y49F mut. Human GSH Trf./ S-hexyl-GSH 5 mM NaCl, 0.1 mM EDTA, 1 mM DTT, 50 mM Na phosphate, pH 6.5 25 -32.0 -71.7 -39.5 112 
SurA/ WEYIPNV peptide 150 mM NaCl, 20 mM NaH2PO4, pH 7.3 20 -31.7 -83.3 -51.6 113 
SurA/ WEYIPNV peptide 150 mM NaCl, 20 mM NaH2PO4, pH 7.3 25 -31.1 -81.2 -50.1 113 
SurA/ WEYIPNV peptide 150 mM NaCl, 20 mM NaH2PO4, pH 7.3 30 -30.8 -77.4 -46.6 113 
SurA/ WEYIPNV peptide 150 mM NaCl, 20 mM NaH2PO4, pH 7.3 37 -29.5 -67.4 -37.9 113 
SurA(ΔP2)/ WEYIPNV peptide 150 mM NaCl, 20 mM NaH2PO4, pH 7.3 20 -32.4 -87.4 -55.0 113 
SurA(ΔP2)/ WEYIPNV peptide 150 mM NaCl, 20 mM NaH2PO4, pH 7.3 25 -32.3 -84.3 -52.0 113 
SurA(ΔP2)/ WEYIPNV peptide 150 mM NaCl, 20 mM NaH2PO4, pH 7.3 30 -31.4 -81.0 -49.6 113 
SurA(ΔP2)/ WEYIPNV peptide 150 mM NaCl, 20 mM NaH2PO4, pH 7.3 37 -28.9 -83.3 -54.5 113 
Fab/e-pep 50 mM sodium phosphate, 0.15 M NaCl, pH 7.2 10 -41.4 -46.9 -5.4 114 
CB4-1/ e-pep 50 mM sodium phosphate, 0.15 M NaCl, pH 7.2 10 -42.3 -45.2 2.9 114 
Fab/e-pep 50 mM sodium phosphate, 0.15 M NaCl, pH 7.2 25 -43.1 -65.3 -22.2 114 
CB4-1/ e-pep 50 mM sodium phosphate, 0.15 M NaCl, pH 7.2 25 -43.5 -65.3 -21.8 114 
CB4-1/ e-pep 50 mM MOPS, 0.15 M NaCl, pH 7.2 25 -43.5 -64.9 -21.3 114 
Fab/e-pep 50 mM sodium phosphate, 0.15 M NaCl, pH 7.2 35 -42.3 -74.5 -32.2 114 
CB4-1/ e-pep 50 mM sodium phosphate, 0.15 M NaCl, pH 7.2 35 43.1 -77.0 -33.9 114 
Fab/h-pep 50 mM sodium phosphate, 0.15 M NaCl, pH 7.2 10 -41.8 -40.6 1.3 114 
CB4-1/ h-pep 50 mM sodium phosphate, 0.15 M NaCl, pH 7.2 10 -42.3 -42.7 -0.4 114 
Fab/h-pep 50 mM sodium phosphate, 0.15 M NaCl, pH 7.2 25 -43.5 -58.6 -15.1 114 
CB4-1/ h-pep 50 mM sodium phosphate, 0.15 M NaCl, pH 7.2 25 -43.9 -58.2 -14.2 114 
CB4-1/ h-pep 50 mM MOPS, 0.15 M NaCl, pH 7.2 25 -44.4 -60.7 -16.3 114 
Fab/h-pep 50 mM sodium phosphate, 0.15 M NaCl, pH 7.2 35 -43.9 -69.0 -25.1 114 
CB4-1/ h-pep 50 mM sodium phosphate, 0.15 M NaCl, pH 7.2 35 43.9 -67.8 -23.8 114 
Fab/u-pep 50 mM sodium phosphate, 0.15 M NaCl, pH 7.2 10 -39.7 -49.0 -9.2 114 
CB4-1/ u-pep 50 mM sodium phosphate, 0.15 M NaCl, pH 7.2 10 -40.2 -50.2 10.0 114 
Fab/u-pep 50 mM sodium phosphate, 0.15 M NaCl, pH 7.2 25 -40.2 -64.9 -24.7 114 
CB4-1/ u-pep 50 mM sodium phosphate, 0.15 M NaCl, pH 7.2 25 -41.4 -64.0 -22.6 114 
CB4-1/ u-pep 50 mM MOPS, 0.15 M NaCl, pH 7.2 25 -40.6 -64.9 -24.3 114 
Fab/u-pep 50 mM sodium phosphate, 0.15 M NaCl, pH 7.2 35 -38.9 -74.5 -35.6 114 
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CB4-1/ u-pep 50 mM sodium phosphate, 0.15 M NaCl, pH 7.2 35 -39.7 -73.2 -33.5 114 
CB4-1/ d-pep 50 mM sodium phosphate, 0.15 M NaCl, pH 7.2 25 -32.2 -51.5 -19.2 114 
CB4-1/ GA-pep 50 mM sodium phosphate, pH 7.2 25 -40.6 -45.2 -4.6 114 
CB4-1/ GA-pep 50 mM sodium phosphate, 0.15 M NaCl, pH 7.2 25 -41.4 -47.7 -6.3 114 
CB4-1/ AT-pep 50 mM sodium phosphate, pH 7.2 25 -38.9 -46.4 -7.5 114 
CB4-1/ SE-pep 50 mM sodium phosphate, pH 7.2 25 -29.3 -72.8 -43.5 114 
Fab/ SE-pep 50 mM sodium phosphate, pH 7.2 25 -29.7 -73.2 -43.5 114 
Ab 131/angiotensin II  20 mM buffer, 50 mM NaCl, pH 7.3  30  -46.0 -37.2 8.8 115 
Endothiapepsin/pepstatin A  20 mM phosphate, pH 7.0  16.1  -38.1 -10.5 27.6 116  
HK 565 peptide/PK 262 peptide  30 mM phosphate, pH 7.0  30  -24.7 1.7 26.8 117  
human Grb2 (SH3)/human Sos peptide  50 mM potassium phosphate, 1 mM DTT, pH 8.0  25  -26.8 -25.9 0.9 118 
Fyn SH3 domain/P2L peptide  10 mM phosphate, pH 6.0  30  -27.6 -51.5 -23.6 119 
Lck SH2 domain/Lck phosphopeptide  50 mM Mops, 100 nM NaCl, 1 mM DTT, pH 6.8  25  -30.5 -35.1 -4.4 120 
p85 SH2 domain/PDGFR phosphopeptide  50 mM Mops, 100 nM NaCl, 1 mM DTT, pH 6.8  25  -36.4 -39.3 -3.0 120 
Src SH2 domain/pYHmT phosphopeptide  50 mM Mops, 100 nM NaCl, 1 mM DTT, pH 6.8  25  -36.0 -35.1 0.5 120 
Fyn SH2 domain/pYHmT phosphopeptide  10 mM potassium phosphate, 30 mM NaCl, 5 mM DTT, pH 6.0  25  -26.4 -18.0 8.2 121 
Fyn SH2 domain/pY531 phosphopeptide  10 mM potassium phosphate, 30 mM NaCl, 5 mM DTT, pH 6.0  25  -35.1 -36.4 -1.6 121 
SHC N-term. Domain/EGFR1148 peptide  100 mM Hepes, 100 mM NaCl, 1 mM DTT, pH 7.5  25  -43.1 -22.8 20.2 122 
SHC N-term. Domain/Trk490 peptide  100 mM Hepes, 100 mM NaCl, 1 mM DTT, pH 7.5  25  -42.3 10.0 52.0 122 
Ab 13AD/peptide LZ  1.46 mM KH2PO4,6.46 mM Na2HPO4,0.14 M NaCl,0.27 mM KCl,pH 7.2 27  -43.9 -52.7 -8.9 123 
Ab 13AD/peptide LZ(7P14P)  1.46 mM KH2PO4,6.46 mM Na2HPO4,0.14 M NaCl,0.27 mM KCl,pH 7.2 27  -39.7 -72.8 -32.7 123 
Ab 29AB/peptide LZ  1.46 mM KH2PO4,6.46 mM Na2HPO4,0.14 M NaCl,0.27 mM KCl,pH 7.2 27  -46.0 -57.7 -11.9 123 
Ab 29AB/peptide LZ(7P14P)  1.46 mM KH2PO4,6.46 mM Na2HPO4,0.14 M NaCl,0.27 mM KCl,pH 7.2 27  -39.7 -71.5 -32.4 123 
Ab 42PF/peptide LZ(7P14P)  1.46 mM KH2PO4,6.46 mM Na2HPO4,0.14 M NaCl,0.27 mM KCl,pH 7.2 27  -43.5 -56.1 -12.6 123 
calmodulinCa2+/melittin  50 mM Pipes/NaOH, 150 mM NaCl, 0.5 mM CaCl2, pH 7.0  25  -49.0 30.1 79.0 124 
Calmodulin/melittin  50 mM Pipes/NaOH, 150 mM NaCl, pH 7.0  25  -33.9 20.1 54.0 124 
ribonuclease S/truncated S peptide  50 mM sodium acetate, 100 mM NaCl, pH 6.0  25  -39.3 -175.3 -136.0 125 
Streptavidin/FSHPQNT peptide  50 mM potassium phosphate, pH 7.62  25  -22.2 -80.8 -58.6 126 
Streptavidin/pStrep-tag  50 mM potassium phosphate, pH 7.62  25  -25.5 -52.7 -27.2 127 
CheR/receptor pentapeptide  20 mM potassium phosphate, 20 mM NaCl, 1 mM EDTA, 1 mM PMSF, 
pH 7.0 
28  -33.1 -56.9 -23.8 128 
Profiling/Pro11  10 mM Tris, 75 mM KCl, 3.1 mM NaN3, pH 7.5  28  -22.6 -21.3 1.4 129 
A/B heterodimeric coiled coil  10 mM sodium phosphate, ionic strength 22 mM, pH 7.2  20  -44.4 -103.3 -59.2 130 
GroEL/unfolded subtilisin BPN’ mutant  50 mM Tris, 100 mM KCl, 1 mM DTT, 0.1 mM EDTA, pH 7.8  14.3  -31.8 83.3 115.1 131 
Jel42 scFv/HPr 15 mM sodium phosphate buffer, pH 7.2 2 -43.5 2.7 46.4 132 
Jel42 scFv/HPr 15 mM sodium phosphate buffer, pH 7.2 9 -44.8 -6.7 38.1 132 
Jel42 scFv/HPr 15 mM sodium phosphate buffer, pH 7.2 15 -45.6 -14.2 31.4 132 
Jel42 scFv/HPr 15 mM sodium phosphate buffer, pH 7.2 21 -46.0 -21.8 24.7 132 
Jel42 scFv/HPr 15 mM sodium phosphate buffer, pH 7.2 29 -46.4 -31.0 15.9 132 
Jel42 scFv/HPr 15 mM sodium phosphate buffer, pH 7.2 37 -46.9 -39.7 7.1 132 
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